3rd September, 2022

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

Scrip Code: BSE - 524500

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

Scrip Code: NSE - KILITCH

Dear Sir,

Sub: Notice of 30th Annual General Meeting and Annual Report for the Financial Year 2021-22

We hereby would like to inform you that the 30th Annual General Meeting of the Company (AGM) will be held on Thursday, 29th September, 2022, at 10:00 am (IST) through Video Conferencing or Other Audio Visual Means.

Pursuant to Regulations 30 and 34 of Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations 2015 ("Listing Regulations"), enclosing herewith the Notice of 30th Annual General Meeting and Annual Report for the Financial Year 2021-22 which is being sent to those members today whose e-mail addresses are registered with the Company/ Registrar & Share Transfer Agent / Depository Participant(s), in accordance with the MCA Circulars and SEBI Circulars.

A member whose name is recorded in the Register of Members / Register of Beneficial Owners as on the Cut-Off Date i.e. Wednesday, 21st September, 2022 shall be entitled to avail the facility of remote e-Voting / e-voting at the AGM. The remote e-Voting facility shall commence on **Sunday, 25th September, 2022 at 9.00 AM (IST) and will end on Wednesday, 28th September, 2022 at 5.00 PM (IST).** Detailed instructions pertaining to remote e-Voting are provided in Notice of the AGM.

We request you to kindly take the same on record and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

MUKUND PRATAPRAI MEHTA

Digitally signed by MUKUND PRATAPRAI MEHTA
DN: c=IN, o=PERSONAL, pseudonym=de3698b434193df53a7b94312dfa7895b18e89a9e2563279b6a31143cf2144ac, postalCode=400037, st=MAHARASHTRA, serialNumber=42eb6afed00f3b1ff1d748907a2c2a1a9536551e0e7a9314c1ddd8ade1e0c2491, cn=MUKUND PRATAPRAI MEHTA
Date: 2022.09.03 16:00:11 +05'30'

Mukund Mehta
Managing Director

ISO 9001:2008 13485:2003 · WHO CERTIFIED · EXPORT HOUSE RECOGNISED BY GOVT OF INDIA · BE INDIA Pharmacy of the World

KILITCH DRUGS (INDIA) LIMITED

Kilitch Drugs (India) Limited

CIN: L24239MH1992PLC066718
Registered Office: C-301/2, M.I.D.C. TTC Industrial Area, Pawane Village,
Navi Mumbai - 400 705.
Tel: 022 61214100 **Website:** www.kilitch.com
E-mail: pushpanyoupane@kilitch.com

NOTICE

Notice is hereby given that the 30th Annual General Meeting of **Kilitch Drugs (India) Limited** will be held on Thursday, 29th September, 2022 at 10:00 am through Video Conferencing (VC) or Other Audio Visual Means (OAVM) to transact the following business:

Ordinary Business:

1. To receive, consider, approve and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the year ended 31st March, 2022, together with the Report of the Board of Directors and Auditors thereon;

2. To re-appoint Mr. Bhavin Mehta (DIN: 00147895), who retires by rotation and being eligible, offers himself for re-appointment.

Special Business:

3. To consider and if thought fit, to pass, the following resolution as a Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 13, 61, 64 and other applicable provisions, if any, of the Companies Act, 2013, (including any statutory modification(s) and re-enactment(s) thereof for the time being in force) and the rules framed thereunder, consent of the members of the Company be and is hereby accorded to increase in Authorized Share Capital of the Company from Rs. 20,00,00,000/- (Rupees Twenty Crore only) divided into 2,00,00,000 (Two Crore) Equity Shares of Rs. 10/- (Rupees Ten only) each to Rs. 25,00,00,000 (Rupees Twenty Five Crore only) divided into 2,50,00,000 (Two Crore Fifty Lakh)Equity Shares of Rs. 10/- each (Rupees Ten only).

RESOLVED FURTHER THAT the Memorandum of Association of the Company be and is hereby altered by substituting the existing Clause V thereof by the following new Clause V as under:
"V. The Authorized share capital of the company is INR 25,00,00,000 (Indian Rupees Twenty Five Crore only) divided into 2,50,00,000 (Two Crore Fifty Lakh) equity shares of INR 10/- (Indian Rupees Ten only) each with power of the company to increase or reduce the capital and the shares in the capital for the time being into several classes and to attach thereto respectively such preferential differed qualified or special rights, privileges or conditions and to vary or modify or abrogate any such rights, privileges or conditions as may for the time being be provided by the regulations of the company and to issue any part of its capital original or increased with or without any preference priority or special privileges or subject to any postponement of any conditions or restrictions and that unless the conditions of issue shall otherwise expressly declare every issue of share whether declared to preference or otherwise shall be subject to the power herein before contained."

RESOLVED FURTHER THAT any Director or Company Secretary of the Company be and is hereby, severally, authorized to do all such act(s), deed(s) and things including all forms, documents filing with Ministry of Corporate Affairs (MCA) as may be necessary and incidental to give effect to the aforesaid Resolution."

4. to ratify the remuneration to Cost Auditor of the Company

"RESOLVED THAT pursuant to Section 148(3) and other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force) and the Companies (Audit and Auditors) Rules, 2014, as amended from time to time, the Company hereby ratifies the remuneration of INR 60,000 (Indian Rupees Sixty Thousand) plus applicable taxes and reimbursement of out-of-pocket expenses payable to M/s Arvind Kumar & Co. Cost Accountants (Firm Registration No. 000646), who have been appointed by the Board of Directors on the recommendation of the Audit Committee, as the Cost Auditors of the Company, to conduct the audit of the cost records maintained by the Company for the Financial Year ending 31st March , 2023."

RESOLVED FURTHER THAT, the Board of the Directors and/or Company Secretary of the Company be and is hereby severally authorised to settle any question, difficulty or doubt that may arise in giving effect to this resolution and to do all such acts, deeds and things as may be necessary, expedient and desirable for the purpose of giving effect to this resolution.",

By order of the Board
For **Kilitch Drugs (India) Limited**

sd/-

Pushpa Nyoupane
Company Secretary

Place : Mumbai
Date: 10th August, 2022
Regd. Office: C-301/2, M.I.D.C.,
TTC Industrial Area, Pawane
Village, Navi Mumbai - 400 705.

NOTES:

1. Explanatory Statement setting out the material facts concerning each item of Special Business to be transacted at the General Meeting pursuant to Section 102 of the Companies Act, 2013, is annexed hereto and forms part of the Notice.

The relevant details pursuant to Regulation 26(4) and 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India in respect of Directors seeking appointment/re-appointment at this Annual General Meeting are also mentioned.

2. In view of the COVID-19 pandemic, the Ministry of Corporate Affairs, Government of India ("MCA") issued General Circular Nos. 14/2020, 17/2020, 20/2020, 02/2021, 19/2021 and 21/2021 dated 8th April 2020, 13th April 2020, 5th May 2020, 13th January 2021, 8th December 2021, 14th December 2021and 5th May, 2022, respectively, ("MCA Circulars") allowing, inter-alia, conduct of AGMs through Video Conferencing/Other Audio-Visual Means ("VC / OAVM") facility on or before 31st December 2022, in accordance with the requirements provided in paragraphs 3 and 4 of the MCA General Circular No. 20/2020.

In compliance with these Circulars, provisions of the Act and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), the Company is convening the 30th AGM through Video Conferencing ('VC') or Other Audio-Visual Means ('OAVM'), without the physical presence of the Members.

The Annual Report including Financial Statements, Auditor's Report, Board Report, Notice of AGM along with all the annexure and attachments thereof is being sent through email to those members whose email addresses are registered with the Company / Depositories and no physical copy of the same will be sent by the Company. Member may please note that the Notice and Annual Report of the Company for the financial year 2021-22 will also be available on the Company's website at www.kilitch.com and website of the stock exchanges.

3. Pursuant to the provisions of the Act, a Member entitled to attend and vote at the AGM is entitled to appoint a proxy to attend and vote on his/her behalf and the proxy need not be a Member of the Company. Since this AGM is being held pursuant to the MCA Circulars through Video Conferencing or Other Audio Visual means, physical attendance of Members has been dispensed with. Accordingly, Attendance Slip and Proxy Form are not annexed to this Notice. However, in pursuance of Section 112 and Section 113 of the Companies Act, 2013, representatives of the members such as the President of India or the Governor of a State or body corporate can attend the 30th AGM through VC/OAVM and cast their votes through e-voting.

4. The Company's Registrar and Share Transfer Agents (RTA) are: Link Intime India Private Limited having its office at C - 101, 247 Park, LBS Marg, Vikhroli (West), Mumbai - 400083, Maharashtra India. Tel: 022 49186000

5. The members who have not yet registered their e- mail ids with the Company may contact **Link Intime India Private Limited,** on rnt.helpdesk@linkintime.co.inor 022- 49186000 for registering their e-mail ids before Wednesday, 21st September, 2022. The Company shall send the Notice to such members whose e-mail ids get registered within the aforesaid time enabling them to participate in the meeting and cast their votes. If there is any change in the e-mail ID already registered with the Company, members are requested to immediately notify such change to the Company or its RTA in respect of shares held in physical form and to DPs in respect of shares held in electronic form.

6. Members holding shares in the same set of names under different ledger folios are requested to apply for consolidation of such folios along with share certificates to the Company.

7. As per Regulation 40 of SEBI Listing Regulations, as amended, securities of listed companies can be transferred only in dematerialized form with effect from 1st April, 2019, except in case of request received for transmission or transposition of securities. In view of this and to eliminate all risks associated with physical shares and for ease of portfolio management, members holding shares in physical form are requested to consider converting their holdings to dematerialized form. Members can contact the Company or Company's Registrar and Share Transfer Agents, Link Intime India Private Limited for assistance in this regard.

8. Members holding shares in physical form are requested to consider converting their holdings to dematerialised form to eliminate all risks associated with physical shares and for ease of portfolio management. Members can contact the Company or RTA for assistance in this regard.

9. To prevent fraudulent transactions, members are advised to exercise due diligence and notify the Company of any change in address or demise of any member as soon as possible. Members are also advised not to leave their Demat account(s) dormant for long. Periodic statement of holdings should be obtained from the concerned depository participant and holdings should be verified.

10. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in electronic from are, therefore requested to submit the PAN to their Depository Participants with whom they are maintaining their Demat accounts. Members holding shares in physical form can submit their PAN details to the Company or RTA.

11.The Company has designated pushpanyoupane@kilitch.com e-mail id for quick redressal of shareholders/investors grievances.

12. In accordance with the provisions of Section 108 and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and amendments thereto and applicable provisions of the SEBI Listing Regulations, the Company has engaged the services of **Link Intime India Private Limited** to provide the facility of voting through electronic means to the members to enable them to cast their votes electronically in respect of all the businesses to be transacted at the aforesaid Meeting.

13. The **Register of Members and Share Transfer Books of the Company shall remain closed from Thursday, 22nd September, 2022 to Thursday, 29th September, 2022** (both days inclusive).

14. Members are requested to note that dividends if not encashed for a consecutive period of 7 years from the date of transfer to Unpaid Dividend Account of the Company are liable to be transferred to the Investor Education and Protection Fund. The shares in respect of such unclaimed dividends are also liable to be transferred to the demat account of the IEPF Authority. Once the amount and shares are transferred by the Company to IEPF, no claim thereof shall lie against the Company. In view of this, members are requested to claim their dividends from the Company, within the stipulated timeline. The Members, whose unclaimed dividends/shares have been transferred to IEPF, may claim the same by making an application to the IEPF Authority in Form No. IEPF - 5 available on www.iepf.gov.in.

15. All the members wishing to ask the questions during the 30th Annual General Meeting of the Company shall forward them to the corporate office of the Company at 37, Ujagar Industrial Estate, W. T. Patil Marg, Deonar, Mumbai - 400088.

16. The Register of Directors and Key Managerial Personnel and their shareholding and Register of Contracts arrangement in which the directors are interested will be available for inspection by the members at the AGM.

17. The Company is providing facility for voting by electronic means (e-voting) through an electronic voting system which will include remote e-voting as prescribed by the Companies (Management and Administration) Rules, 2014 as presently in force and the business set out in the Notice shall be transacted through such e-voting facility.

18. The facility of e-voting through the same portal provided by **Link Intime India Private Limited** will be available during the Meeting through VC also to those Members who do not cast their votes by remote e-voting prior to the Meeting. Members, who cast their votes by remote e-voting, may attend the Meeting through VC but shall not be entitled to cast their votes once again.

19. Voting rights of the members for voting through remote e-voting or e-voting system provide in the Meeting itself shall be in proportion to shares of the paid-up equity share capital of the Company as on the **cut-off date i.e. Wednesday, 21st September, 2022.** A person, whose name is recorded in the Register of Members or in the Register of Beneficial owners (as at the end of the business hours) maintained by the depositories as on the cut-off date shall only be entitled to avail the facility of remote e-voting or e- voting facility to be provide in the Meeting. In case of joint holders attending the Meeting, only such joint holder who is higher in the order of names shall be entitled to vote.

20. The remote **e-voting facility shall commence on Sunday, 25th September, 2022 (9:00 a.m.IST) and ends on Wednesday, 28th September, 2022 (5:00 pm IST).** The e- voting Module shall be disabled by Link Intime India Private Limited for voting thereafter. Once the vote on a resolution is cast by a member, it cannot be changed subsequently.

21. The Scrutiniser (Deep Shukla & Associates, Company Secretaries) shall, immediately after the conclusion of voting at the AGM, will first count the votes cast at the meeting, thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and will make, not later than 48 hours from the conclusion of the AGM, a consolidated scrutiniser's report of the total votes cast in favour or against, if any, to the Chairperson or a person authorised by him in writing who shall countersign the same. The Chairperson or a person authirised by him in writing will declare the results of voting forthwith.

22. The voting results declared along with the report of the scrutinizershall be placed on the Company's website at www.kilitch.com and on the website of Link Intime India Private Limited immediately after the result is declared by the Chairman and simultaneously communicated to the Stock Exchanges.

23. Corporate members intending to send their authorized

representatives to attend the Meeting are requested to send to the Company a certified copy of the Board Resolution authorizing their representative to attend and vote on their behalf at the Meeting.

24. Nomination Facility: As per the provisions of Section 72 of the Act and Rule 19(1) of the Companies (Share Capital and Debentures) Rules, 2014, as amended, Members holding shares in physical form may file nomination in the prescribed Form SH-13 with the Company's Registrar and Share Transfer Agent. In respect of shares held in dematerialized form, the nomination form may be filed with the respective Depository Participant.

25. Members attending the AGM through Video Conferencing / Other Audio Visual Mode shall be counted for the purpose of reckoning the quorum under Section 103 of the Act.

26. Since the AGM will be held through Video Conferencing / Other Audio Visual Mode, the Route Map is not annexed in this Notice.

27. In order to exercise strict control over the transfer documents, members are requested to send the transfer documents/ correspondence, if any, directly to:

UNIT: KILITCH DRUGS (INDIA) LIMITED
CC: Link Intime India Private Limited
Registrar & Share Transfer Agent
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai - 400083.
Tel: 022- 49186000; Fax: 022-49186060

Explanatory statement pursuant to section 102of the Companies Act, 2013

Item No: 3
The present Authorised Share Capital of the Company is Rs. 20,00,00,000 (Rupees Twenty crore) comprising of 2,00,00,000 (two crore) Equity Shares of Rs.10/- each. Considering the increased fund requirements of the Company, the Board at its Meeting held on 10th August, 2022, had accorded its approval for increasing the Authorised Share Capital from Rs. 20,00,00,000 (Rupees Twenty crore) to Rs. 25,00,00,000 (Rupees Twenty Five Crore), subject to shareholders approval.

It is therefore proposed to increase the Authorised Share Capital of the Company from Rs. 20,00,00,000 (Rupees Twenty crore) to Rs. 25,00,00,000 (Rupees Twenty Five Crore) comprising of 2,50,00,000 equity share of Rs.10/- each ranking pari passu with the existing Equity Shares in all respects as per the Memorandum and Articles of Association of the Company.

Consequently, Clause V of the Memorandum of Association would also require alteration so as to reflect the changed Authorised Share Capital.

The proposal for increase in Authorised Share Capital and amendment of Memorandum of Association of the Company requires approval of members at a general meeting.

The consent of the members is, therefore, being sought for passing the resolution mentioned in item no. 3 of the notice as an Ordinary Resolution.

None of the Directors or Key Managerial Personnel of the Company or their respective relatives, are in any way concerned or interested, financially or otherwise in the said resolution.

Item No: 4
The Board of Directors of the Company ('the Board') at the meeting held on 10th August, 2022, on the recommendation of the Audit Committee, approved the appointment and remuneration of M/s Arvind Kumar & Co. Cost Accountants (Firm Registration No. 000646), as a Cost Auditor, to conduct audit of Cost Records maintained by the Company for the financial year 2022-23.

In terms of Section 148 of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014, the remuneration of the Cost Auditor needs ratification by the Members.

None of the Directors and Key Managerial Personnel of the Company, or their relatives, is interested in these Resolutions. The Board recommends these Resolutions for your approval.

For & on behalf of Board of Directors of
Kilitch Drugs (India) Limited

Sd/-

Pushpa Nyoupane
Company Secretary
Place: Mumbai
Date: 10th August, 2022
Registered Office:
C-301/2, M.I.D.C. TTC Industrial Area,
Pawane Village, Navi Mumbai: 400 705

KILITCH DRUGS (INDIA) LIMITED

Annexure to Notice
Details of Directors seeking appointment/re-appointment at the Annual General Meeting

[In pursuance of Clause 36 (3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015]

Name of Director	Mr. Bhavin Mehta
Date of Birth	30/09/1976
Actual date of Appointment	29/09/2007
Qualifications	Post Graduate Diploma in Management & Bachelor of Pharmaceutical Sciences,
Expertise in Specific Functional Area	25 years of experience in phramaceutical industry with good command over international market
Directorships held in other listed companies (As on 31st March, 2022)	NIL
Chairmanships/ Memberships of the Committees of the Board of Directors of other listed companies (As on 31st March, 2022)	NIL
Shareholding of Directors (As on 31st March, 2022)	20,02,416 equity shares (12 .85 %)
Relationship between Directors inter -se	Son of Mr. Mukund Mehta, Managing Director and Husband of Mrs. Mira Mehta

The instructions for remote e-voting are as under:

i. In compliance with the provisions of Section 108 of the Act and Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the Listing Regulations, the Company provides to Members the facility of exercising their right to cast vote(s) before or at the AGM by electronic means and the business may be transacted, accordingly.

ii. The facility of casting votes by the Members using an electronic voting system from a place other than the venue of the AGM ("remote e-voting") and e-voting at the AGM is being provided by the Link Intime India Private Limited ("RTA")

iii. The voting rights of Members shall be in proportion to their shareholding in the paid-up equity share capital. A person, whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Company / RTA / depositories **as on the record date ("Cut-off" Date), Wednesday 21st September, 2022** shall only be entitled to avail the facility of remote e-voting or e-voting at the AGM.

iv. In this regard, the Member's demat account/ folio number as on the Cut-off Date shall be considered by the Company for participation in voting on resolutions placed by the Company on the e-voting system.

v. **Members can opt for only one mode of voting i.e. either by remote e-voting or e-voting at the AGM.** Members attending the AGM, who have not cast their vote(s) earlier by remote e-voting shall be able to exercise their right at the Meeting through e-voting at the AGM. Member(s) who have cast their vote(s) by remote e-voting prior to the AGM, may also attend/ participate in the AGM through VC/OAVM but shall not be entitled to cast their vote(s) again.

vi. The e-voting period begins on **Sunday, 25th September, 2022 at 9.00 a.m. and ends on Wednesday, 28th September, 2022 at 5.00 p.m.** During this period, Members of the Company, holding shares either in physical form or in dematerialised form, as on the **Cut-off Date** may cast their vote(s) electronically. The remote e-voting module shall be disabled for voting thereafter. Once the vote on a resolution is cast by the Member, the Member shall not be allowed to change it subsequently.

vii. A person who is a Member as on the Cut-off Date shall only be entitled for availing the facility of remote e-voting or e-voting at the Meeting. A person who is not a Member as on the Cut-off Date should treat this Notice for information purpose only.

viii. The procedure for casting vote through remote e-voting module is as under:

Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 9th December, 2020 on "e-voting facility provided by Listed Companies", e-voting process has been enabled for all the individual demat account holders, by way of single login credential, through their respective demat account / website of Depositories / DPs in order to increase the efficiency of the voting process.

Individual demat account holders would be able to cast their vote without having to register again with the e-voting service provider.

Accordingly, Members are advised to update their mobile number and email ID in their demat accounts to access e-voting facility.

Login method for Individual shareholders holding securities in demat mode/physical mode is given below: -

Type of Shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL	**1. User already registered for NSDL IDeAS facility** i. Please visit the e-Services website of NSDL at the URL: https://eservices.nsdl.com. ii. Once the home page of e-Services is launched, click on the 'Beneficial Owner' icon under 'Login' which is available under 'IDeAS' section. iii. On the new screen, please enter your User ID and Password. iv. After successful authentication, you will be able to see e-voting services. Click on 'Access to e-voting' under e-voting services. v. On the e-voting page, you will see Company's name or e-voting service provider's name. Click on Company name or that of the e-voting service provider. vi. You will be re-directed to e-voting service provider's website for casting

	your vote during the remote e-voting period or for joining virtual Meeting and voting during the Meeting. **2. User not registered for NSDL IDeAS facility** i. Option to register is available at the link https://eservices.nsdl.com. ii. Select 'Register Online for IDeAS' or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp. iii. Visit the e-voting website of NSDL and follow the steps given in point 1 under this section. **3. Alternatively by directly accessing the e-voting** i. Open web browser by typing the URL viz. https://www.evoting.nsdl.com. ii. Once the home page of e-voting system is launched, click on the icon 'Login' which is available under 'Shareholder/Member' section. iii. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number held with NSDL starting with IN – DP ID and Client ID), password/OTP and a verification code as shown on the screen. iv. After successful authentication, you will be redirected to NSDL's website wherein you can see e-voting page. Click on the Company's name or e-voting service provider's name and you will be redirected to e-voting service provider's website for casting your vote during the remote e-voting period or for joining virtual Meeting and voting during the Meeting.
Individual Shareholders holding securities in demat mode with CDSL	**1. Existing users who have opted for Easi / Easiest** I. Please visit the e-Services website of CSDL at the URL: https://web.cdslindia.com/myeasi/home/login or URL: www.cdslindia.com, thereafter, please click on New System 'Myeasi'. ii. On the new screen, please enter your User ID and Password for accessing Easi / Easiest. iii. After successful login of Easi / Easiest you will also be able to see the e-voting menu. The menu will have links of e-voting service provider's i.e. Link Intime, NSDL, CDSL and KFinTech. Click on e-voting service provider's name to cast your vote. **2. If the user is not registered for Easi/Easiest** i. An option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration. ii. Then visit the e-voting website of CSDL and follow the steps given in point 1 under this section. **3. Alternatively by directly accessing the e-voting page** I. You can directly access e-voting page by providing demat Account Number and PAN from the link www.cdslindia.com. ii. The system will authenticate your details by sending OTP on registered mobile and email ID as recorded in the demat Account. After successful authentication, you will enter the e-voting module of CDSL. Click on the e-voting link available against Company's name or e-voting service provider's name and you will be re-directed to the e-voting page of service provider to cast your vote.
Individual Shareholders (holding securities in demat mode) and login through their depository participants	1. Users can also login using the login credentials of their Demat Account through their Depository Participant registered with NSDL/CDSL for e-Voting facility. 2. When you login, you will see e-Voting option.

	Once you click on the same, you will be redirected to NSDL/CDSL sites after successful authentication, wherein you can see e-Voting feature. 3. Click on Company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining the virtual meeting and voting during the meeting.
Individual Shareholders holding securities in Physical mode and e-Voting Service Provider is LINKINTIME i.e. RTA.	1. Open the internet browser and launch the URL: https://instavote.linkintime.co.in 2. Click on 'Sign Up' under '**SHARE HOLDER**' tab and register with your following details: - **A. User ID:** Shareholders/members holding shares in physical form shall provide Event No + Folio Number registered with the Company. **B. PAN:** Enter your 10-digit Permanent Account Number (PAN) (Members who have not updated their PAN with the Depository Participant (DP)/ Company) shall use the sequence number provided to you, if applicable. **C. DOB/DOI:** Enter the Date of Birth (DOB)/Date of Incorporation (DOI) (As recorded with your DP/ Company - in DD/MM/YYYY format). **D. Bank Account Number:** Enter your Bank Account Number (last four digits), as recorded with your DP/Company. Shareholders holding shares in physical form but have not provided or updated the information at 'C' or 'D' with their RTA/ Company, should provide their Folio number in 'D' above. 3. Set the password of your choice (The password should contain minimum 8 characters, at least one special Character (@!#$&*), at least one numeral, at least one alphabet and at least one capital letter). 4. Click "confirm" (Your password is now generated). 5. Click on 'Login' under **'SHARE HOLDER'** tab. 6. Enter your User ID, Password and Image Verification (CAPTCHA) Code and click on **'Submit'**. 7. After successful login, you will be able to see the notification for e-voting. Select **'View'** icon. 8. E-voting page will appear on the screen. 9. Refer the Resolution description and cast your vote by selecting your desired option **'Favour / Against'** (If you wish to view the entire Resolution details, click on the **'View Resolution'** file link). 10. After selecting the desired option i.e. '**Favour/ Against'** click on **'Submit'**. A confirmation box will be displayed. If you wish to confirm your vote, click on **'Yes'**, else to change your vote, click on **'No'** and accordingly modify your vote. 11. Once you confirm, you will not be allowed to modify your vote subsequently. During the voting period, Members can login any number of times till you have voted on the resolution(s) for a particular **"Event"**.

ix. If Individual Shareholders, holding securities in **"PHYSICAL MODE"**, whose evoting service provider is LINKINTIME and who have **"FORGOTTEN"** their password, the follow the below steps:

a. Click on 'Login' under **'SHARE HOLDER'** tab and further Click 'forgot password?'

b. Enter **User ID**, select **Mode** and Enter Image Verification (CAPTCHA) Code and Click on **'Submit'**.

c. Shareholders/Members having valid email address, the Password will be sent to his/her registered e-mail address. Else, Shareholders/Members can set the password of his/her choice by providing the information about the particulars of the Security Question and Answer, PAN, DOB/DOI, Bank Account Number (last four digits) etc. as mentioned above. (The Password should contain minimum 8 characters, at least one special character (@!#$&*), at least one numeral, at least one alphabet and at least one capital letter.)

Important Note :

- Shareholders/Members holding shares in physical form, the details can be used only for voting on the Resolutions contained in this Notice.
- It is strongly recommended not to share your Password with any other person and take utmost care to keep your password confidential.

x. If Individual Shareholders holding securities in **dematerialised mode** are unable to retrieve User ID/ Password are advised to use Forgot User ID and Forgot Password options available at the Depository's /DP's website.

Important note:

- It is strongly recommended not to share your password with any other person and take utmost care to keep it confidential.
- During the voting period, Members can login any number of times till they have voted on the resolution(s) for a particular "Event".

Helpdesk of Depositories "for Individual Shareholders holding securities in DEMAT"

Shareholders/Members holding securities **in demat mode** may contact the respective helpdesk given below for any technical issues related to login through Depository i.e. NSDL/CDSL:

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free nos.: 1800 1020 990 and 1800 22 44 30
Individual Shareholders holding securities in demat mode with CDSL	Members facing technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022 - 2305 8738 or 022 - 2305 8542/43.

General Guidelines for shareholders:

i. Institutional shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on the e-voting system of Link in Time Pvt. Ltd. (LIIPL) at https://instavote.linkintime.co.in and register themselves as **'Custodian/ Mutual Fund/Corporate Body'**.

ii. They are also required to upload a scanned certified true copy of the Board Resolution/Authority Letter/Power of Attorney, etc. together with attested specimen signature of the duly authorised representative(s) in PDF format in the 'Custodian/Mutual Fund/Corporate Body' login for the Scrutinizer to verify the same.

iii. Members holding multiple folios/demat accounts shall choose the voting process separately for each of the folios/demat accounts.

iv. Any person who acquires shares of the Company and becomes a Member of the Company after the dispatch of this AGM Notice and holds shares as on the Cut-off Date may obtain the login id and password by sending a request at rnt.helpdesk@linkintime.co.in/ insta.vote@linkintime.co.in or call on 022 - 49186175 / 49186000.

Helpdesk for Individual Shareholders holding securities in physical mode/Institutional shareholders and e-Voting service Provider is LINKINTIME.

In case Shareholders/Members holding securities in physical mode/Institutional shareholders have any queries regarding e-Voting, they may refer the **Frequently Asked Questions ('FAQs') and InstaVote e-Voting manual available** at https://instavote.linkintime.co.in, under **Help Section** or send an email to enotices@linkintime.co.in or contact on: - Tel: 022 - 4918 6000.

1. Instructions for Members to Vote during the AGM through InstaMeet (VC/OAVM):

Once the electronic voting is activated by the Scrutiniser during the Meeting, the Members who have not exercised their vote(s) through the remote e-voting can cast their vote(s) as under:

i. On the Member's page/VC page, click on the link for e-voting **"Cast your vote"**.

ii. Enter demat account no. / folio no. and **OTP** (One Time Password), received on the registered mobile number/ registered e-mail ID, during registration for InstaMeet and click on **'Submit'**.

iii. After successful login, see "Resolution Description" and against the same the options **"Favour/ Against"** for voting.

iv. Cast vote by selecting appropriate option i.e. Favour/Against, as desired.

v. Enter the number of shares (which represents no. of votes) as on the Cut-off Date under 'Favour/ Against'. You may also choose the option 'Abstain' and the shares held will not be counted under 'Favour/Against'.

vi. After selecting the appropriate option i.e. Favour/ Against as desired, click on **"Save"**. A confirmation box will be displayed. If you wish to confirm your vote, click on "Confirm", else to change your vote, click on **"Back"** and accordingly modify your vote.

vii. Once the vote is confirmed on the resolution, any modification or change is not allowed subsequently.

Notes:
Members who will be present in the AGM through InstaMeet facility and have not cast their vote(s) on the resolutions through remote e-voting and/are otherwise not barred from doing so, shall be eligible to vote through e-voting facility during the Meeting.

Members who have voted through remote e-voting prior to the AGM will be eligible to attend/participate in the Meeting through InstaMeet. However, they will not be eligible to vote again during the Meeting.

In case the members have any queries or issues regarding e-voting, you may write an email to instameet@linkintime.co.in or call on: 022 - 49186000 / 49186175 InstaMeet support desk, of the RTA.

2. Instructions for Members attending the AGM through InstaMeet:

Instructions for Members to attend the AGM through InstaMeet are as under:

a) Members are entitled to attend the AGM through VC/OAVM provided by the RTA by following the below mentioned process. Facility for joining the AGM through VC/ OAVM shall be open 30 minutes before the time scheduled for the AGM and shall expire 15 minutes after the scheduled time of the Meeting, and will be available to the Members on first come first serve basis.

b) Members are requested to participate on first come first serve basis as participation through VC/OAVM is limited and will be closed on expiry of 15 minutes from the scheduled time of the AGM. Members with >2% shareholding, Promoters, Institutional Investors, Directors, Key Managerial Personnel, Chairpersons of Audit Committee, Nomination and Remuneration Committee, Stakeholders' Relationship Committee, Risk Management Committee and Auditors, etc. may be allowed to attend the Meeting without restrictions of first come first serve basis. Members may log-in and join 30 minutes prior to the scheduled time of the Meeting and window for joining shall be kept open till the expiry of 15 minutes after the scheduled time.

c). Members will be provided with InstaMeet facility wherein they shall register their details and attend the AGM as under:

➡ Open the internet browser and launch the URL for InstaMeet https://instameet.linkintime.co.in and register with following details:

a) DP ID / Client ID or Beneficiary ID or Folio No.: Enter your 16 digit DP ID / Client ID or Beneficiary ID or Folio Number registered with the Company

- Members holding shares in CDSL demat account shall provide 16 Digit Beneficiary ID

- Members holding shares in NSDL demat account shall provide sixteen digit demat number - 8 Character DP ID followed by 8 Digit Client ID

- Members holding shares in physical form shall provide Folio Number registered with the Company

b) PAN: Enter your 10-digit PAN. (Members who have not updated their PAN with the DP/Company shall use the sequence number provided to them, if applicable)

c) Please enter your mobile number.

d) Please enter your email ID as recorded with your DP/RTA/Company.

➧ Click on "Go to Meeting". You are now registered for InstaMeet and your attendance is marked for the meeting.

3. Instructions for Members to register themselves as speakers during AGM:

a) Members who would like to express their views/ ask questions during the Meeting may register themselves as a speaker by sending their request mentioning their name, demat account number/ folio number, e-mail address, mobile number at pushpanyoupane@kilitch.com on or before **24th September, 2022.**

b) Members will receive "speaking serial number" once they mark attendance for the Meeting.

c) Other Members may ask questions to the panelist(s), via active chat-board during the Meeting.

d) Please quote your serial number and start your conversation with panelist(s) by switching on the video and audio of your device.

e) Members who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.

f) Members are requested to speak only when the moderator of the Meeting will announce the name and serial number for speaking.

g) The caption/subject of the email may please be mentioned as "Speaker for AGM_<DP ID>_<Client ID>". Those Members who have registered themselves as speaker will only be allowed to express their views / ask questions during the Meeting. The Company reserves the right to restrict the number of speakers depending on the availability of time for the AGM.

h) Members, who would like to ask questions, may send their questions in advance mentioning their name demat account number/folio number, email ID, mobile number at pushpanyoupane@kilitch.com The same will be replied by the Company, suitably.

I) Members should be allowed to use camera and required to use internet with a good speed (preferably 2 MBPS download stream) to avoid any disturbance while speaking.

4. M/s Deep Shukla & Associated, Company Secretaries (Membership No. FCS: 5652; CP No. 5364) has been appointed as the Scrutinizer to scrutinize the remote e-voting and ensure that the voting process at the AGM is conducted in a fair and transparent manner and issue a report on the votes through remote e-voting and those cast at the AGM.

5. Declaration of results on the resolutionns:

a) The Scrutiniser shall, immediately after the conclusion of voting at the AGM, count the votes cast at the Meeting, thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company. The Scrutiniser shall make, not later than two working days from conclusion of the Meeting, a consolidated Scrutiniser's Report of the total votes cast in favour or against each resolution, invalid votes, if any, and whether the resolution(s) has/ have been carried or not. This report shall be submitted to the Chairperson or a person authorised by him, in writing, who shall countersign the same.

b) The results shall be declared after the AGM of the Company and shall be deemed to be passed on the date of AGM. The results along with the Scrutiniser's Report shall be placed on the website of the Company www.kilitch.com within two working days of passing of the resolutions at the AGM of the Company and shall be communicated to BSE Limited (BSE) and National Stock Exchange of India Limited (NSE), where the Company's equity shares are listed. RTA, who has provided the platform for facilitating remote e-voting, will also display these results on its website https://instavote.linkintime.co.in The said results shall also be displayed at the registered office of the Company.

6. Members may note that the Notice will also be available on the Company's website www.kilitch.com, RTA's website https://instavote.linkintime.co.in ; websites of the stock exchanges i.e. BSE Limited at www.bseindia.com and The National Stock Exchange of India Limited at www.nseindia.com

7. Members are requested to kindly keep the Annual Report sent to their registered e-mail ID with them while attending the AGM through VC/ OAVM.

8. The recorded transcript of the AGM, shall also be made available on the website of the Company www.kilitch.com under the tab of 'Investor'.

KILITCH DRUGS (INDIA) LIMITED

Guidelines to attend the AGM Proceedings of Link Intime India Private Limited: InstaMEET

i. Please refer the following instructions for the software requirements and kindly ensure to install the same on the device which would be used to attend the AGM. You may also call upon the InstaMeet Support Desk for any support on the dedicated number provided to you below / at InstaMeet website.

ii. Guidelines for the registered speakers for speaking at the AGM through Link Intime India Private Limited's InstaMeet <<https://instameet.linkintime.co.in>>

a) For a smooth experience of viewing the AGM proceedings through LIIPL's InstaMEET, shareholders/ members who are registered as speakers for the event i.e. AGM, are requested to download and install the Webex Meetings application in advance. Please download and install the Webex Meetings application by clicking on the link https://www.webex.com/downloads.html/

OR

b) If you do not want to download and install the Webex Meetings application, you may join the meeting through InstaMEET and follow the process mentioned as under:

Step 1	Enter your First Name, Last Name and Email ID and click on Join Now
1(A)	If you have already installed the Webex Meetings application on your device, join the meeting by clicking on Join Now
1(B)	If Webex Meetings application is not installed, a new page will appear giving you an option to either Add Webex to chrome or Run a temporary application. Click on Run a temporary application, an exe file will be downloaded. Click on this exe file to run the application and join the meeting by clicking on Join Now by filling your first name, last name and email address.

iii. The following URLs need to be white-listed in your own laptop, desktop, tablet, smartphone etc. on the AGM date:
A. https://camonview.com
B. https://instameet.linkintime.co.in

iv. Members are encouraged to join the Meeting through tablets/ laptops connected through broadband for better experience.

v. Members are required to use internet with a good speed preferably 2 MBPS download stream to avoid any disturbance during the Meeting.

vi. Any internet outage or fluctuation in connectivity at your site may have an adverse impact on the audio/ video quality during the meeting. LIIPL or the Company shall not be responsible for the same.

vii. In case the members have both the computer and telephone audio active or the speakers on members' computers or telephones are too close to each other or there are multiple computers with active audio in the same room, there will be instances of audio echo in the meeting.

viii. In case two or more Members are joining the meeting through a Board Room/Common Location, proper arrangements of audio & video should be in place and Webex will be run on only one system.

ix. Please note that Members connecting from mobile devices or tablets or through laptops connecting via mobile hotspot may experience Audio/Visual loss due to fluctuation in their network. It is, therefore, recommended to use stable Wi-Fi or LAN connection to mitigate any kind of aforesaid glitches.

x. Members are encouraged to speak in the Meeting after un-muting themselves once their turn arrives as per the name announcement. Once the member has finished communicating, he/she should mute themselves immediately. (Mute your device if you're not speaking. Your microphone can pick up a lot of background noise, so muting allows others to easily hear others)

xi. In case the Members have any queries or issues regarding login/ e-voting, they can write an e-mail to instameet@linkintime.co.in or call on 022 - 49186175 / 49186000, the InstaMeet support desk.

21
22
Annual Report

KILITCH DRUGS (INDIA) LIMITED



In pursuit of
Growth and Excellence

Contents

Kilitch Group: Contributing for affordable, equitable and Sustainable Healthcare	**01**
Letter from the Managing Director	**04**
Directors' Report	**05**
Management Discussion and Analysis	**14**
Secretarial Audit Report	**20**
Report on Corporate Governance	**26**
FINANCIAL STATEMENTS	
Standalone	**40**
Consolidated	**87**



Visit:
www.kilitch.com
to view our report online

Cautionary Statement

Certain statements made in the Management Discussion and Analysis Report relating to the Company's objectives, projections, outlook, expectations, estimates, and others may constitute forward-looking statements within the meaning of applicable laws and regulations. Actual results may differ from such expectations, whether expressed or implied. Several factors could make a significant difference to our operations. These include climatic and economic conditions affecting demand and supply, government regulations and taxation, any epidemic or pandemic and natural calamities over which we do not have any direct/indirect control. Readers are cautioned not to place undue reliance on any forward - looking statements. The report should be read in conjunction with the Company's financial statements included herein and the notes thereto.

Corporate Information

Kilitch Drugs (India) Limited

Registered Office:

C-301/2, MIDC,
TTC Industrial Area, Pawane Village,
Navi Mumbai - 400 705.

Tel.: 022-62996300

Fax: 022-27680912

Corporate Office:

37, Ujagar Industrial Estate, W.T. Patil Marg, Deonar, Mumbai - 400 088.

Tel.: 022-61214100

Website: www.kilitch.com
Email: info@kilitch.com

Bankers

Kotak Mahindra Bank Ltd

Shamrao Vithal Co-op Bank Ltd

Registrar & Share Transfer Agents

Link Intime India Private Limited

C-101, 247 Park, LBS Marg,
Vikhroli (West), Mumbai - 400 083.

Tel.: 022-49186000

Fax: 022-49186060

Board of Directors

Mr. Mukund P. Mehta
Managing Director

Mr. Bhavin Mehta
Whole-time Director

Mrs. Mira Mehta
Whole-time Director

Mr. Hemang J. Engineer
Independent Director

Prof. Vasudev K. Murti
Independent Director

Mr. Venkita S. Rajan
Independent Director

Statutory Auditors

Suryaprakash Maurya & Co.
Chartered Accountants
Shop No. 5, Akshar Apt.,
M. B. Estate, Behind Ram Mandir, Virar (W),
Palghar - 401303

Secretarial Auditors

Deep Shukla & Associate
Company Secretaries
603/A Wing Maruti Bhuvan,
Parsi Panchayat Rd, Opp. Sona Udyog Industrial Estate,
Andheri East, Mumbai - 400069

Chief Financial Officer

Mr. Sunil Jain

Company Secretary and Compliance Officer

Ms. Pushpa Nyoupane
(w.e.f. 5th May, 2022)

KILITCH DRUGS (INDIA) LIMITED

Kilitch Group: Contributing for affordable, equitable and Sustainable Healthcare

Kilitch Drugs (India) Limited is a Pharmaceutical Manufacturing Company providing services ranging from manufacturing to marketing a host of formulations in all dosage form i.e. Solid, Liquid and Parental. Today with more than three decades of successful pharmaceutical solutions, new markets and partnership enhancement makes Kilitch stronger and more customer-centric.

The company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India & Ethiopia.

Manufacturing Units:

1) C-301/2, MIDC, TTC Industrial Area, Pawane Village, Navi Mumbai - 400 705.

2) House No. New, Lega Bari Lega Bolo Kebele, Barak Wereda, Oromia Special Zone Finfine Surrounding, Oromia, Ethiopia.

30+ Year of Presence

400+ Products registered across the world

450+ Products under Registration

Our Reach in **45+** Countries in Africa, CIS, Latam & Asia

LEADING Company with an Cephalosporin Formulation manufacturing facility at Ethiopia

Committed to improve the lives of people at large



KILITCH DRUGS (INDIA) LIMITED

Kilitch Estro Biotech

Africa is the future and Ethiopia is the 2nd most populous country in Africa. We are among the primary entrant with a state of art plant in Addis Ababa with commissioning of production in 2022.

The facility produces generic Cephalosporin in different dosage forms like Tables, Capsules, Injectable and Dry powder for suspension Syrups with an objective to lead in the African market.


It also manufactures antiseptics, disinfectants and laboratory reagents for local consumption.




Sustaining Growth with a purpose

The Company believe in total quality management system, with highly trained QA, QC, Production & engineering staff from India transferring their expertise know how to fellow Ethiopians for sustainable production of quality medicines. It has the best and genuine quality laboratories with specialized analytical instrument and control laboratories for testing raw materials and finished formulations.


Category & Brands





Geographic Presence

The Company has a leading presence in African Countries as well as several Asian Counties. It has a very strong presence in French speaking countries of Africa. The Company has also successfully forayed in Asian countries of Myanmar and Phillipines.



Map for illustration purpose only.

Setting a Path to Development

The company proposes to setup a New Green Field Pharmaceutical Project at Khopoli, Maharashtra, India for Development and Manufacturing of various Pharmaceutical product dosage to meet the requirements of World Health Organization (WHO), Schedule M, EU standard guidelines, USFDA GMP & other regulatory requirements.

The said project is estimated to be in operational by the financial year 2023-24 and shall provide exciting opportunities to growth and expansion of product portfolio.



Proposed Unit

KILITCH DRUGS (INDIA) LIMITED

Letter from the Managing Director



Expanding our own manufacturing capacities will ensure high quality products, more robust supply chain and reduce our dependency on outsourcing.

Dear Shareholder,

I sincerely hope that you and your family are safe and healthy. I am pleased to present to you the Annual Report for the year 2021-22 of Kilitch Drugs (India) Limited.

Last two years, we have seen unpredictable challenges and emergence of health crisis caused by the pandemic with severe impact on people, economics and businesses. This outbreak of COVID-19 has made people more conscious about health and wellness. This behavioral trend will define the journey of healthcare sector in the coming years.

Diversified revenue streams at Kilitch has led to consistent performance and sustainable practices. Kilitch has a well diversified business model in terms of products, therapics and markets. This enables us to mitigate the business risk from possible uncertain events in the business environment.

Green Field Project

Striving upon our beloved Prime Minister Shri Narendra Modi's vision of Aatmanirbhar Bharat, we are setting up a manufacturing plant in India to fortify our position in the injectable segment through increasing our capacities and introducing new dosage form with capex.

This facility with upgraded technology which will make our entry into semi and fully regulated international market and in turn to increase our export while playing impressive role in domestic market.

Expanding our own manufacturing capacities will ensure high quality products, more robust supply chain and reduce our dependency on outsourcing.

As you are well aware that company's manufacturing plant in Addis Ababa has started with the vision of becoming a formidable player in Ethiopia with a wide scope of development and expansion in African countries. This subsidiary has contributed positively in the growth and should add to profitability of the Company in coming years. I believe Kilitch will be very well positioned and shall benefit from the pharmaceutical trend in the coming decade.

Our employees being our most valued assets, we are continuously making efforts to build an engaged and progressive workforce. Making meaningful progress during such a challenging years would not have been possible without the tireless efforts of each of our employees and we are indebted to each of them.

The Company has been conducting business in a sustainable manner and in a way that delivers long-term shareholder value and create maximum value for the society.

To conclude, I would like to express sincerely gratitude to the Members of the Board for their constant contribution toward organisational growth. I would like to thank all employees, our shareholders, Government of India and foreign countries and all other associates for their continued faith, support and confidence towards us.

I hope this Diwali brings light in your life. Wish you a joyous and prosperous Diwali and New Year.

Warm Regards
Mukund Mehta
Managing Director

Total Revenue	EBITDA	PAT
(₹ in Lakh)	(₹ in Lakh)	(₹ in Lakh)
10,971.88	1,555.51	1,052.77

KILITCH DRUGS (INDIA) LIMITED

DIRECTORS' REPORT

To,
The Members,

The Board of Directors take pleasure in presenting 30th Annual Report on the business and operations of Kilitch Drugs (India) Limited ("the Company") along with its standalone and consolidated financial statements for the financial year ended 31st March, 2022.

1. Financial Performance (Standalone and Consolidated):

[Amount in Lakhs]

Particulars	Standalone		Consolidated	
	2021-22	2020-21	2021-22	2020-21
Revenue from Operations	10,515.98	7, 001.68	11,423.42	6,852.31
Other Income	455.90	419.43	290.93	266.73
Total Revenue	**10,971.88**	**7,421.11**	**11,714.35**	**7,119.04**
Total Expenses	9,579.06	6,670.28	10,752.91	6,607.08
Profit/(Loss) before exceptional and extraordinary items and tax	**1,392.82**	**750.83**	**961.44**	**511.96**
Exceptional Items	-	-	-	-
Extraordinary Items	-	-	-	-
Net Profit Before Tax	**1,392.82**	**750.83**	**961.44**	**511.96**
Provision for Tax				
- Current Tax	363.37	166.55	363.37	166.55
- Deferred Tax (Liability)/Assets	(23.32)	(31.26)	(23.30)	(31.25)
Net Profit After Tax	1,052.77	615.54	621.37	376.66
Profit/(Loss) from continuing operations	**1,052.77**	**615.54**	**621.37**	**376.66**
Other Comprehensive Income (After Tax)	198.15	522.87	198.15	522.87
Total Comprehensive income for the period (Comprising Profit (Loss) and Other Comprehensive Income for the period)	**1,250.92**	**1,138.41**	**819.52**	**899.53**
Paid up Equity Share Capital (Face Value Rs. 10/- per Share)	1,558.23	1,549.45	1,558.23	1,549.45
Earning per share (for continuing operation) (Amount in Rs.)				
- Basic	6.76	3.98	4.73	2.37
- Diluted	6.76	3.98	4.73	2.37

2. State of Company's Affairs

The financial statements for the year ended 31st March, 2022 has been prepared in accordance with the Indian Accounting Standards (IndAS) notified under section 133 of the Companies Act, 2013 (hereinafter referred to as "the Act" read with the Companies (Accounts) Rules, 2014. The estimates and judgement relating to the financial statements are made on a prudent basis so as to reflect true and fair manner, the form and substances of transactions and reasonably present the state of affairs.

2.1 Standalone Financial Results

During the year under review, the Company achieved income from operations of Rs. 10,515.98 lakh as compared to Rs. 7,001.68 lakh in the previous year. The total comprehensive income was Rs. 1,250.92 for the year ending 31stMarch, 2022 as compared to Rs. 1,138.41 lakh in the previous year.

During the year under review, there was no change in the nature of the business of the Company.

2.2 Consolidated Financial Results

During the year under review, the Company achieved income from operations of Rs 11,423.42 lakh as compared to Rs. 6,852.31 lakh in the previous year. The profit after tax was Rs. 819.52 lakh for the year ending 31 st March, 2022 as compared to profit after tax of Rs. 899.53 lakh in the previous year.

3. Dividend and Reserves

In order to conserve the resources for the further growth of the Company, your Directors think fit not to recommend any dividend for the year under review. The Board of Directors has decided to retain the entire amount of profits in the profit and loss account.

4. Share Capital

The Paid-up Equity Share Capital of the Company as on 1st April, 2021 was Rs.15,49,45,440/- comprising of 1,54,94,544 equity share capital of Rs. 10 each.

During the year under review, pursuant to Employee Stock Option Scheme, 2007 the Board of Directors of the Company approved the allotment of 67,470 Equity Shares at Rs. 10/- each on 20th April, 2021 and 20,305 equity shares at Rs. 10/- each on 13 th October, 2021.
The Paid-up Equity Share Capital of the Company as on 31st March, 2022 stood Rs. 15,58,23,190/- comprising of 1,55,82,319 Equity Shares of Rs.10 each.

Pursuant to the Company's Employees Stock Option Scheme (ESOPs) 2020 the Board of Directors, at their meeting held on Wednesday, 13 th October, 2021, approved grant of 1,05,264 ESOPs to eligible employees of the Company and its Subsidiary at an exercise price of Rs. 145/- per stock option.

5. Annual Return

Pursuant to Notification dated 28th August, 2020 issued by the Ministry of Corporate Affairs as published in the Gazette of India on 28th August, 2020, the details forming part of the extract of Annual Return in Form MGT-9 is not required to be annexed herewith to this report. However, the Annual Return will be made available at the website of the Company at https://kilitch.com/investor-relations/.

6. Management Discussion and Analysis Report

The Management Discussion and Analysis report including the result of operations of the Company for the year as required under Schedule IV of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 is appended to the Annual Report as Annexure - I

7. Details of Subsidiary Companies

As on 31 st March, 2022, the Company has two subsidiaries namely Monarchy Healthserve Private Limited and Kilitch Estro Biotech. In line with the requirements of the Act and Listing Regulations, the Company has formulated a policy for determining Material Subsidiaries and the same can be accessed on the Company's website at https://kilitch.com/investor-relations/

According to Section 129(3) of the Companies Act, 2013, financial statements of the Company are prepared in accordance with the relevant Indian Accounting Standard specified under the Act and the rules thereunder. A statement containing the salient features of the financial statements of the Company's subsidiaries in Form no. AOC-1 is appended as Annexure - II to the Board Report. The statement also provides the details of performance and financial position of each subsidiary.

8. Directors and Key Managerial Personnel

8.1 Appointments and Cessation of Directors and Key Managerial Personnel

Mr. Mukund Mehta, Managing Director of the Company (DIN: 00147876) was re-appointed as Managing Directors of the Company for a further term of 5 years with effect from 1st April, 2021 as per the recommendation made by Nomination and Remuneration Committee of the

Company and same was approved by the members at the 29th Annual General Meeting of the Company held on Wednesday, 29th September, 2021.

Mrs. Mira Mehta, Whole-time Director of the Company (DIN: 01902831), who was retiring by rotation at the 29th Annual General Meeting of the Company held on Wednesday, 29th September, 2021 was re-appointed by members at the said AGM.

Ms. Garima Trivedi, Company Secretary and Key Managerial Personnel of the Company had resigned from the Company with effect from 13th October, 2021 and Ms. Princy Asati, an associate member of the Institute of Company Secretaries of India was appointed as Company Secretary and Key Managerial Personnel of the Company with effect from 5th October, 2021.

Mrs. Princy Asati, an associate member of the Institute of Company Secretaries of India has resigned from the post of Company Secretary and Key Managerial Personnel with effect from 15th April, 2022.

Ms. Pushpa Nyoupane, an associate member of the Institute of Company Secretaries of India was appointed as Company Secretary and Key Managerial Personnel of the Company with effect from 5th May, 2022

8.2 Details of Directors re-appointment at the ensuing Annual General Meeting

In pursuance of Section 152 of the Companies Act, 2013, at-least two-third of the Directors (excluding Independent Directors) shall be subject to retirement by rotation. One-third of such Directors must retire from office at each AGM and a retiring director is eligible for re-appointment.

Mr. Bhavin Mehta, Whole-time Director of the Company (DIN: 00147895) retires by rotation and being eligible, offer himself for re-appointment. A resolution seeking shareholders' approval for his re- appointment forms part of the AGM Notice.

8.3 Key Managerial Personnel

As on 31st March, 2022, the following were the Key Managerial Personnel (KMP) of the Company in accordance with the provisions of Section 203 of the Act.
Mr. Mukund Mehta, Managing Director
Mr. Bhavin Mehta, Whole-time Director
Mrs. Mira Mehta, Whole-time Director
Mr. Sunil Jain, Chief Financial Officer
Mrs. Princy Asati, Company Secretary

During the year under review, Non-Executive Directors of the Company had no pecuniary relationship or transactions with the Company other than sitting fees, commission, and reimbursement of expenses incurred by them for the purpose of attending meetings of the Board/Committee(s) of the Company.

9. Board of Directors and Meeting

The Board of Directors of the Company is comprised of eminent persons with proven competence and integrity. Besides the experience, strong financial acumen, strategic astuteness and leadership qualities, they have a significant degree of commitment towards the Company and devote adequate time to the meetings and preparation. In terms of the requirement of the Listing Regulations, the Board has identified core skills, expertise, and competencies of the Directors in the context of the Company's businesses for effective functioning, which are detailed in the Corporate Governance Report.

During the year under review, 7 meetings of the Board of Directors were held. Details of the meetings of the Board and its Committee are furnished in the Report on Corporate Governance which forms part of this report.

Pursuant to provisions of part VII of the Scheduled IV of the Companies Act, 2013 and Regulation 25 of the SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015, one meeting of Independent Director was held on 13th August, 2021.

10. Declaration by Independent Director

Pursuant to Section 149(7) of the Companies Act, 2013 read with the rules made thereunder, all the Independent Directors of the Company have given the declaration that they meet the criteria of independence as laid down in section 149(6) of the Act and regulation 16(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

11. Annual Evaluation of Board, its Committee and Individual Directors

The Company has formulated a Policy for performance evaluation of the Board, Committee and other individual Director (including independent directors) which includes criteria for performance evaluation of Non-Executive Director and Executive Director.

In pursuant of section 134(3)(p) of the Companies Act, 2013 read with rules made thereunder and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors carried out the performance

evaluation of the Board as a whole and of its Committees and individual directors. A structured questionnaire was prepared after taking into consideration the various aspects of the Board's functioning, composition of the Board and its Committees, culture, execution and performance of specific duties, obligations and governance etc.

The Board of Directors took note of the observations on board evaluation carried out during the year as follows;

a) Observation of board evaluation carried out for the year - there were no observations in the Board Evaluation carried for the year

b) Previous year's observations and actions taken - there were no observations of the Board for the last financial year

c) Proposed actions based on current year observation - Not applicable

12. Audit Committee

The primary objective of the Committee is to monitor and provide effective supervision of the Management's financial reporting process, to ensure accurate and timely disclosures, with the highest levels of transparency, integrity and quality of financial reporting.

The Composition of the Audit Committee is in line with the provisions of Section 177 of the Act read with Regulation 18 of SEBI Listing Regulations. Chairman of the Audit Committee is an Independent Director. The details of the composition of the Audit Committee are given in the Corporate Governance Report which is part of this report.

13. Nomination and Remuneration Committee

In accordance with Section 178 and all other applicable provisions, if any, of the Act read with the rules issued thereunder and regulation 19 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have duly constituted Nomination and Remuneration Committee. Further, the Board of Directors on the recommendations of the Nomination and Remuneration Committee have put in place a Nomination and Remuneration Policy of the Company. The Company's remuneration policy is driven by the success and performance of the individual employees, senior management, executive directors of the Company and other relevant factors including the following criteria;

a) The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate Directors and employees.

b) Relationship of remuneration to performance is clear and meets appropriate performance industry benchmarks; and

Remuneration to Directors, Key Managerial Personnel and Senior Management involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the Company and its goals.

The information required under section 197 of the Act read with the Rule 5(1)(I) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 in respect of employees of the Company and Directors is enclosed as Annexure - III.

14. Stakeholders Relationship Committee

The composition of the Stakeholders Relationship Committee (SRC) is in line with Section 178 of the Act read with Regulation 20 of SEBI Listing Regulations. The details of the composition of the Stakeholders Relationship Committee are given in the Corporate Governance Report.

15. Directors Responsibility Statement

Pursuant to Section 134(3)(c) & 134(5) of the Companies Act, 2013, the Board of Directors of the Company hereby confirm that:
(a) in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;

(b) appropriate accounting policies been selected and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;

(c) proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) annual accounts have been prepared on a going concern basis; and

(e) internal financial controls were in place and that such internal financial controls are adequate and were operating effectively.

16. Statutory Auditors and Audit Report

At the 29th Annual General Meeting of the Company held on Wednesday, 29th September, 2021, the members had approved the appointment of M/s Suryaprakash Maurya & Co, Chartered Accountants (FRN:147410W) as Statutory Auditors of the Company for a period of five year to hold office from the conclusion of 29th AGM till the conclusion of 34th AGM to be held in the year 2026.

The Statutory Audit Report for the financial year 2021-22 on the financial statements of the Company forms part of the annual report. Auditors have expressed their unmodified opinion on the Standalone and Consolidated Financial Statements and their reports do not contain any qualifications, reservations, adverse remarks or disclaimer.

The Statutory Auditors of the Company have not reported any fraud as specified under Section 143(12) of the Act in the year under review.

17. Secretarial Auditors and Audit Report

Pursuant to the provisions of Section 204 of the Act and the Companies (Appointment and remuneration of Managerial Personnel) Rules, 2014, the Company has appointed M/s Deep Shukla & Associates, Company Secretaries as the Secretarial Auditor of Company to carry out the Secretarial Audit of the Company for a period of 5 years i.e. for the Financial Year 2020-21 to Financial Year 2025-26. The Report of the Secretarial Auditor for Financial Year 2021-22 is attached herewith as Annexure-IV. There are no qualifications, observations or adverse remarks, or disclaimer in the said report.

18. Annual Secretarial Compliance Report

M/s. Deep Shukla & Associates, Company Secretaries, have been appointed to give Annual Secretarial Compliance Certificate. The Annual Compliance Certificate is enclosed as Annexure-V to this report.

19. Internal Audit & Controls

The Company has in place adequate internal financial controls with reference to the financial statement. The Audit Committee of the Board periodically reviews the internal control systems with the management, Internal Auditors and Statutory Auditors. Significant internal audit findings are discussed and follow-ups are taken thereon.

Further, Mr. Agnel Fernandes was appointed as Internal Auditors of the Company pursuant to section 138 of the Companies Act, 2013.

20. Cost Auditors and Cost Audit

During the period under review, for the purpose of section 148 of the Act read with rules made thereunder maintaining of the cost accounting records were exempted considering the volume of the export made by the company. However, the Board of Directors of the Company ('the Board') at the meeting held on 10th August, 2022, on the recommendation of the Audit Committee, approved the appointment and remuneration of M/s Arvind Kumar & Co. Cost Accountants (Firm Registration No. 000646) as a Cost Auditor to conduct audit of Cost Records maintained by the Company for the financial year 2022-23.

21. Particulars of Loans, Investment and Guarantees

The particulars of loans, guarantee, and investments covered under the provisions of Section 186 of the Act have been disclosed in notes of the financial statements of the Company forming part of the annual report.

22. Particulars of Contracts and Arrangements with related parties.

During the year under review, all Related Party Transactions (RPTs) entered into by the Company were on an arms' length basis and in the ordinary course of business. These RPTs did not attract provisions of Section 188 of the Companies Act, 2013 and were also not material RPTs under Regulation 23 of the Listing Regulations. All related party transactions were approved by the Audit Committee and are periodically reported to the Audit Committee. Prior approval of the Audit Committee was obtained periodically for the transactions which were planned and/or repetitive in nature and omnibus approvals were also taken as per the policy laid down for unforeseen transactions.

None of the transactions with related parties falls under the scope of Section 188(1) of the Act. The information on transactions with related parties pursuant to Section134(3)(h) of the Act read with Rule 8(2) of the Companies (Accounts) Rules, 2014 in Form AOC-2 does not apply to the Company for the FY 2021-22 and hence the same is not provided. The disclosure of the transactions with related parties during FY 2021-22 as required under IndAS have been made in notes of the financial statements of the company forming part of the Annual Report.

During the year under review, the Policy was reviewed and amended by the Audit Committee and the Board of

Directors to encompass inter-alia the regulatory changes brought as per amendment in Regulation 23 of the Listing Regulations (effective from 1st January, 2022) as well to bring more clarity on certain other operational aspects as per industry benchmark.

In line with the requirements of the Act and the Listing Regulations, the Company has formulated a Policy on Related Party Transactions and the same can be accessed on the Company's website at https://kilitch.com/investor-relations/

23. Material Changes and Commitments affecting the financial position of the company

There was no material change / commitment affecting the financial position of the Company during the period from the end of the financial year under review to the date of the report.

24. Particulars of Energy Conservation, Technology Absorption, and Foreign Exchange Earnings and Outgo [Pursuant To Companies (Accounts) Rules, 2014]

24.1 Conversation of Energy

a) steps taken or impact on conservation of energy;

The use of energy is being optimized through improved operational methods. Continuous efforts are being made to optimize and conserve energy by improvement in production process. Even though its operations are not energy-intensive, significant measures are taken to reduce energy consumption by using energy-efficient equipment. The Company regularly reviews power consumption patterns in its all locations and implements requisite improvements/changes in the process in order to optimize energy/ power consumption and thereby achieve cost savings.

b) Steps taken for utilizing alternate sources of energy;

The Company has not made any investment for utilizing alternate source of energy.

c) Capital investment on energy conservation equipment;

The Company has taken adequate measures to conserve energy by way of optimizing usage of power.

24.2 Absorption of Technology:

a) The efforts made towards technology absorption:

The Company has been engaging with various Suppliers, Research Institutes, Analytical Service providers and technology providers for technical collaborations for product & process development, new packaging development, research-oriented projects, and analytical service support. Technical discussions were held to identify the appropriate technologies, solutions and development and process improvement support. This drives development of distinctive new products, ever improving quality standards and more efficient processes.

The Company uses the service of in-house designers as well as those of free-lancers in developing product designs as per the emerging market trends. The Company uses innovation in design as well as in technology to develop new products.

b) Benefits derived as a result of the above efforts:

As a result of the above, the following benefits have been achieved:

i. Better efficiency in operations,
ii. Reduced dependence on external sources for technology for developing new products and upgrading existing products,
iii. Expansion of product range and cost reduction,
iv. Greater precision,
v. Retention of existing customers and expansion of customer base,
vi. Lower inventory stocks resulting in low carrying costs.

c) The Company has not imported any technology during the year under review;

d) The Company has not expended any expenditure towards Research and Development during the year under review.

24.3 Foreign Exchange Earning And Outgo:

[Amount in Lakhs]

Particulars	2021-22	2020-21
Foreign Exchange Earned	5,088.34	1,893.26
Foreign Exchange Outgo	584.94	486.04

25. Corporate Social Responsibility Policy

Pursuant to the section 135 of the act, the Corporate Social Responsibility Committee of the Company has formulated and recommended to the Board, a Corporate Social Responsibility Policy (CSR Policy) indicating the activities to be undertaken by the Company which has been approved by the Board. The CSR Policy is displayed on the website of the Company at https://kilitch.com/investor-relations/.

Report on CSR activities undertaken by the Company is appended to this report as Annexure - VI.

Detailed composition of the CSR Committee and its meeting is given in detailed in the Report on Corporate Governance which forms part of the Annual Report.

26. Vigil Mechanism / Whistler Blower Policy

Pursuant to the provisions of Section 177 of the Companies Act, 2013 read with the rules made thereunder, the Company has formulated and implemented Vigil Mechanism/ Whistle Blower Policy for disclosing of any unethical behavior, actual or suspected fraud or violation of company's code of conduct and other improper practices or wrongful conduct by employees or directors of the Company. The Vigil Mechanism/ Whistle Blower Policy has been posted and is available on the website of the Company at https://kilitch.com/investor-relations/

27. Risk Management Policy

Pursuant to section 134(3)(n) of the Act, the Company has a Risk Management (RM) framework to identify, monitor, evaluate business risks and opportunities. The framework seeks to create transparency, minimize adverse impact on the business objectives and enhance the Company's competitive advantage.

The Risk Management framework defines the risk management approach across the enterprise at various levels including documentation and reporting. The framework helps in identifying risk trend, exposure and potential impact analysis at a Company Level.

The Risk Management Policy formulated by the Company has identifies the key business risks an also plans to mitigate the risks.

28. Disclosure as per the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013

As per the provisions of Section 4 of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, the Company has constituted an Internal Complaints Committee for redressal of complaints against sexual harassment.

There were no compliant relating to sexual harassment pending at the beginning of the financial year, received during the year and pending at the end of the financial year 2021-22.

29. Significant and Materials Orders passed by the Regulators or Courts

There were no significant and material orders passed by the Regulators / Courts which impact the going concern status of the Company and its future operations.

30. Internal Financial Control Systems and their adequacy

The Board has adopted policies and procedures for the governance of orderly and efficient conduct of its business, including adherence to the Company's policies, safeguarding its assets, prevention, and detection of frauds and errors, accuracy and completeness of the accounting records, and timely preparation of reliable financial disclosures. The Company's internal control systems are commensurate with the nature of its business, the size and complexity of its operations and such internal financial controls concerning the Financial Statements are adequate.

The Management evaluates the efficacy and adequacy of internal control system in the Company, its compliance with the operation systems, accounting policies and procedures of the Company.

31. Deposit from Public

The Company has not accepted any deposits from the public during the year under review. No amount on account of principal or interest on deposits from the public was outstanding as on 31st March, 2022.

32. Prevention of Insider trading

The Company has adopted a Code of Conduct for Prevention of Insider Trading in compliance with SEBI (Prohibition & Insider Trading) Regulation, 2015 duly amended and approved at its board meeting with a view to regulate trading in securities by Directors and Designated Employees of the Company.

33. Corporate Governance Report

We ensure that we evolve and follow the corporate governance guidelines and best practices sincerely not only to boost long-term shareholder value but also to respect minority rights. We consider it as our inherent responsibility to disclose timely and accurate information regarding our operations and performance as well as the leadership and governance of the Company.

Pursuant to the Listing Regulations, the Corporate Governance Report along with the Certificate from a Practicing Professionals regarding compliance of conditions of Corporate Governance is annexed as Annexure-VII and forms part of this Report.

34. Secretarial Standards

The Institute of Company Secretaries of India has mandated compliance with the Secretarial Standards on board meetings and general meetings. During the year under review, the Company has complied with the applicable Secretarial Standards.

35. Investor Education and Protection Fund (IEPF)

Pursuant to the provisions of Section 124 of the Act read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended ('IEPF Rules'), total amount of dividend remained unpaid / unclaimed for a period of seven consecutive years or more from the date of transfer to the Unpaid Dividend Account of the Company are liable to be transferred to the Investor Education and Protection Fund.

Further, all the shares (excluding the disputed cases having specific orders of the Court, Tribunal or any Statutory Authority restraining such transfer) on which dividends remain unpaid or unclaimed for a period of seven consecutive years or more from the date of transfer of dividend to Unpaid Dividend Account shall also be transferred to the demat account of the IEPF Authority as notified by the Ministry of Corporate Affairs within statutory timelines.

The following are the details regarding unclaimed dividend and their corresponding shares would become due to transferred to the IEPF on the dates mentioned below;

Financial Year Ended	Date of Declaration of Dividend	Last date for claiming unpaid dividend	Due date for transfer to IEPF
2017-18	27/09/2018	02/11/2025	02/12/2025
2018-19	30/09/2019	05/11/2026	05/11/2026

36. Employee Stock Option Scheme

36.1 Employee Stock Option Scheme, 2007

During the year under review, the Company has allotted 87,775 Equity Shares of Rs. 10 each upon exercise of stock options by eligible employees pursuant to Employee Stock Option Scheme, 2007.

There has been no material change in ESOP Scheme during the year. The ESOP Scheme is in compliance with Securities and Exchange Board of India (Share Based Employee Benefit) Regulations, 2014. The disclosures relating to ESOPs required to be made under the provisions of Rule 12 of the Companies (Share Capital and Debentures) Rules, 2014 is as follows:

Particulars	Options
Options Outstanding at the beginning of the year	1,06,030
Options granted	-
Options vested	1,06,030
Options exercised / settled	87,775
the total number of shares arising as a result of exercise of option	87,775
Options lapsed	729
The exercise price	10/-
Variation of terms of options	-
Money realized by exercise of options	8,77,750
Total number of options in force	17,526
Employee wise details of options granted to:-	
(I) Key managerial personnel	
1. Sunil Jain-Chief Financial Officer	-
2. Garima Trivedi- Company Secretary & Compliance Officer (upto 13th October, 2021) 3. Mrs. Princy Asati - Company Secretary & Compliance Officer (w.e.f 5th October, 2021)	-
(ii) any other employee who receives a grant of options in any one year of option amounting to five per cent or more of options granted during the year	-

(iii) identified employees who were granted option, during any one year, equal to or exceeding one per cent of the issued capital (excluding outstanding warrants and conversions) of the company at the time of the grant	-

36.2 Employee Stock Option Scheme, 2020

Pursuant to the Company's Employees Stock Option Scheme (ESOPs) 2020, the Board of Directors, at their meeting held on Wednesday, 13th October, 2021, approved grant of 1,05,264 ESOPs to eligible employees of the Company and its Subsidiary at an exercise price of Rs. 145/- per stock option. Detailed disclosure as required under the relevant provisions of the Act and SEBI regulations are given herein below;

Particulars	Options
Options Outstanding at the beginning of the year	-
Options granted	1,05,264
Options vested	-
Options exercised / settled	-
The total number of shares arising as a result of exercise of option	-
Options lapsed	-
The exercise price	-
Variation of terms of options	-
Money realized by exercise of options	-
Total number of options in force	-
Employee wise details of options granted to:-	-
(I) Key managerial personnel	
1. Sunil Jain-Chief Financial Officer	-
2. Garima Trivedi- Company Secretary & Compliance Officer (upto 13th October, 2021) 3. Mrs. Princy Asati - Company Secretary & Compliance Officer (w.e.f 5th October, 2021)	-
(ii) any other employee who receives a grant of options in any one year of option amounting to five per cent or more of options granted during the year	-
(iii) identified employees who were granted option, during any one year, equal to or exceeding one per cent of the issued capital (excluding outstanding warrants and conversions) of the company at the time of the grant	-

37. Acknowledgement

The Directors wish to convey their appreciation to all the investors, customers, vendors, employees, and consultants/advisors of the Company for their collective contribution to the Company's performance as well as sincere and dedicated services toward achievement of the Vision of the Company. The Directors take pleasure to thank the Central Government, State Governments, Government of other Countries and concerned Government departments for their continuous co-operation.

The Directors appreciate and value the contribution made by every member, employee, and their families Kilitch Drugs (India) Group.

For & on behalf of the Board of Directors of
Kilitch Drugs (India) Limited

sd/-
Mukund Mehta
Managing Director
[DIN: 00147876]

sd/-
Bhavin Mehta
Whole-Time Director
[DIN: 00147895]

Place: Mumbai
Date: 10th August, 2022

Annexure - I

Management Discussion and Analysis Report

1. Economy and Industry Outlook

Economic Review:

Global growth is projected to slow from an estimated 6.1 percent in 2021 to 3.6 percent in 2022 and 2023. The war in Ukraine has triggered a costly humanitarian crisis that demands a peaceful resolution. At the same time, economic damage from the conflict will contribute to a significant slowdown in global growth in 2022 and add to inflation. This crisis unfolds while the global economy was on a mending path but had not yet fully recovered from the COVID-19 pandemic, with a significant divergence between the economic recoveries of advanced economies and emerging market and developing ones. Multilateral efforts to respond to the humanitarian crisis, prevent further economic fragmentation, maintain global liquidity, manage debt distress, tackle climate change, and end the pandemic remain essential.The downside to global economic growth is likely to wane gradually throughout 2023.

Understandably, the crisis has clouded India's growth outlook as well. India's underlying economic fundamentals are strong and despite the short-term turbulence, the impact on the long-term outlook will be marginal.

Though the economic growth of the country for the current year set to slow, it will still be higher than it was before the pandemic. After recording the strongest GDP rebound in 2021, the Indian economy is progressively losing momentum as inflationary expectations remain elevated due to rising global energy and food prices. Real GDP is projected to grow by 6.9% in fiscal year 2022-23 and 6.2% in fiscal year 2023-24.

Industry Overview

The pharmaceutical industry, one of the top performing industries in the world, is under significant pressure to bring in cost-effective and innovative drugs. The discipline of precision medicine and genomic medicine has gained significant interest from researchers and healthcare providers globally. The pharmaceutical landscape has undergone a massive transformation with the emergence of new technologies, cost-effective, and more efficient manufacturing approaches. In addition, increasing investment flow in this space has impacted the market growth positively.

India's pharmaceutical sector forms a major component of the country's foreign trade, with attractive avenues and opportunities for investors. India supplies affordable and low-cost generic drugs to millions of people across the globe and operates a significant number of United States Food and Drug Administration (USFDA) and World Health Organization (WHO) Good Manufacturing Practices (GMP)-compliant plants. India has occupied a premier position among pharmaceutical manufacturing countries of the world.

Over the last few decades, the Indian Pharmaceutical industry has experienced rapid expansion. We can consider the time before 1970 as the first stage of pharma industry. At that time, the Indian market was dominated by foreign companies. Second stage covers 1970 to 1990 when several domestic companies began operations. 1990 to 2010 is the third stage, where liberalization led Indian components to launch operations in foreign countries.

India is the largest provider of generic drugs globally. India is one of the biggest suppliers of low-cost vaccines in the world. Because of the low price and high quality, Indian medicines are preferred worldwide, thereby rightly making the country the "Pharmacy of the World". Pharma sector currently contributes to around 1.72% of the country's GDP. According to the Indian Economic Survey 2021, the domestic market is expected to grow 3 times in the next decade. India's domestic pharmaceutical market is at US$ 42 billion in 2021 and likely to reach US$ 65 billion by 2024 and further expand to reach ~US$ 120-130 billion by 2030.

COVID-19 Pandemic

With the rise of COVID-19 pandemic, economics around the world have suffered and several businesses also experienced challenges in operations and supply chains again with the rise in 2nd wave of the pandemic in India. Domestic market growth in India was slightly impacted upto second wave of COVID-19 since first lockdown but it is seen an upward trend which has made a good rebound during second half of the year under review.

The Pharma Industry is at the forefront to combat COVID-19 and was gearing up to develop and manufacture vaccines and medicines to fight the virus, taking support of internal / external research. The pandemic has clearly highlighted the importance of a strong healthcare system. As India continues to fight COVID-19 and stabilise its

economic growth trajectory, it is the right time for the country to apply learning s from the challenges and best practices that emerged during the pandemic.

Business overview

Kilitch Drugs (India) Limited (hereinafter referred to as "the Company") is a pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia. Its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms with nearly four decades of creating safe pharmaceutical solutions and the ultimate purpose of making the world a healthier place.


The Company has been carrying on and has acquired experience with regard to the manufacture and marketing of a wide range of drugs and pharmaceutical products and is in possession of techniques, formulae, recipes, processes, standards, specifications and know how relating to the manufacture of such drugs and pharmaceutical products.

Over three decades of pharmaceutical solutions, the company has expanded its footprint and more focused to enhanced its operation across key African countries. Indo-Ethiopean Chamber of Commerce and Industry (IECC) was incorporated in December, 2020 to explore new areas of mutual co-operation between India and Ethiopia relating to business, commerce and technology transfer. IECC aims to facilitate trade, commerce and industrial development between India and Ethiopia.

Growing Segments

Particulars	Revenue		
	2021-22	2020-21	Growth
OSD	1600	724	121%
General Injections	3655	2282	60.17%
Ophthalmic	288	193	102.15%
Cephalosporins	1765	736	139.81%
Others	3,208	3,067	4.60%

Segment wise growth in FY 2021-22



2. Financial Performance

In the financial year 2021-22, the Company achieved an income from operations of Rs. 10,515.98 Lakh as compared to Rs. 7,001.68 Lakh in the previous year. The Company's total income stood Rs. 10,971.88 Lakh. The total comprehensive income for the year ended 31st March, 2022 from continuing operations was Rs.1,250.92 Lakh.

In the financial year 2021-22, the Company's consolidated income from operation was Rs.11,423.42 Lakh as compared to Rs. 6,852.31 Lakh. Total consolidated income stood Rs. 11,714.35 Lakh. The total comprehensive income for the year ended 31st March, 2022 was Rs. 819.52 Lakh.

Key Financial Ratio

Particulars	31.03.2022	31.03.2021
Return on Net Worth (%)	5.91	3.90
Debtor Turnover	3.27	3.51
Inventory Turnover	15.48	6.14
Interest Coverage	22.02	12.47
Current Ratio	1.81	2.21
Debt Equity Ratio	0.11	0.09
Operating Profit Margin (%)	42.71	50.2
Net Profit Margin (%)	9.60	10.72

3. Risk and Concerns

The Company emphasis on risk management and has an enterprise - wide approach to risk management which identify and manage key operational and strategic risks. The Company strives to identify opportunities that enhance organisational values while managing or

mitigating risks that can adversely impact its future performance through integrated process for identification, assessment and reporting, decentralised management of specific opportunities and risks and aggregation at corporate level monitored by the Risk Management Committee with the overall direction and control by the Board.

The Company continues its initiatives aimed at assessment and avoidance of various risks affecting its business and towards cost control and efficiency across its businesses and functions, taking appropriate measures and reviewing them from time to time. The Company's risk management and control procedures involve prioritisation and continuous assessment of these risks and devise appropriate controls, evaluating and reviewing the control mechanism and redesigning from time to time in the light of its effectiveness.

Category of risks experienced and mitigated by the Company are related to Global Market, Competition, Covid -19 Pandemic, Regulatory and Quality Compliance, Intellectual Properties, Commercial and Financial Risk, Environment, Health and Safety, Human Resource, Regulatory and Sustainable Operations.

4. Internal Control Systems

The Company has in place adequate internal financial controls over financial reporting. It has adopted necessary policies and procedures for ensuring the orderly and efficient conduct of its business, including adherence to Company's policies safeguarding of its assets, prevention and detection of frauds and errors, accuracy and completeness of the accounting records and timely preparation of reliable financial information.

The Company maintains a system of well established policies and procedures for internal control of operations and activities and these are continually reviewed for effectiveness.

The internal control system is supported by qualified personnel and a continuous programme of internal audit. The prime objective of such audits is to test the adequacy and effectiveness of all internal control systems laid down by the management and to suggest improvements. Kilitch's overall system of internal control is adequate given the size and nature of operations and has effective implementation of internal control self assessment procedures to ensure compliance to policies, plans and statutory requirements.

The Audit Committee of the Company periodically review the functions of Internal Audit. The Management of the Company assessed the effectiveness of the Company's internal control over financial reporting. Based on its evaluation, the Audit Committee has concluded that the internal financial controls of the Company are adequate and operating effectively.

5. Human Resource

Kilitch and its subsidiaries are striving to build and maintain a positive employee experience with high satisfaction and quality of life, so that employees can contribute their best efforts to their work. We consider employees as an integral part of our operations and we put in place appropriate compensation plans, feedback processes, continuing training and upgradation of skills in their functional areas while maintaining safe and healthy working environment to ensure all round contribution and participation in the self growth as well as growth of the Company.

Our motive has been to create a committed work force through people-enabling processes and knowledge sharing practices based upon our value system. The key element of our Human Resource strategy is to provide a healthy working environment that empowers people, encourages innovation, enhances work satisfaction and builds a merit - driven organisation. As on 31st March, 2022, there were 146 employees of the Company.

For & on behalf of the Board of Directors of
Kilitch Drugs (India) Limited

sd/-	sd/-
Mukund Mehta	**Bhavin Mehta**
Managing Director	**Whole-Time Director**
[DIN: 00147876]	**[DIN: 00147895]**

Place: Mumbai
Date: 10th August, 2022

Annexure - II

Form AOC-1

Statement containing salient features of the financial statement of subsidiaries/ associate companies/joint ventures

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies Accounts) Rules, 2014

Part "A": Summary of Financial Information of Subsidiary Companies

(Rs. in Lakh)

Sr. No.	1.	2.
Name of the subsidiary	Monarchy Healthserve Private Limited	Kilitch Estro Biotech PLC
Reporting period for the subsidiary concerned, if different from the holding company's reporting period.	NA	NA
Reporting currency and Exchange rate as on the last date of the relevant financial year in the case of foreign subsidiaries.	INR	BIRR (1 Birr is = to Rs. 1.48/- as on 31/03/2022)
Share capital	5.09	645.25
Reserves & surplus	1,989.21	(279.44)
Total assets	2,115.53	6,437.00
Total Liabilities	121.23	6,071.19
Investments	-	-
Turnover	44.91	946.77
Profit before taxation	(81.81)	(349.58)
Provision for Deferred Tax	(0.02)	-
Profit after taxation	(81.83)	(349.58)
Proposed Dividend	-	-
% of shareholding	100%	67%

Part "B": Associates and Joint Ventures

Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures
Not Applicable

For & on behalf of the Board of Directors of
Kilitch Drugs (India) Limited

sd/-	sd/-
Mukund Mehta	**Bhavin Mehta**
Managing Director	**Whole-Time Director**
[DIN: 00147876]	**[DIN: 00147895]**

Place: Mumbai
Date: 10th August, 2022

Annexure - III

Statement of Particulars

As Per Rule 5(1) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014. As Amended

I. The Ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year 2021-22; and

II. The percentage increase in remuneration of each Director, Chief Executive Officer, Chief Financial Officer Company Secretary or Manager, if any, of the Company in the financial year 2021-22.

Name & Designation	Remuneration of each Director & KMP for the FY 2021 - 22 (Rs. in Lakh)	Increase / Decrease in Remuneration in the FY 2021-22	Ratio of Remuneration of each Directors to median remuneration of employees
A. Directors			
Mr. Mukund Mehta - Managing Director	60.00	0.00%	26.54:1
Mr. Bhavin Mehta - Whole Time Director	84.00	0.00%	37.16:1
Mrs. Mira Mehta - Whole Time Director	24.00	0.00%	10.62:1
Mr. Hemang Engineer - Independent Director	Nil	-	-
Mr. Vasudev Krishna Murti - Independent Director	Nil	-	-
Mr. Venkita Subramanian Rajan - Independent Director	Nil	-	-
B. Key Managerial Personnel			
Mr. Sunil Jain - Chief Financial Officer	15.00	NA	6.64:1
Ms. Garima Trivedi - Company Secretary (upto 13 th October, 2021)	1.98	NA	NA
Ms. Princy Asati - Company Secretary (w.e.f. 5th October, 2022)	1.57	NA	NA

Notes:
Independent Directors were paid sitting fees for attending the Board and its Committee Meetings.

III. The percentage increase in the median remuneration of employees in the financial year 2021-22

Name & Designation	Financial Year 2021 -22 (Rs. in lakh)	Financial Year 2020 -21 (Rs. in lakh)	Increase /Decrease (%)
Median remuneration of all employees	2.26	2.71	-16.50

IV. The number of permanent employees on the rolls of Company as on 31st March, 2022 were 146

V. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration.

Average percentile increase already made in the salaries of employees other than the managerial personnel in the financial year was -16.50, whereas there was no increase in the managerial remuneration.

It is hereby affirmed that the remuneration paid is as per the Remuneration Policy.

VI. Affirmation that the remuneration is as per the Remuneration Policy of the Company

Pursuant to Rule 5(1)(xii) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, it is affirmed that the remuneration paid to the Directors, KMPs, Senior Management and other employees of the Company is as per the Remuneration Policy of the Company.

For & on behalf of the Board of Directors of
Kilitch Drugs (India) Limited

sd/-
Mukund Mehta
Managing Director
[DIN: 00147876]

sd/-
Bhavin Mehta
Whole-Time Director
[DIN: 00147895]

Place: Mumbai
Date: 10th August, 2022

Annexure - IV
Secretarial Audit Report

For the financial year ended 31st March , 2022
[Pursuant to section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To
The Members
Kilitch Drugs (India) Limited
C - 301/2, MIDC. TTC Industrial Area, Pawane Village,
Navi Mumbai - 400705, Maharashtra, India.

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Kilitch Drugs (India) Limited (hereinafter called the Company). In light of ongoing COVID-19 pandemic situation, due to limitations of physical verifications of various records, the Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/ statutory compliance and expressing our opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the Company has, during the audit period covering the financial year ended on 31st March, 2022 ('Audit Period') complied with the statutory provisions listed hereunder and subject to the observations mentioned in this report, the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March, 2022 according to the provisions of:

(I) The Companies Act, 2013 (the Act) and the rules made there under as amended;

(ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under as amended;

(iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;

(iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings (to the extent as may be applicable to the Company);

(v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'): —

(a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
(b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
(c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;
(d) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 (Not Applicable to the Company during the Audit Period);
(e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2015 (Not Applicable to the Company during the Audit Period);
(f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;

(g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; (Not Applicable to the Company during the Audit Period) ;and
(h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998; (Not Applicable to the Company during the Audit Period);

I have also examined compliance with the applicable clauses of the following:

(a) Secretarial Standards issued by The Institute of Company Secretaries of India
(b) The Listing Agreement entered into by the Company with the Stock Exchanges viz BSE and NSE along with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as applicable for respective periods.

During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

I further report that:

- The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes that took place in the composition of the Board of Directors were in proper compliance during the period under review.

- Adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

- All the decisions at the Board Meetings and the Committee Meetings were carried out unanimously as recorded in the minutes of the Board of Directors and minutes of the Committee Meetings as the case may be.

I further report that:

- There are adequate systems and processes in the Company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

I further report that during the audit period there were no specific events/actions having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, guidelines and standards.

For **M/s. DEEP SHUKLA & ASSOCIATES**
COMPANY SECRETARIES

Sd/-

DEEP SHUKLA
{PROPRIETOR}
FCS: 5652
CP NO.5364
UDIN: F005652D000761761

Place: Mumbai
Date: 8th August, 2022

Annexure to the Secretarial Audit Report

To
The Members
Kilitch Drugs (India) Limited

I further state that my said report of the even date has to be read along with this letter.

1. Maintenance of Secretarial/ Statutory Records is the responsibility of the Management of the Company. My responsibility is to express an opinion on these records based on the audit.

2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial Records.

3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

4. Wherever required I have obtained the Management representation about the compliance of laws, rules and regulations and happenings of events etc.

5. The compliance of the provisions of corporate and other applicable laws, rules, regulations, standard is the responsibility of management. My examination is limited to the verification of procedures on test basis.

6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

For **M/s. DEEP SHUKLA & ASSOCIATES**
COMPANY SECRETARIES

Sd/-

DEEP SHUKLA
{PROPRIETOR}
FCS: 5652
CP NO.5364
UDIN: F005652D000761761

Place: Mumbai
Date: 8th August, 2022

Annexure - V

Annual Secretarial Compliance Report of "Kilitch Drugs (India) Limited"

for the year ended 31st March, 2022

We, Deep Shukla & Associates have examined:

(a) all the documents and records made available to us and explanation provided by Kilitch Drugs (India) Limited [CIN: L24239MH1992PLC066718] ("the listed entity"),
(b) the filings/ submissions made by the listed entity to the stock exchanges,
(c) website of the listed entity,
(d) other relevant document(s)/ filing, which has been relied upon to make this certification,

for the year ended 31st March, 2022 ("Review Period") in respect of compliance with the provisions of :

(a) the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and

(b) the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI");

The specific Regulations, whose provisions and the circulars/ guidelines issued thereunder, have been examined, are:-

(a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
(b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (to the extent applicable);
(c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (to the extent applicable);
(e) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; [Not applicable during the review period]
(f) Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; (to the extent applicable)
(g) Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; [Not applicable during the review period]
(h) Securities and Exchange Board of India (Issue and Listing of Non-Convertible and Redeemable Preference Shares) Regulations, 2013; [Not applicable during the review period]
(i) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (to the extent applicable);
(j) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993, as amended;
(k) The Securities and Exchange Board of India (Intermediaries) Regulations, 2008; [Not applicable during the review period]
(l) Securities and Exchange Board of India (Depositories and Participant) Regulations, 2018; and circulars/guidelines issued thereunder.

And based on the above examination, we hereby report that, during the Review Period:

(a) The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder;
(b) The listed entity has maintained proper records under the provisions of the above Regulations and circulars/ guidelines issued thereunder in so far as it appears from our examination of those records;
(c) The following are the details of actions taken against the listed entity/ its promoters/ directors/ material subsidiaries either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under the aforesaid Acts/ Regulations and circulars/ guidelines issued thereunder:

Sr. No	Action taken by	Details of violation	Details of action taken E.g. fines, warning letter, debarment , etc.	Observations/ remarks of the Practicing Company Secretary , if any.
NIL				

(d) The listed entity has taken the following actions to comply with the observations made in previous reports:

Sr. No	Observations of the Practicing Company Secretary in the previous reports	Observations made in the secretarial compliance report for the year ended...	Actions taken by the listed entity, if any	Comments of the Practicing Company Secretary on the actions taken by the listed entity
NIL				

For **M/s. DEEP SHUKLA & ASSOCIATES**
COMPANY SECRETARIES

Sd/-

DEEP SHUKLA
{PROPRIETOR}
FCS: 5652
CP NO.5364
UDIN: F005652D000305105

Place: Mumbai
Date: 11th May, 2022

Annexure - VI

Report on CSR Expenditure

a. A brief outline on CSR Policy of the Company - CSR policy are disclosed on the website of the company - www.kilitch.com

b. The web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the company - www.kilitch.com

c. The details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social responsibility Policy) Rules, 2014, if applicable- Not Applicable

d. Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social responsibility Policy) Rules, 2014 and amount required for set off for the financial year, if any- NIL

e. Average net profit of the company for last three financial years- INR 10,75,18,228.62

f. i) Two percent of the average net profits of the Company as per Section 135(5)- INR 21,50,365/-
ii) Surplus arising out of the CSR Projects or programmes or activities of the previous Financial Years- NIL
iii) Amount required to be set off for the financial year, if any- NIL

g. Total CSR obligation (i + ii - iii) - INR 21,50,365/-

h. i) CSR amount spent or unspent for the financial year:

Total Amount spent for the Financial Year (if any)	Amount unspent (in Rs.)				
	Total Amount transferred to Unspent CSR Account as per section 135(6).		Amount transferred to any fund specified under Schedule VII as per second proviso to section 135(5)		
	Amount	Date of transfer	Name of the Fund	Amount	Date of transfer
21,77,250/-	NIL	NA	NA	NA	NA

ii) Details of CSR amount spent against ongoing projects for the financial year: NIL
iii) Details of CSR amount spent against other than ongoing projects for the financial year: INR 21,77,250/-
iv) Amount spent in Administrative Overheads: NIL
v) Amount spent on Impact Assessment, if applicable: NA
vi) Total amount spent for the financial year: INR 21,77,250/-
vii) Excess amount for set off, if any- INR 26,635/-

For & on behalf of the Board of Directors of
Kilitch Drugs (India) Limited

sd/-
Mukund Mehta
Managing Director
[DIN: 00147876]

sd/-
Bhavin Mehta
Whole-Time Director
[DIN: 00147895]

Place: Mumbai
Date: 10th August, 2022

Annexure - VII
Corporate Governance Report

Good Corporate Governance is the ethical business practices for promoting corporate fairness, transparency and accountability to safeguard the interest of owners, employees, environment, local community, suppliers, customers, lenders and government while complying with the applicable legal and regulatory requirements.

The detailed Report on Corporate Governance as per the requirement of Companies Act, 2013, (hereinafter referred to as the "Act" and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 (hereinafter referred to as "the SEBI Listing Regulations") is set out below;

1. COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE:

The Company firmly believes that good corporate governance and compliance practices are of paramount importance in order to safeguard the interest of the stakeholders of the Company. Company has committed to bring the good corporate governance practices to attain highest level of transparency, accountability and equity, in all its operations and in its interaction with stakeholders including shareholders, employees, government and lenders. The Company keeps itself abreast with the best governance practices on the global front, at the same time conforming to the regulatory requirements.

2. BOARD OF DIRECTORS:

2.1 Composition and Category of Board

The Board of the Company is formed with an optimum combination of executive and non-executive directors which not only meet the legal obligation but also make a diversified Board with a mixed blend of experiences, expertise and professionals. The Board, while discharging its responsibilities and providing effective leadership to the business, uphold the corporate value, promote the ethical culture, endorse sustainability and leverages innovation. Independent directors play a pivotal role in upholding Corporate Governance norms and ensuring fairness in decision-making. Being experts in various fields, they also bring independent judgement on matters of strategy, risk management, controls and business performance.

As on 31st March, 2022, the Board comprises of 6 directors consisting of 3 executive directors including one woman director and 3 non-executive independent directors. The composition of the Board is in conformity with Regulation 17 of the SEBI Listing Regulations read with Section 149 of the Companies Act, 2013 ("the Act"). The name and category of each directors as on 31st March, 2022 is given below;

Name of Director	Category
Mr. Mukund Mehta	Managing Director
Mr. Bhavin Mehta	Wholetime Director
Mrs. Mira Mehta	Wholetime Director
Mr. Vasudev Krishnamurti	Non-executive and Independent Director
Mr. Venkita S. Rajan	Non-executive and Independent Director
Mr. Hemang J. Engineer	Non-executive and Independent Director

2.2 Attendance of each directors at Board Meetings and Annual General Meeting

The Directors' attendance at the Board and General Meetings held during the financial year 2021-22 is as follows :

Name of Directors	No. of Board Meeting Held	No. of Board Meeting attended	Attendance at last Annual General Meeting
Mr. Mukund Mehta	7	6	Yes
Mr. Bhavin Mehta	7	5	Yes
Mrs. Mira Mehta	7	7	Yes
Mr. Vasudev Krishnamurti	7	6	Yes
Mr. Venkita S. Rajan	7	7	Yes
Mr. Hemang J. Engineer	7	7	Yes

2.3 Number and dates of the Meetings of Board of Directors

During the year under review, the Company held 7 Board Meetings dated 22nd June, 2022, 13th August, 2021, 13th October, 2021, 12th November, 2021, 21th January, 2022 and 14th February, 2022. The gap between the two meetings did not exceed on hundred and twenty days. During the year under review, one meeting of the Independent Directors was held on 13th August, 2021.

2.4 Directorship and Chairmanship/Membership of Committees in other Companies

Name of Directors	No. of other director ship	No. of Mandatory Committees #		Director ship in other listed entity
		Committee Member ship	Committee Chairman ship	
Mr. Mukund Mehta	3	-	-	-
Mr. Bhavin Mehta	3	-	-	-
Mrs. Mira Mehta	3	-	-	-
Mr. Vasudev Krishnamurti	3	-	-	-
Mr. Venkita S. Rajan	3	-	-	-
Mr. Hemang J. Engineer	3	-	-	1. Paramount Print Packaging Limited

in accordance with the provisions of regulation 72 of the SEBI Listing Regulations, Membership/Chairman of Audit Committee and Stakeholders Relationship Committee in all Companies (excluding Kilitch Drugs (India) Limited have been considered.

None of the directors of the Board,

- holds directorship in more than ten public companies;
- serves as Director or as Independent Director in more than seven listed entities;
- holds more than ten board committee memberships or 5 board committee chairmanships; and
- who are the Executive Directors serves as IDs in more than three listed entities;

2.5 Disclosure of relationship between Directors inter-se

Mr. Mukund Mehta, Managing Director of the Company is the father of Mr. Bhavin Mehta, Whole-time Director and father-in-law of Mrs. Mira Mehta, Whole-time Director. Mrs. Mira Mehta, Whole-time Director of the Company is wife of Mr. Bhavin Mehta. None of the other Directors are related to each other.

2.6 Meeting of Independent Directors

There is no pecuniary or business relationship between the Non-Executive/Independent Directors of the Company except for the payment of sitting fees for attending Board and Committee Meetings in accordance with the applicable laws.

A declaration to this effect is also submitted by all the Directors at the beginning of each financial year. None of the Non-Executive Directors hold any equity shares in the Company.

2.7 Details of Familiarization Programme for Independent Directors

Details of familiarization programme of the Independent Directors are available on the website of the Company at https://kilitch.com/investor-relations/

2.8 Key Board qualification, skills, competencies fundamental for the effective functioning of the Company

The Board of the company comprises of qualified members who bring in the required skills, competence and expertise that allows them to make effective contributions to the Board and its Committees. The Board members are committed to ensure that the Kilitch Board is in compliance with the highest standard of Corporate Governance.

The Board has identified the following skills /expertise/ competences fundamental for the effective functioning of the Company which are currently available with the Board;

Name of Directors	Global Business	Strategy, Planning and Marketing	Financial & Legal	Governanc	Leadership and Operational Expertise
Mr. Mukund Mehta	✓	✓	✓	✓	✓
Mr. Bhavin Mehta	✓	✓	✓	✓	✓
Mrs. Mira Mehta	✓	✓	✓	✓	✓
Mr. Vasudev Krishnamurti	✓	✓	✓	✓	✓
Mr. Venkita S. Rajan	✓	✓	✓	✓	✓
Mr. Hemang J. Engineer	✓	✓	✓	✓	✓

2.9 In terms of Regulation 25(8) of SEBI Listing Regulations, Independent Directors have confirmed that they are not aware of any circumstance or situation which exist or may be reasonably anticipated that could impair or impact their ability to discharge their duties. Based on the declarations received from the Independent Directors, the Board of Directors have confirmed that they meet the criteria of independence as mentioned under Regulation

16(1)(b) of the SEBI Listing Regulations and that they are independent of the management.

3. Audit Committee

3.1 Terms of Reference

The primary objective of the Audit Committee of the Company is to monitor and provide effective supervision of the management's financial reporting process with a view to ensure accurate, timely and proper disclosures and transparency, integrity and quality of financial reporting.

The constitution, terms of reference, role and scope shall be as prescribed by Regulation 18 of SEBI Listing Regulations read with Section 177 of the Companies Act, 2013, inter-alia, covering;

a) Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;

b) Scrutiny and review of all financial transactions, inter corporate loans, investments, funds utilization, related party transactions and the general financial condition of the Company;

c) Recommendation for appointment, remuneration and terms of appointment of auditors of the Company and approval of remuneration of auditors;

d) Review and monitor the auditor's independence and performance, and effectiveness of audit process;

e) Reviewing, with the management, the periodic financial statements and auditor's report thereon before submission to the Board for approval;

f) Reviewing, with the management, performance of statutory and internal auditors, adequacy of the internal control systems;

g) Evaluation of internal financial controls and risk management systems;

h) To review the functioning of the Whistle Blower mechanism;

i) To review statement of deviations in reporting to monitoring agencies

j) Approve policies in relation to the implementation of the Insider Trading Code and to supervise implementation of the same.

k) To carry out any other function as is mandated by the Board from time to time and/ or required by any statutory notification, amendment or modification, as may be applicable.

3.2 Composition of the Committee and details of meetings held and attended by its members

With a view to have a better governance and accountability, the Board has constituted an Audit Committee in line with the provisions of Regulation 18 of SEBI Listing Regulation and Section 177 of the Act. During the year under review, four audit committee meetings were held and the gap between two meetings did not exceed 120 days. The Audit Committee meetings were held on 22nd June, 2021, 13th August, 2021, 12th November, 2021 and 14th February, 2022. The Composition of Audit Committee is as under;

Name of Members	Category	No. of Meeting	
		held	attended
Prof. V. K. Murti - Chairman	Non-Executive, Independent	4	4
Mr. V. S. Rajan	Non-Executive, Independent	4	4
Mr. Hemang Jagdish Engineer	Non-Executive, Independent	4	4

4. Nomination and Remuneration Committee

4.1 Terms of Reference

Term of reference of the Committee include the following;
a) To formulate the criteria for determining qualifications, positive attributes and independence of a Director, and recommend to the Board a policy, relating to the remuneration for the Directors, Key Managerial Personnel and other employees.

b) To formulate the criteria for evaluation of performance of Independent Directors and the Board; and evolve and review the policy on Board diversity.

c) To identify/ evaluate persons for appointment to the Board or in senior management in accordance with the criteria laid down and to recommend to the Board their appointment and/ or removal.

d) Support the Board and Independent Directors in evaluation of the performance of the Board, its committees and individual directors.

e) Recommend to the Board, all remuneration, in whatever form, payable to senior management.

f] To carry out any other function as is mandated by the Board from time to time and/ or required by any statutory notification, amendment or modification, as may be applicable.

4.2 Composition of the Committee and details of meetings held and attended by its members

The Company has constituted a Nomination and Remuneration Committee as required under section 178 of the Act read with Rule 6 of the Companies (Meetings of Board and its Powers) Rules, 2014 and Regulation 19 of SEBI Listing Regulations. During the year under review, four meetings of the Committee were held on 22nd June, 2021, 13th August, 2021, 12th November, 2021 and 14th February, 2022.

Name of Members	Category	No. of Meeting	
		held	attended
Mr. Hemang Jagdish Engineer - Chairman	Non-Executive, Independent	4	4
Mr. V. S. Rajan	Non-Executive, Independent	4	4
Prof. V. K. Murti	Non-Executive, Independent	4	4

4.3 Performance Evaluation

Pursuant to the relevant provisions of the Companies Act, 2013 and SEBI Listing Regulations, the annual performance evaluation of the Board and its Committees has been carried out by all the directors. The performance evaluation of the Independent Directors was carried out by the Board excluding the director being evaluated. The performance evaluation of the Chairman and Executive Directors was carried out by all Independent Directors. Based on the feedback received from the Directors, the Board was of the opinion that the individual performance of the Independent Directors was effective for the financial year 2021-22.

4.4 Nomination and Remuneration Policy

a] The Company has formulated the Nomination and Remuneration Policy to lay down the criteria and terms and condition with regard to identifying persons who are qualified to become a member of the Board of the Company (executive and non-executive) and persons who are qualified to be appointed in Senior Management and Key Managerial Positions and to determine their remuneration;

b] To carry out evaluation of the performance of Directors as well as Key Managerial and Senior Managerial Personnel;

c] Devising a Policy on Board diversity.

The details of Remuneration paid to the Executive Directors & KMP for the Financial year 2021-2022 is given below;

(Rs. in Lakhs)

Executive Director and Key Managerial Personnel	Category	Salary	Perqu-isite	Allow-ances	Total
Mr. Mukund Mehta	Managing Director	60.00	-	-	60.00
Mr. Bhavin Mehta	Whole-time Director	84.00	-	-	84.00
Mrs. Mira Mehta	Whole-time Director	24.00	-	-	24.00
Mr. Sunil Jain	Chief Financial Officer	15.00	-	-	15.00
Ms. Garima Trivedi (Upto 13th October, 2021	Company Secretary	1.98	-	-	1.98
Ms. Princy Asati (w.e.f 5th October, 2021	Company Secretary	1.57	-	-	1.57

There were no pecuniary relationship / transactions of Non-Executive Director / Independent Directors with the Company except for the payment of sitting fees paid to them for attending Board and Committee meetings in accordance with the applicable laws.

Sitting fees

Independent Directors	Sitting Fees (Rs.)
Prof. V. K. Murti	30,000/-
Mr. V. S. Rajan	4,440/-
Mr. Hemang Engineer	40,000/-

5. Stakeholder Relationship Committee

5.1 Terms of Reference

The Committee is empowered to consider and resolve shareholders grievances including transfer of shares,

transmission, non-receipt of dividend, annual report ect. while ensuring cordial investors relations.

5.2 Composition of the Committee and details of meetings held and attended by its members

The Committee has been constituted as required under Section 178(5) of the Act and Regulation 20 of the SEBI Listing Regulations. During the year under review, four meetings of the Committee were held on 22nd June, 2021, 13th August, 2021, 12th November, 2021 and 14th February, 2022. The composition of the Committee and details of attendance of meeting by the committee members are as follows;

Name of Members	Category	No. of Meeting	
		Held	Attended
Mr. V. S. Rajan - Chairman	Non-Executive, Independent	4	4
Mr. Hemang Jagdish Engineer	Non-Executive, Independent	4	4
Prof. V. K. Murti	Non-Executive, Independent	4	4

Ms. Pushpa Nyoupane, Company Secretary is the Compliance Officer of the Company for attending complaints/grievances of the shareholders.

6. Corporate Social Responsibility Committee

6.1 Terms of Reference

The responsibility of Corporate Social Responsibility Committee is to assist the Board in undertaking CSR activities by way of formulation and monitoring CSR Policy of the Company. Brief terms of reference of the Committee are as follows:

a) Formulate and recommend to the Board, a Corporate Social Responsibility Policy in line with the requirement of the Companies Act, 2013 which shall indicate the activities to be undertaken by the Company.

b) Recommend the amount of expenditure to be incurred on CSR activities and

c) Monitor the implementation of Corporate Social Responsibility Policy of the Company from time to time.

6.2 Composition of the Committee and details of meetings held and attended by its members

The meeting of the Committee was held on 22nd June, 2021.

The composition of the Committee and details of attendance of meeting by committee members is given below;

Name of Members	Category	No. of Meeting	
		Held	Attended
Mr. Bhavin Mehta - Chairman	Executive Director	1	1
Mrs. Mira Mehta	Executive Director	1	1
Mr. V. S. Rajan	Non-Executive, Independent	1	1

7. Compensation Committee

The Board of Directors of the Company has Constituted Compensation Committee to administer Employee Stock Option Scheme 2007 having following members;

Name of Members	Category	No. of Meeting	
		Held	Attended
Mr. Hemang J. Engineer	Non-Executive, Independent	2	2
Mr. V. S. Rajan	Non-Executive, Independent	2	2
Prof. V. K. Murti	Non-Executive, Independent	2	2

During the year under review, the Committee met two time on 30th April, 2021 and 13th October, 2021 to consider and approve the allotment of 20,305/- equity shares of Rs. 10 each and 67,470/- equity share of Rs. 10 each respectively to the employees of the Company under ESOP Scheme, 2007.

8. General Body Meetings

Location and time of the last three Annual General Meeting are given below;

Location	Date	Time	Special Resolution(s) Passed
C - 301/2, MIDC, TCC Industrial Area, Pawane Village, Navi Mumbai - 400705	29th September, 2021	9:00 am	1
	30th September, 2020	9:00 am	1
	30th September, 2019	9:00 am	3

Extra-ordinary general meeting of the company was held on 19th January, 2022 through video conferencing at 1:00 pm wherein 1 special resolution was passed.

No resolution was passed through ballot during the year under review and no resolution is proposed to be passed through postal ballot.

9. Means of Communication

a) Quarterly, half - yearly and annual financial results of the Company are communicated to the Stock Exchanges immediately after the same are considered by the Board and are published in The Free Press Journal (English Edition) and Navshakti (Marathi Edition)

b) Financial Results and other shareholder's information are also made available on the Company's website i.e. https://kilitch.com/investor-relations/

10. General Shareholder Information

10.1 Annual General Meeting
Date : 29th September, 2022
Time: 10:00 am
Venue: Through Video Conferencing / Other Audio Visual Means

10.2 Financial Year - 1st April, 2021 to 31st March, 2022

Financial Calendar (Tentative) – Financial Year 2022-23
1st Quarter : On or before 14th August, 2022
2nd Quarter : On or before 14th November, 2022
3rd Quarter : On or before 14th February, 2023
4th Quarter : On or before 30th May, 2023

10.3 Book Closure Date - as mentioned in the Notice of AGM

10.4 Dividend Payment Date - Not Applicable

10.5 Stock Exchanges

Name and Address of Stock Exchange	Stock Code	Listing Fees	ISIN No.
BSE Limited Phiroze Jeejee-bhoy Towers, Dalal Street, Mumbai 400001	524500	Paid	INE729D01010
The National Stock Exchange of India Limited Exchange Plaza, Bandra Kulra Complex, Bandra (East), Mumbai - 400051	KILITCH	Paid	

10.6 Address for Correspondence

Registrar and Share Transfer Agent	Company
Link Intime India Private Limited C - 101, 247 Park, LBS Marg, Vikhroli (West), Mumbai - 400083, Maharashtra India Tel. : 022 49186000 Fax: 022 49186060	Company Secretary and Compliance Officer 37, Ujagar Industrial Estate, W. T. Patil Marg, Deonar Mumbai - 400705 Tel. 022 61214100 E-mail - pushpanyoupane@kilitch.com

10.7 Plant Location

Pawane Unit	C 301/2, MIDC T.T.C Indl Area, Pawane, Thane Maharashtra 400705 INDIA.
Ethiopia Unit	House No. New, Lega Bari Lega Bolo Kebele, Barak Wereda, Oromia Special Zone Finfine Surrounding, Oromia, Ethiopia.

10.8 Share Transfer System

Transfer, transmission or transposition of securities are conducted in accordance with the provisions of SEBI Listing Regulations and Companies Act, 2013. Securities lodged for transfer at the Registrar's/Company address are normally processed within statutory timelines from the date of lodgement, subject to documents are submitted as required by law.

In terms of SEBI Listing Regulations, as amended, securities can be transferred only in dematerialised form with effect from 1st April, 2019 except in case of request received for transmission or transposition of securities. The Shareholders who continue to hold shares and other types of securities of listed companies in physical form even after this date, will not be able to lodge the shares with Company / its RTA for further transfer. Hence, members holding shares in physical form are requested to consider converting their shares to demat form.

10.9 Dematerialisation of Shares and Liquidity

The Company's shares have been mandated for compulsory trading in demat form only. Valid demat requests received by the Company's Registrar are confirmed within the statutory period.

International Securities Identification Number (ISIN) allotted for the Company by NSDL and CDSL is INE729D01010. In case a member wants his/her shares to be dematerialised, he/she may send the shares along with the request through his depository participants (DP) to the Registrar and Share Transfer Agent, Link Intime India Private Limited.

The Company's Registrars promptly intimate the Depository Participants in the event of any deficiency and shareholders are also kept abreast. Pending demat requests in the record of the Depositories, if any, are continually reviewed and appropriate actions are initiated.

10.10 Distribution of Shareholding

Category (Shares) From - To	No. of share-holders	No. of shares held	% of Share Capital
1 to 500	8,258	10,75,903	6.9046
501 to 1000	493	3,99,635	2.5647
1001 to 2000	247	3,75,529	2.4100
2001 to 3000	81	2,08,735	1.3396
3001 to 4000	41	1,45,356	0.9328
4001 to 5000	46	2,13,237	1.3685
5001 to 10000	49	3,60,022	2.3105
10000 to 20000	46	1,28,03,902	82.1694
TOTAL	**9,261**	**1,55,82,319**	**100**

10.11 Shareholding Pattern as on 31st March, 2022

Particulars	Shares	
	Number	% to total Capital
Promoter and Promoter Group	1,06,34,173	68.25
Financial Institutions / Bank	100	0.00
Individuals	42,98,295	27.58
IEPF	2,34,016	1.50
HUF	1,64,595	1.06
NRI's	1,36,924	0.88
Body Corporate	1,00,487	0.64
Clearing Member	13,729	0.09
Total	**1,55,82,319**	**100**

Top 10 Public Shareholders as on 31st March , 2022

S.N.	For Each of the Top 10 Shareholders	Shareholding as on 31st March, 2022	
		No. of shares	% of total shares of the company
1.	Dipak Kanayalal Shah	4,13,000	2.6504
2.	Kamlesh Vrajlal Shah	1,33,901	0.8593
3.	Neeta Manoj Ruparel	1,29,494	0.8310
4.	Jatin Keshavji Chande	1,08,000	0.6931
5.	Darshana Jignesh Kothari	90,000	0.5776
6.	Jayantilal Bheemraj Jain	87,622	0.5623
7.	Anuj Somchand Shah	73,495	0.4717
8.	Mita Dipak Shah	72,900	0.4678
9.	Jignesh Praful Mehta	66,370	0.4259
10.	Bhavin Ramakant Saraiya	49,152	0.3154

10.12 Commodity Price Risk or Foreign Exchange Risk and Hedging Activities

The Company has not undertaken in any transactions related to commodity and hedging activities.


10.13 Market Price Data


The equity shares of the Company are actively traded on BSE Limited and National Stock Exchange of India Limited. The Securities of the Company were not suspended from trading during the year. Monthly high and low quotations as well as the volume of shares traded at BSE and National Stock Exchanges for the financial year 2021-22 are as follows;

Month	BSE Price		BSE Index		NSE Price		NSE Index	
	High	Low	High	Low	High	Low	High	Low
Apr-21	118.50	79.75	50,375.77	47,204.50	119.40	80.45	15,044.35	14,151.40
May-21	187.00	106.05	52,013.22	48,028.07	185.00	105.45	15,606.35	14,416.25
Jun-21	172.35	145.00	53,126.73	51,450.58	173.25	146.10	15,915.65	15,45090
Jul-21	224.50	141.20	53,290.81	51,802.73	224.80	141.10	15,962.25	15,513.45
Aug-21	228.05	162.15	57,625.26	52,804.08	228.90	160.85	17,153.50	15,834.65
Sep-21	187.00	160.50	60,412.32	57,263.90	187.10	159.50	17,947.65	17,055.05
Oct-21	183.00	148.60	62,245.43	58,551.14	183.40	150.00	18,604.45	17,452.90
Nov-21	194.15	149.40	61,036.56	56,382.93	195.00	148.05	18,210.15	16,782.40
Dec-21	251.85	150.70	59,203.37	55,132.68	251.00	150.30	17,639.50	16,410.20
Jan-22	276.40	218.80	61,475.15	56,409.63	275.10	217.15	18,350.95	16,836.80
Feb-22	234.35	163.50	59,618.51	54,383.20	233.60	161.40	17,794.60	16,203.25
Mar-22	186.90	162.35	58,890.92	52,260.82	188.10	162.60	17,559.80	15,671.45


Performance in comparison


The company Fully Paid Share Price versus BSE Sensex





The company Fully Paid Share Price versus Nifty 50





10.14 Other Disclosures

Disclosures

I. Related Party Transactions

All related party transactions which were entered into during the financial year were on an arm's length basis and were in the ordinary course of business and did not attract provisions of section 188 of the Companies Act, 2013 and were also not material RPTs under regulation 23 of Listing Regulations.

II. Managing Director Certification

Certification on financial statements pursuant to Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been obtained from the Managing Director of the Company. Extract of the same is given at the end of this Report.

III. Code of Conduct for Directors

The Board has laid down Codes of Conduct for Executive Directors and for Non-Executive/ Independent Directors of the Company. The Codes of Conduct have been circulated to the Board and the compliance of the same has been affirmed by them. A declaration signed by the MD in this regard is given at the end of this Report.

IV. Subsidiary Companies

As on 31st March, 2022, the Company has two subsidiaries namely Monarchy Healthserve Private Limited and Kilitch Estro Biotech. In line with the requirements of the Act and Listing Regulations, the Company has formulated a policy for determining Material Subsidiaries.

V. Risk Management & Internal Control

The board has ultimate responsibility for risk management and internal control, including for the determination of the nature and extent of the principal risks it is willing to take to achieve its strategic objectives and for ensuring that an appropriate culture has been embedded throughout the organization. The Company has implemented a comprehensive 'Enterprise Risk Management' framework in order to understand the risks they are exposed to, put controls in place to counter threats, and effectively pursue their objectives and further to anticipate, idenify, measure, mitigate, monitor and report the risks, details of which are given in the Risk Management section under 'Management Discussion and Analysis Report' which forms part of this Annual Report.

The team presents their key audit findings of every quarter to the Audit Committee. The management updates the members about the remedial actions taken or proposed for the same. The suggestions and comments from the Committee members are vigilantly incorporated and executed by the Company.

VI. Independent Directors

The Independent Directors of the Company have the option and freedom to meet and interact with the Company's Management as and when they deem it necessary. They are provided with necessary resources and support to enable them to analyse the information/data provided by the Management and help them to perform their role effectively.

VII. Compliance with mandatory / discretionary requirements under Regulation 27 read with Schedule II Part E of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

The Company has complied with all mandatory requirements under Regulation 27 and Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The status of compliance with non mandatory recommendations under Regulation 27 and Part E of Schedule II of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is provided below:

- Modified opinion in Audit Report: The Company has moved to unmodified audit opinion regime

- Reporting of Internal Auditor: The Internal Auditor reports to the Audit Committee.

VIII. Review of Directors' Responsibility Statement:

The Board in its report has confirmed that the annual accounts for the financial year ended 31st March, 2022 have been prepared as per applicable Accounting Standards and policies and that sufficient care has been taken for maintaining adequate accounting records.

IX. Details of utilization of funds raised through preferential allotment or qualified institutions placement:

The details as per Regulation 32(7A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 during the financial year ended 31st March, 2022 are as follows:

The company has partially utilised the fund raised through preferential allotment of convertible warrants to meet the working capital requirements and completion of existing projects of the company.

X. Recommendation by Committee:

The Board has accepted all recommendations made by its committees during the financial year ended 31st March, 2022.

XI. Total fees for all services paid by the listed entity and its subsidiaries, on a consolidated basis, to the statutory auditors and all entities in the network firm/network entity of which the statutory auditor is a part, given below:

(Rs. In Lakhs)

Nature of Payments	31st March, 2022	31st March, 2021
Statutory Audit	15.30	15.30
Tax Audit	-	-
Other Services including reimbursement of expenses	-	0.25
Total	**15.30**	**15.55**

XII. Disclosures in relation to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

Sr. No.	Particulars	No. of Complaints
a.	Complaints filed during the financial year	Nil
b.	Complaints disposed of during the financial year	Nil
c.	Complaints pending as on end of the financial year	Nil

XIII. Disclosure of the compliance with Corporate Governance:

The Company has complied with the Regulations 17-20, 22-23, 24A, 25-27 and Clauses (b) to (i) of sub regulations (2) of Regulation 46 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, during the financial year ended 31st March, 2022. Regulations 21 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 are not applicable to the Company.

XIV. No penalty or strictures was imposed on the Company by the stock exchanges / SEBI or any other statutory authority on any matter related to capital markets during the last three years.

XV. To strengthen its policy of corporate transparency, the Company has established an empowering mechanism for employees and accordingly formulated a Whistle Blower Policy to provide a mechanism for directors and employees of the Company to report instances of unethical behaviour, actual or suspected fraud, or violation of the Code of Ethics and Business Conduct, in good faith. No person has been denied the access to the Chairman of the Audit Committee.

XVI. Policy on determining material subsidiaries is disseminated on the website of the Company https://kilitch.com/investor-relations/

XVII. The Company has obtained a certificate from Mr. Deep Shukla, Practicing Company Secretary that none of the Directors on the Board of the Company has been debarred or disqualified from being appointed or continuing as Directors of Companies by the Board / Ministry of Corporate Affairs or any such statutory authority.

XVIII. There were no shares in Demat suspense account or unclaimed suspense account during the FY 2021-22.

XIX. Outstanding GDRs / ADRs / Warrants or Any Convertible Instruments - Conversion Date and Likely Impact on Equity The Company does not have any outstanding GDRs / ADRs or any other convertible instruments. The Board of Directors of the Company, with the approval of the shareholders by way of Special Resolution, approved the allotment of warrants convertible into equity shareholders at a price Rs. 177.15/- per warrant including premium of Rs. 167.15/- per warrant. Warrants shall be converted into equity shares within the statutory timelines.

XX. The Company has complied with all the mandatory requirements of the Corporate Governance as stipulated in Schedule V of the SEBI Listing Regulations. Certificate from M/S Deep Shukla & Associates confirming compliance with the conditions of Corporate Governance is annexed. The Company does not send half yearly declaration of financial performance to its shareholders. The financial results are displayed on the Company's website at https://kilitch.com/investor-relations/. During the year under review, there were no audit qualifications on the Company's financial statements.

For & on behalf of the Board of Directors of
Kilitch Drugs (India) Limited

sd/-	sd/-
Mukund Mehta	**Bhavin Mehta**
Managing Director	**Whole-Time Director**
[DIN: 00147876]	**[DIN: 00147895]**

Place: Mumbai
Date: 10th August, 2022

Annexure - I of Report on Corporate Governance

Declaration by the CEO on Code of Conduct
[as required by Schedule V of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015]

I, Mukund Mehta, Managing Director of the Company hereby declare that all the members of the Board of Directors and Senior Management Personnel have affirmed compliance with the Code of Conduct, as applicable to them, in respect of the financial year 2021-22.

For **Kilitch Drugs (India) Limited**

sd/-

Mukund Mehta
Managing Director
DIN: 00147876
Date: 10th August, 2022
Place: Mumbai

Annexure - II of Report on Corporate Governance
CEO CFO Certification in respect of Financial Statement and Cash Flow Statement

For the Financial Year ended 31st March, 2022
[pursuant to regulation 17 (8) of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015]

We have reviewed the Financial Statements and the Cash Flow Statement for the year ended 31st March, 2022 and we hereby certify and confirm to the best of our knowledge and belief the following:

(a) The Financial Statements and Cash Flow statement do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading

(b) The Financial Statements and the Cash Flow Statement together present a true and fair view of the affairs of the Company and are in compliance with existing accounting standards, applicable laws and regulations.

(c) There are no transactions entered into by the Company during the year ended 31st March, 2022, which are fraudulent, illegal, or violative of the Company's Code of Conduct.

(d) We accept responsibility for establishing and maintaining internal controls for Financial Reporting and we have evaluated the effectiveness of these internal control systems of the Company pertaining to financial reporting. Deficiencies noted, if any, are discussed with the Auditors and Audit Committee, as appropriate, and suitable actions are taken to rectify the same.

(e) There have been no significant changes in the above-mentioned internal controls over financial reporting during the relevant period.

(f) That there have been no significant changes in the accounting policies during the relevant period.

(g) We have not noticed any fraud, particularly those involving the management or an employee having a significant role in the Company's internal control system over Financial Reporting.

For **Kilitch Drugs (India) Limited**

Sd/-	Sd/-
Mukund Mehta	**Sunil Jain**
Managing Director	**Chief Financial Officer**

Place: Mumbai
Date: 26th May, 2022

Certificate on Corporate Governance

To,
The Members of
Kilitch Drugs (India) Limited

I have examined the compliance with the conditions of Corporate Governance by Kilitch Drugs (India) Limited ('the Company') for the year ended 31st March, 2022, as stipulated in the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Listing Regulations).

The compliance of the conditions of Corporate Governance is the responsibility of the management. My examination was limited to a review of procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In my opinion and to the best of my information and according to the explanations given to me, and the representations made by the Directors and the Management and considering the relaxations granted by the Ministry of Corporate Affairs (MCA) and Securities and Exchange Board of India (SEBI) in the light of COVID-19 situation, I certify that the Company has complied with the conditions of Corporate Governance as stipulated in the Listing Regulations during the year ended 31st March, 2022

I state that such compliance is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For **M/s. DEEP SHUKLA & ASSOCIATES**
COMPANY SECRETARIES

Sd/-

DEEP SHUKLA
{PROPRIETOR}
FCS: 5652
CP NO.5364
UDIN: F005652D000761803

Place: Mumbai
Date: 8th August, 2022

KILITCH DRUGS (INDIA) LIMITED

Certificate of Non-disqualification of Directors

[Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To,
The Members of
Kilitch Drugs (India) Limited
C-301/2, MIDC, TTC Industrial Area,
Pawane Village, Navi Mumbai 400705

I have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Kilitch Drugs (India) Limited having CIN: L24239MH1992PLC066718 and having registered office at C-301/2, MIDC, TTC Industrial Area, Pawane Village, Navi Mumbai 400705 (hereinafter referred to as 'the Company'), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number(DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to me by the Company & its officers, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2022 have been debarred or disqualified from being appointed or continuing as Directors of Companies, by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authority.

Sr. No.	Name of Director	DIN	Designation	Date of Appointment as per MCA Records
1	Mukund Mehta	00147876	Managing Director	12/05/1992
2	Bhavin Mehta	00147895	Whole-time Director	29/09/2007
3	Mira Mehta	01902831	Whole-time Director	30/09/2014
4	Hemang Jagadish Engineer	02317989	Director	01/04/2015
5	Vasudev Krishna Murti	00567672	Director	16/03/2018
6	Venkita Subramanian Rajan	00059146	Director	28/06/2018

Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. My responsibility is to express an opinion on these based on my verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For **M/s. DEEP SHUKLA & ASSOCIATES**
COMPANY SECRETARIES

Sd/-

DEEP SHUKLA
{PROPRIETOR}
FCS: 5652
CP NO.5364
UDIN: F005652D000761748

Place: Mumbai
Date: 8th August, 2022

INDEPENDENT AUDITORS' REPORT

To,
The Members of
KILITCH DRUGS (INDIA) LIMITED

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying Standalone Ind AS financial statements of **Kilitch Drugs (India) Limited ("the Company"),** which comprise the Balance Sheet as at March 31, 2022 the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Changes in Equity and the Statement of Cash Flows for the year ended on that date, and a summary of the significant accounting policies and other explanatory information (hereinafter referred to as "Standalone financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, the profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the standalone financial statements and our auditor's report thereon. Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, total comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease

INDEPENDENT AUDITORS' REPORT

operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

• Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of

INDEPENDENT AUDITORS' REPORT

our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

Sr. No.	Key Audit Matter	Auditor's Response
1	**Revenue Recognition [Export Sales]**	Obtaining an understanding of and assessing the design, implementation and operating effectiveness of the Company's key internal controls over revenue recognition process. • Testing a sample of contracts and testing the revenues recognised with respect thereto by agreeing information back to contract terms. • Testing the controls over the sale data collated for the purpose of recognizing the revenue on sample basis. • Assessing the adequacy of company's disclosure with respect to revenue recognised.
2	**Trade Receivables**	Our audit procedures to assess the appropriateness of Trade receivables disclosure and provision against trade receivables included the Note 12 & Note 3 paragraph "H" of significant accounting policies.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of section 143(11) of the Act, we give in the Annexure "A" a statement on the matters specified in paragraph 3 and 4 of the Order.

2. As required under provisions of section 143(3) of the Act, we report that:

a.We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b. In our opinion, proper books of account as required by law have been kept by the Company so far as appears from our examination of those books.

c. The Balance Sheet, Statement of Profit and Loss including other comprehensive income, Cash Flow Statement and statement of changes in Equity dealt with by this report are in agreement with the books of account.

d. In our opinion, the aforesaid financial statements comply with the accounting standards specified under section 133 of the Act.

e. On the basis of written representations received from the directors as on 31st March, 2022, taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2022, from being appointed as a director in terms of section 164(2) of the Act.

f. With respect to the adequacy of the internal financial control over financial reporting of the company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.

g. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197 (16) of the Act, as amended:

In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

h. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company has disclosed the impact of the pending litigations on its financial position vide Note No. 36 to the standalone Ind AS financial statements.

INDEPENDENT AUDITORS' REPORT

ii. The Company did not have any long term contracts including derivative contracts that require provision under any law or accounting standards for which there were any material foreseeable losses.

iii. There has been no delay in transferring amounts required to the Investor Education and Protection Fund by the Company during the year.

vi. (a) The management has represented that, to the best of its knowledge and belief, as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries (Refer Note 49) to the financial statements);

(b) The management has represented that, to the best of its knowledge and belief, as disclosed in the notes to the accounts, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries (Refer Note 49 to the financial statements); and

(c) Based on such audit procedures that we considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.

v. The Company has not declared or paid any dividend during the year.

For Suryaprakash Maurya & Co.
Chartered Accountants
Registration No : 147410W

Suryaprakash Maurya
Membership No. : 178258

ICAI UDIN: 22178258AJQUMU1604

Place : Mumbai
Dated : 26th May,2022

INDEPENDENT AUDITORS' REPORT

Annexure "A" referred to in paragraph 1 under the heading Report on other legal and regulatory requirements of our report of even date

To the best of our information and according to the explanations provided to us by the Company and the books of account and records examined by us in the normal course of audit, we state that:

i.In respect of company's Property, Plant and Equipment and Intangible Assets:-

(a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangible Assets.

(b)The Property, Plant and Equipment of the Company have been physically verified by the Management during the year and no material discrepancies have been noticed on such verification. In our opinion, the frequency of verification is reasonable.

(c)The Title Deeds of immovable properties are held in the name of company.

(d)The Company has not revalued any of its Property, Plant and Equipment and intangible assets during the year.

a.No proceedings have been initiated during the year or are pending against the Company as at March 31, 2022 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.

ii.(a) According to the information and explanations given to us, the inventories have been physically verified during the year by the management at year end. The company has maintained proper records of inventory and discrepancies noticed on physical verification of the inventory as compared to books record which has been properly dealt with in the books of account were not material.

(b) The company has borrowings from banks on the basis of security of current assets. The quarterly returns or statements of current assets filed by the company with banks are in agreement with the books of accounts.statements of current assets filed by the company with banks are in agreement with the books of accounts.

iii. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not provided an guarantee or security or granted any advances in the nature of loans, secured or unsecured to companies, firms, limited liability partnership or any other parties during the year. The Company has made investments and granted loans to companies, in respect of which the requisite information is as below:

(a)Based on the audit procedures carried on by us and as per the information and explanations given to us, the Company has provided loans to any other entity as below:

Particulars	Loans given (Rs in lakhs)
Aggregate amount during the year: Others	135.28
Balance outstanding as at balance sheet date: Others	4,614.79

(b) According to the information and explanations given to us and based on the audit procedures conducted by us, in our opinion the investments made and the terms and conditions of the grant of loans during the year are, prima facie, not prejudicial to the interest of the Company.

© According to the information and explanations given to us and on the basis of our examination of the records of the Company, loan given toKilitch Estro Biotech PLC amounting to Rs 94.84 lakhs is repayable on demand. The interest on aforementioned loan given is payable on demand. As informed to us, the Company has not demanded repayment of the loan and payment of interest during the year. Thus, there has been no default on the part of the party to whom the money has been lent. Further, the Company has not given any advance in the nature of loan to any party during the year.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the loan given to Monarchy Healthserve Private Limited amounting to Rs 40.44 lakhs is repayable on demand. The interest on aforementioned loan given is payable on demand. As informed to us, the Company has not demanded repayment of the loan and payment of interest during the year. Thus, there is no overdue amount

INDEPENDENT AUDITORS' REPORT

(d)for more than ninety days in respect of loan given. Further, the Company has not given any advances in the nature of loans to any party during the year.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan or advance in the nature of loan granted falling due during the year, which has been renewed or extended or fresh loans granted to settle the overdues of existing loans given to same parties.

(f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion the Company has not granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment except for the following loans to its related party as defined in Clause (76) of Section 2 of the Companies Act, 2013 ("the Act"):

Particulars	Related Parties (Rs in lakhs)
Aggregate of loans - Repayable on demand (A) - Agreement does not specify any terms or period of Repayment (B)	 4,614.79 Nil
Total (A+B)	4,614.79
Percentage of loans	100%

iv. According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not provided any guarantee or security as specified under Section 185 and 186 of the Act. In respect of the investments made and loan given by the Company, in our opinion the provisions of Section 186 of the Act have been complied with.

v. According to the information and explanations given to us, the company has not accepted any deposits within the meaning of provisions of section 73 to 76 or any other relevant provisions of the Act and rules framed hereunder. Therefore, provisions of Clause (v) of paragraph 3 of the Order are not applicable to the company.

vi. We have broadly reviewed the cost records maintained by the Company pursuant to the Companies (Cost Accounting Records) Rules, 2014 prescribed by the Central Government under Sub Section (1) of Section 148 of the Act and are of the opinion that, prima facie, the prescribed cost records have been maintained. We have, however, not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.

vii. In respect of Statutory dues :
a. According to the records of the Company, undisputed statutory dues including Provident Fund, Employees' State Insurance, Income Tax, GST, Service Tax, Duty of Customs, Duty of Excise, Value Added Tax, Cess and other material statutory dues which are applicable to the company, have been regularly deposited with the appropriate authorities. According to the information and explanations given to us, no undisputed amounts payable in respect of the aforesaid dues were outstanding as at March 31, 2022 for a period of more than six months from the date of becoming payable. According to the information and explanations given to us and on the basis of our examination of the records of the Company, no undisputed amounts payable in respect of GST, Provident fund, Employees' State Insurance, Income-Tax and other statutory dues were in arrears as at 31 March 2022 for a period of more than six months from the date they became payable.

b. The disputed statutory dues aggregating to Rs. 50.31 Lakh that have not been deposited on account of the matters pending before the appropriate authorities are as under:

Name of the Statute	Nature of Dues	Amount in Lakhs	Period to which the amount relates	Forum where the dispute is pending
Property Tax NMMC	Property Tax CESS	53.20 22.85	A.Y. 2020-2021 A.Y. 2000-2001 A.Y. 2001-2002	Supreme Court Supreme Court

viii. There were no transactions relating to previously unrecorded income that have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

ix. (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to any lender.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful

INDEPENDENT AUDITORS' REPORT

defaulter by any bank or financial institution or government or government authority.

(c) In our opinion and according to the information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained.

(d) According to the information and explanations given to us and on an overall examination of the financials of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.

(e) According to the information and explanations given to us and on an overall examination of the financials of the Company, we report that the Company has not taken any fund from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint venture.

(f) According to the information and explanations given to us and on an overall examination of the financials of the Company, we report that the Company has not taken loans during the year on the pledge of securities held in subsidiaries, associates or joint venture.

x.(a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.

(b) In our opinion and as per the information and explanations given to us, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Accordingly, the provisions of clause (x)(b) of paragraph 3 of the Order are not applicable to the Company.

xi.(a) No fraud by the Company and no material fraud on the Company has been noticed or reported during the year.

(b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.

© No whistle-blower complaints have been received during the year by the Company. Accordingly, the reporting under clause 3(xi)© of the Order is not applicable to the Company.

xii. In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause (xii) of the Paragraph 3 of the Order are not applicable to the Company.

xiii. In our opinion, the Company is in compliance with Section 177 and 188 of the Companies Act, 2013 with respect to applicable transactions with the related parties and the details of related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.

xiv. (a) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.

(b) We have considered the internal audit reports for the year under audit, issued to the Company during the year and till date, in determining the nature, timing and extent of our audit procedures.

xv. In our opinion during the year the Company has not entered into any non-cash transactions with its Directors or persons connected with its directors. Hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.

xvi. (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) The Company has not conducted non-banking financial / housing finance activities during the year. Accordingly, the reporting under clause 3(xvi)(b) of the Order is not applicable to the Company.

(c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)© of the Order is not applicable.

(d) The Company is not part of any group (as per the provisions of the Core Investment Companies (Reserve Bank) Directions, 2016 as amended). Accordingly, the requirements of clause 3(xvi)(d) are not applicable.

xvii. The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.

INDEPENDENT AUDITORS' REPORT

xviii. There has been no resignation of the statutory auditors of the Company during the year.

xix. On the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

xx. In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Act pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicabl.

For Suryaprakash Maurya & Co.
Chartered Accountants
Registration No : 147410W

Suryaprakash Maurya
Membership No. : 178258

ICAI UDIN: 22178258AJQUMU1604

Place : Mumbai
Dated : 26th May,2022

INDEPENDENT AUDITORS' REPORT

"Annexure B" referred to in paragraph 2 under the heading Report on other legal and regulatory requirements of our report of even date

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of Kilitch Drugs (India) Limited ("the Company") as of March 31, 2022 in conjunction with our audit of the standalone Ind AS financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on "the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India". These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to

INDEPENDENT AUDITORS' REPORT

future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2022, based on "the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India".

For Suryaprakash Maurya & Co.
Chartered Accountants
Registration No : 147410W

Suryaprakash Maurya
Membership No. : 178258

ICAI UDIN: 22178258AJQUMU1604

Place : Mumbai
Dated : 26th May, 2022

KILITCH DRUGS (INDIA) LIMITED

Balance Sheet

as on 31st March 2022

.

			(Rs. In Lakhs)
Particulars	**Notes**	**As at 31 March, 2022**	**As at 31st March, 2021**
ASSETS			
Non - current assets			
- Property, Plant and Equipment	6	1394.83	679.07
- Capital work-in-progress		-	-
- Other Intangible Assets	6	23.41	15.40
Financial assets			
- Investments	7	7,014.88	7,010.04
- Loans & Advances	8	4,659.80	4,400.31
- Other Financial Assets	9	213.59	176.34
- Deferred tax assets (Net)	10	150.76	127.44
(A)		**13,457.27**	**12,408.60**
Current Assets			
- Inventories	11	500.02	358.61
Financial assets			
- Investments	7	4,723.42	3,640.05
- Trade Receivables	12	4,142.19	2,291.84
- Cash & Cash Equivalents	13	244.96	577.39
- Other Financial Assets	14	2.02	1.97
- Other Current Assets	15	159.38	306.30
(B)		**9,771.99**	**7,176.16**
TOTAL (A + B)		**23,229.26**	**19,584.76**
EQUITY AND LIABILITIES			
Equity			
- Equity Share Capital	16	1558.23	1,549.45
- Other Equity	17	16,244.89	14,743.96
(A)		**17,803.12**	**16,293.41**
Liabilities			
Non-Current liabilities			
- Provisions	18	27.54	38.06
Current liabilities			
- Financial Liabilities			
- Borrowings	19	2,033.48	1,470.68
- Trade Payables	20		
Micro and Small Enterprises		-	-
Others		2,776.84	1,355.74
- Other Financial Liabilities	21	3.88	3.88
- Provisions	22	100.88	80.60
- Current Tax Liabilities (Net)	23	439.62	262.30
- Other Current Liabilities	24	43.90	80.09
(B)		**5398.60**	**3291.35**
TOTAL (A+B)		**23,229.26**	**19584.76**
Significant Accounting Policies and Notes on Financial Statements 1 to 48			

As per our report of even date	
For Suryaprakash Maurya & Co. Chartered Accountants	For and on behalf of the Board of Directors Kilitch Drugs India Limited
FRN: 147410W	Mukund P. Mehta (Managing Director) [DIN: 00147876]
Suryaprakash Maurya Partner M. No.178258	Bhavin M. Mehta (Whole-time Director) [DIN: 00147895]
	Sunil Jain (Chief Financial Officer)
Place: Mumbai Dated: 26th May 2022	Pushpa Nyoupane (Company Secretary)

KILITCH DRUGS (INDIA) LIMITED

Statement of Profit and Loss

For the year ended 31st March 2022

(Rs. In Lakhs)

	Particulars	Notes	Year Ended 31st March 2022	Year Ended 31st March 2021
	Income			
I	Revenue from operations	25	10,515.98	7,001.68
II	Other Income	26	455.90	419.43
III	**Total Income (I+II)**		**10,971.88**	**7,421.11**
	Expenses			
	Cost of materials consumed	27	6,028.55	3,797.46
	Variation in inventories of finished goods & work-in-progress	28	(4.69)	108.81
	Employee benefits expenses	29	615.45	521.74
	Finance Cost		66.27	75.44
	Depreciation and amortization expense	6	96.42	114.10
	Export Product Registration/Commission	30	542.79	448.30
	Other expenses	31	2,234.27	1,604.43
IV	**Total Expenses**		**9,579.06**	**6,670.28**
V	Profit/ (loss) before tax		**1,392.82**	**750.83**
	Less: Tax Expense:-			
	a) Current Tax		363.37	166.55
	b) Tax adjustments of earlier years			
	c) Deferred Tax		(23.32)	(31.26)
	Profit/ (loss) for the year		**1,052.77**	**615.54**
	Other comprehensive income			
	A) Items that will not be reclassified To Profit & Loss A/c			
	a. Change in fair value of Investments		259.96	695.23
	b. Employee Benefits – Gratuity		5.78	8.40
	B) Income Tax relating to the items that will not be reclassified to Profit & Loss A/c			
	Change in fair value of Investments		(67.59)	(180.76)
	Total Other comprehensive income for the year (A+B)		198.15	522.87
	TOTAL COMPREHENSIVE INCOME		**1250.92**	**1,138.41**
	EARNINGS PER EQUITY SHARE [Face Value Rs. 10]	35		
	Basic (In Rs.)		6.76	3.98
	Diluted(In Rs.)		6.76	3.98
	Significant Accounting Policies and Notes on Financial Statements	1 to 48		

As per our report of even date	
For Suryaprakash Maurya & Co. Chartered Accountants	For and on behalf of the Board of Directors Kilitch Drugs India Limited
FRN: 147410W	Mukund P. Mehta (Managing Director) [DIN: 00147876]
Suryaprakash Maurya Partner M. No.178258	Bhavin M. Mehta (Whole-time Director) [DIN: 00147895]
	Sunil Jain (Chief Financial Officer)
Place: Mumbai Dated: 26th May 2022	Pushpa Nyoupane (Company Secretary)

KILITCH DRUGS (INDIA) LIMITED

Cash Flow Statement

For the year ended 31st March 2022

				(Rs. In Lakhs)
Particulars	**Year Ended 31st March 2022**		**Year Ended 31st March 2021**	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit / (Loss) before extraordinary items and tax		1392.82		750.83
Adjustments for:				
Depreciation and amortisation	96.42		114.10	
Interest income	(195.96)		(177.34)	
Dividend income	(3.05)		(5.55)	
(Profit)/Loss on sale of Investments	(135.92)		(120.31)	
Sundry Balances written back	-		(1.03)	
Provision for Gratuity & Leave Encashment	3.41		4.83	
Bad Debts / Provision for Doubtful Debts	-		153.44	
(Profit) / Loss from Investment in Partnership Firm	106.46		0.20	
Employee Stock Option Cost	0.20		(15.74)	
Net unrealised exchange (gain) / loss	71.76	(56.70)	1.25	(46.15)
Operating profit / (loss) before working capital changes		**1336.12**		**704.67**
Changes in working capital:				
Operating Assets:				
Inventories	(141.41)		197.06	
Trade receivables	(2028.59)		(745.97)	
Other current assets	146.92		(16.61)	
Deposits & advances	(2.16)		(8.03)	
Other financial assets	(0.05)		0.57	
Operating Liabilities:				
Trade Payables	1352.51		566.16	
Other Financial Liabilities				
Other current liabilities	32.40		19.91	
Short Term Provision	12.13	**(628.25)**	(3.97)	**9.12**
Gross cash flow from / (used in) operating activities		**774.16**		**713.79**
Direct Taxes (Paid) /refunded		**(253.66)**		**(101.25)**
Net cash flow from / (used in) operating activities (A)		**520.50**		**612.54**
B. CASH FLOW FROM INVESTING ACTIVITIES				
Purchases of Property, Plant & Equipment	(820.18)		(41.93)	
Loans/Advances to related Parties	(257.33)		(525.98)	
Proceeds (Net) from the sale of Current investments	(687.48)		(43.47)	
- Others	(5.03)		16.27	
Movement in other Bank balance	(37.25)		(122.51)	
Interest received	195.96		177.34	
Dividend received	3.05		5.55	
		(1608.26)		(534.73)
Net cash flow from / (used in) investing activities (B)		**(1608.26)**		**(534.73)**

Cash Flow Statement

For the year ended 31st March 2022

C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from Shares issued [incl. ESOPs]	8.79		6.04	
Application money received against Share Warrants	250.00		-	
Proceeds from Borrowings (Net of Repayments)	562.81		219.46	
Interest paid	(66.27)		-	
Dividends paid(Inclusive of tax on Dividend)	-		1.81	
Net cash flow from / (used in) financing activities (C)		**755.33**		**227.31**
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		**(332.43)**		**305.12**
Cash and cash equivalents at the beginning of the year		577.39		272.27
Cash and cash equivalents at the end of the year		**244.96**		**577.39**
Cash and cash equivalents at the end of the year *				
* Comprises:				
(a) Cash on hand		0.45		0.71
(b) Balances with banks				
(i) In current accounts		240.63		572.80
(ii) In earmarked accounts		3.88		3.88
		244.96		**577.39**

As per our report of even date	
For Suryaprakash Maurya & Co. Chartered Accountants	For and on behalf of the Board of Directors Kilitch Drugs India Limited
FRN: 147410W	Mukund P. Mehta (Managing Director) [DIN: 00147876]
Suryaprakash Maurya Partner M. No.178258	Bhavin M. Mehta (Whole-time Director) [DIN: 00147895]
	Sunil Jain (Chief Financial Officer)
Place: Mumbai Dated: 26th May 2022	Pushpa Nyoupane (Company Secretary)

KILITCH DRUGS (INDIA) LIMITED

Statement of Change in Equity

For the year ended 31st March 2022

(a) Equity Share Capital				(Rs.In Lakhs)
As at 1st April 2020	Changes during the Year	As at 31st March 2021	Changes during the Year	As at 31st March 2022
1,543.42	6.03	1549.45	8.78	1558.23

(b) Statement of Changes in Other Equity

Particulars	Securities Premium account	General Reserve	Employee Stock Options	Other Equity	Other Reserves (Call on shares forfeited A/c)	Other Comprehensive Income	Surplus in the Statement of Profit and Loss	Total
Balance as on 1st April 2020	**3,832.63**	**1,511.76**	**119.13**	**-**	**58.00**	**(55.99)**	**8,155.76**	**13,621.29**
Profit/(Loss) for the Year	-	-	-	-	-	-	615.54	615.54
Change In Fair Value of Investments	-	-	-	-	-	522.87	-	522.87
Premium on issue of Shares during the year	-	67.98	(83.72)	-	-	-	-	(15.74)
Balance as on 31st March 2021	**3832.63**	**1579.74**	**35.41**	**-**	**58.00**	**466.88**	**8771.30**	**14743.96**
Profit/(Loss) for the Year	-	-	-	-	-	-	1052.77	1052.77
Change In Fair Value of Investments	-	-	-	-	-	198.15	-	198.15
Money Received Against Share Warrents	-	-	-	250.00	-	-	-	250.00
Balance as on 31st March 2022	**3832.63**	**1579.74**	**35.41**	**250.00**	**58.00**	**665.03**	**9824.07**	**16244.89**

As per our report of even date	
For Suryaprakash Maurya & Co. Chartered Accountants	For and on behalf of the Board of Directors Kilitch Drugs India Limited
FRN: 147410W	Mukund P. Mehta (Managing Director) [DIN: 00147876]
Suryaprakash Maurya Partner M. No.178258	Bhavin M. Mehta (Whole-time Director) [DIN: 00147895]
	Sunil Jain (Chief Financial Officer)
Place: Mumbai Dated: 26th May 2022	Pushpa Nyoupane (Company Secretary)

Notes to the Financial Statements

For year ended 31st March 2022

Note 1 - Corporate Information:

The Company is a public limited company domiciled in India and is incorporated under the provisions of the Companies Act applicable in India and its shares are publicly traded on the National Stock Exchange ('NSE') and the Bombay Stock Exchange ('BSE'), in India. The registered office of the company is located at C-301-2, M.I.D.C. TTC Industrial Area, Pawane Village, Thane – 400705.

These financial statements were approved and adopted by the Board of Directors of the Company in their meeting dated 26th May 2022.

Note 2 - Basis of Preparation of Financial Statements:

The Financial Statements have been prepared to comply in all material aspects with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015, as amended.

The significant accounting policies used in preparing financial statements are set out in Note 3 of the Notes on Financial Statements and are applied consistently to all the periods presented.

Note 3 - Significant Accounting Policies:

A. Functional and presentation of currency:
The financial statements are presented in Indian Rupees, which is the Company's functional currency and all amounts are rounded to the nearest rupees in lakhs.

B. Basis of measurement:
The Financial Statements have been prepared on historical cost basis, except the following:

- Certain financial assets and liabilities are measured at fair value.
- Defined benefit plans – plan assets measured at fair value.
- Share Based Payments.

C. Use of Estimates:
The preparation of the financial statements requires management to make estimates, judgements and assumptions that affect the reported balances of assets and liabilities, disclosure of contingent liabilities as on the date of financial statements and reported amounts of income and expenses during the period.

Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year. The Company based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. Such changes are reflected in the assumptions when they occur.

D. Property, Plant and Equipment:
Freehold land is carried at historical cost. Capital work in progress, and all other items of property, plant and equipment are stated at historical cost net of accumulated depreciation and accumulated impairment losses, if any.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

Depreciation methods, estimated useful lives and residual value

Depreciation is calculated using the Written down Value method to allocate their cost, net of their residual values, over their estimated useful lives as specified by Schedule to the Companies Act; 2013. The residual values are not more than 5% of the original cost of the asset. The assets' residual values and useful lives and method of depreciation are reviewed, and adjusted if appropriate, at the end of each reporting period.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by

Notes to the Financial Statements

For year ended 31st March 2022

comparing proceeds with carrying amount. These are included in profit or loss.

E. Intangible assets:

Identifiable intangible assets are recognised when the Company controls the asset & it is probable that future economic benefits attributed to the asset will flow to the Company and the cost of the asset can be reliably measured.

Intangible assets acquired are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses.

Intangible assets are amortised over the period on straight line basis. The assets useful life reviewed at each financial year end.

Amortisation methods and periods

Estimated useful lives of Intangible assets are considered as 5 years. Intangible assets are amortised over its useful life using the straight-line method. The amortisation period and the amortisation method for an intangible asset are reviewed at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates. The amortisation expense on intangible assets with finite lives is recognised in the statement of profit and loss.

F. Impairment of Non – Financial Assets:

The Company assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or Cash Generating Unit's (CGU) fair value less costs of disposal and its value in use. It is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or a groups of assets. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing the value in use, the estimated future cash flows are discounted to their present value using pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

In determining fair value less costs of disposal, recent market transactions are taken into account, if no such transactions can be identified, an appropriate valuation model is used.

G. Financial Instruments:

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instruments of another entity. Classifications of financial instruments are in accordance with the substance of the contractual arrangement and as per the definitions of financial assets, financial liability and an equity instruments.

Financial Assets and investments
I. Initial recognition and measurement:

At initial recognition, the company measures a financial asset (other than financial asset at fair value through profit or loss) at its fair value plus or minus, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through profit or loss are expensed in the statement of profit & loss.

II. Subsequent recognition and measurement:

Subsequent measurement of financial asset depends on the company's business model for managing the asset and the cash flow characteristics of the asset. For the purpose of subsequent recognition and measurement financial assets are classified in four categories:

• Debt instrument at amortised cost:

Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. A gain or loss on a debt investment that is subsequently measured at amortised cost and is not part of a hedging relationship is recognised in profit or loss when the asset is derecognised or impaired. Interest income from these financial assets is included in finance income using the effective interest rate method.

Notes to the Financial Statements

For year ended 31st March 2022

• Debt instrument at fair value through other comprehensive income (FVOCI):

Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest, are measured at fair value through other comprehensive income (FVOCI). Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses and interest revenue which are recognised in the statement of profit & loss. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to profit or loss and recognised in other gains/ (losses). Interest income from these financial assets is included in other income using the effective interest rate method.

• Debt instrument at fair value through profit and loss (FVTPL):

Assets that do not meet the criteria for amortised cost or FVOCI are measured at fair value through profit or loss. A gain or loss on a debt investment that is subsequently measured at fair value through profit or loss and is not part of a hedging relationship is recognised in the statement of profit & loss and presented net in the statement of profit & loss within other gains/(losses) in the period in which it arises. Interest income from these financial assets is included in other income.

• Equity instruments:

All equity instruments are initially measured at fair value. Any subsequent fair value gain / loss is recognised through profit or loss if such investments are held for trading purposes. The fair value gains or losses of all other equity investments are recognised in Other Comprehensive Income.

• Investment in Subsidiary and Associates:

The company has accounted for its Investment in subsidiaries and associates at cost.

III. De-recognition:

A financial asset is primarily derecognised i.e. removed from Company's financial statement when:

- The rights to receive cash flows from asset have expired, or
- The Company has transferred its right to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under 'pass- through' arrangement and either;

a) The Company has transferred substantially all the risks and rewards of the assets,
b) The Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the company could be required to repay.

IV. Trade receivables:

A receivable is classified as a 'trade receivable' if it is in respect to the amount due from customers on account of goods sold or services rendered in the ordinary course of business. Trade receivables are recognised initially at fair value and subsequently measured at fair value less provision for impairment.

Financial Liabilities:

I. Initial recognition and measurement:

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts.

Notes to the Financial Statements

For year ended 31st March 2022

II. Subsequent measurement:

The measurement of financial liabilities depends on their classification, as described below:

Financial liabilities at fair value through profit and loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and has designated upon initial measurement recognition at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term.
Gains or losses on liabilities held for trading are recognised in the statement of profit & loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied.

III. Loans and Borrowings:

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the effective interest rate (EIR) method. Gains and losses are recognised in the statement of profit & loss when the liabilities are derecognised as well as through the EIR amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The EIR amortisation is included as finance costs in the statement of profit and loss.

IV. Trade and other payables:

These amounts represent liabilities for goods and services provided to the company prior to the end of financial year which are unpaid. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period.

V. De-recognition:

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the De-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

H. Impairment of Financial assets:

The company assesses impairment based on expected credit losses (ECL) model to the following:

- Financial assets carried at amortised cost;
- Financial asset measured at FVOCI debt instruments.

The Company follows 'simplified approach' for recognition of impairment loss allowance onTrade receivables or contract revenue receivables.

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

The Company uses a provision matrix to determine impairment loss allowance on its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed.

For recognition of impairment loss on other financial assets and risk exposure, the company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If, in a subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12-month ECL.

Lifetime ECL are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12-month ECL is a portion of the lifetime ECL which results from default events that are possible within 12 months after the reporting date.

For assessing increase in credit risk and impairment loss,

Notes to the Financial Statements

For year ended 31st March 2022

the company combines financial instruments on the basis of shared credit risk characteristics with the objective of facilitating an analysis that is designed to enable significant increases in credit risk to be identified on a timely basis.

I. Cash and cash equivalents:

Cash and cash equivalents includes cash on hand and at bank, deposits with banks and other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

J. Inventories

Inventories are valued at lower of cost or net realisable value. Cost is determined on FIFO basis.

Cost of inventories also includes all other costs incurred in bringing the inventories to their present location and condition. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

K. Foreign currency transactions:

The transactions denominated in foreign currency are recorded at the exchange rate prevailing on the date of transaction. Monetary items denominated in foreign currency at the end of year are translated using the closing rate of exchange. Non- monetary items that are to be carried at historical cost are recorded using exchange rate prevailing on the date of transaction. Non- monetary items that are to be carried at fair value are recorded using exchange rate prevailing on the date of fair value measured. Any income or expenses on account of exchange difference either on settlement or on translation is recognised in the statement of profit & loss.

L. Classification of assets and liabilities as current and non-current:

The Company presents assets and liabilities in Balance Sheet based on current/non-current classification.
An asset is classified as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle,
- Held primarily for the purpose of trading,
- Expected to be realised within twelve months after the reporting period, or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is classified as current when:

- It is expected to be settled in normal operating cycle,
- It is held primarily for the purpose of trading,
- It is due to be settled within twelve months after the reporting period, or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

All other liabilities are classified as non-current.
Deferred tax assets and liabilities are classified as non-current assets and liabilities.

M. Equity share capital:

Ordinary shares are classified as equity. Incremental costs net of taxes directly attributable to the issue of new equity shares are reduced from retained earnings, net of taxes.

N. Revenue Recognition:

Revenue is recognised to the extent that it is probable that the future economic benefits will flow to the entity and it can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government.

• Sale of goods

Revenue from sale of goods is recognised when the significant risks and rewards of ownership have been transferred to the buyer, usually on delivery of goods, it is probable that the economic benefit will flow to the Company, the associated costs and possible return of goods can be estimated reliably, there is neither continuing management involvement to the degree usually associated with ownership nor effective control over the goods sold and the amount of revenue can be measured reliably.

Notes to the Financial Statements

For year ended 31st March 2022

Provisions for chargeback, rebates, discounts and medical aid payments are estimated and provided for in the year of sales and recorded as reduction of revenue.

• Sales Returns

With respect to established products, the Company considers its historical experience of sales returns, levels of inventory in the distribution channel, estimated shelf life, product discontinuances, price changes of competitive products, and the introduction of competitive new products, to the extent each of these factors impact the Company's business and markets. With respect to new products introduced by the Company, such products have historically been either extensions of an existing line of product where the Company has historical experience or in therapeutic categories where established products exist and are sold either by the Company or the Company's competitors.

• Interest income:

Interest income from debt instrument is recognised using effective interest rate method. The effective interest rate is the rate that discounts estimated future cash receipts through the expected life of financial asset to the gross carrying amount of financial asset. When calculating effective interest rate, the company expects cash flows by considering all contractual terms of financial instrument but does not consider the expected credit losses.

• Dividends

Dividends are recognised when the right to receive the payment is established.

O. Employee's benefits:

i. Short-term Employee benefits:
All employees' benefits payable wholly within 12 months rendering services are classified as Short Term obligations.
Benefits such as salaries, wages, short term compensated absences, performance incentives, expected cost of bonus and ex-gratia are recognised during the period in which the employees renders related services.

ii. Post-employment benefits

a. Defined Contribution Plan
The defined contribution plan is post-employment benefit plan under which the Company contributes fixed contribution to a government administered fund and will have no legal or constructive obligation to pay further contribution. The Company's defined contribution plan comprises of Provident Fund, Labour Welfare Fund and Employee State Insurance Scheme. The Company's contribution to defined contribution plans are recognised in the statement of profit & loss in the period in which the employee renders the related services.

b. Defined benefit plan

The Company has defined benefit plans comprising of gratuity. Company's obligation towards gratuity liability is partially funded as Management has initiated a decision to be funded and managed by Life Insurance Corporation of India over the period of 20 equated quarterly instalments over a period of 5 years.

The present value of the defined benefit obligations is determined based on actuarial valuation using the projected unit credit method. The rate used to discount defined benefit obligation is determined by reference to market yields at the Balance Sheet date on Indian Government Bonds for the estimated term of obligations.

Based on actuarial valuation using the projected unit credit method. The rate used to discount defined benefit obligation is determined by reference to market yields at the Balance Sheet date on Indian Government Bonds for the estimated term of obligations.

Actuarial gains or losses arising on account of experience adjustment and the effect of changes in actuarial assumptions are recognised immediately in the statement of profit & loss as income or expense.

Re-measurements comprising of
(a) Actuarial gains and losses,
(b) the effect of the asset ceiling (excluding amounts included in net interest on the net defined benefit liability) and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability) are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through other comprehensive income in the period in which they occur. Re-measurements are not reclassified to the statement of profit & loss in subsequent periods.

The expected return on plan assets is the Company's expectation of average long-term rate of return on the

Notes to the Financial Statements

For year ended 31st March 2022

investment of the fund over the entire life of the related obligation. Plan assets are measured at fair value as at the Balance Sheet date.

The interest cost on defined benefit obligation and expected return on plan assets is recognised under finance cost.

Gains or losses on the curtailment or settlement of defined benefit plan are recognised when the curtailment or settlement occurs.

c. Other long-term benefits

The Company has other long-term benefits in the form of leave benefits. The present value of the other long term employee benefits is determined Gains or losses on the curtailment or settlement of other long-term benefits are recognised when the curtailment or settlement occurs.

d. Share-based payments

Share-based compensation benefits are provided to employees via Employee Stock Option Plans with the ESOS 2007.

The fair value of options granted under the Employee Option Plan is recognised as an employee benefits expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted: Including any market performance conditions (e.g., the entity's share price) excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales growth targets and remaining an employee of the entity over a specified time period), and

Including the impact of any non-vesting conditions (e.g. the requirement for employees to save or holdings shares for a specific period of time).

The total expense, other than in respect of options granted to employees of group companies, is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. The cost of options granted to employees of group companies is debited to the cost of the investment of the respective companies.

At the end of each period, the company revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions. It recognises the impact of the revision to original estimates, if any, in the statement of profit & loss / Investment, with a corresponding adjustment to other equity.

P. Borrowing Cost:

General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalised during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for such capitalisation.

Other borrowing costs are expensed in the period in which they are incurred.

Borrowing costs consist of interest and other costs that are incurred in connection with the borrowing of funds.

Q. Income Taxes:

• Current Income Tax:

Current Income Tax liabilities are measured at the amount expected to be paid to the taxation authorities using the tax rates and tax laws that are enacted or subsequently enacted at the end of the reporting period. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and creates provisions where appropriate.

• Deferred Tax:

Deferred Tax is provided, using the Balance sheet approach, on temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred Tax is determined using the tax rates and tax laws that are enacted or subsequently enacted at the end of the reporting period.

Deferred Tax liabilities are recognised for all temporary differences.

Notes to the Financial Statements

For year ended 31st March 2022

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and the deferred tax balances relate to the same taxation authority. Current tax asset and liabilities are offset where the company has a legally enforceable right and intends either to settle on net basis, or to realise the asset and settle the liability simultaneously.

R. Provisions and contingencies:

Provisions are recognised when the company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. If the effect of the time value of money is material, provisions are discounted using the government securities' interest rate for the equivalent period. Unwinding of the discount is recognised in the Statement of Profit and Loss as a finance cost. Provisions are reviewed at each balance sheet date and are adjusted to reflect the current best estimate. Provisions are not recognised for future operating losses.

Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the company or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made. Information on contingent liability is disclosed in the notes to the financial statements. Contingent assets are not recognised. However, when the realisation of income is virtually certain, then the related asset is no longer a contingent asset, but it is recognised as an asset.

S. Earnings per share:

Basic earnings per share is calculated by dividing the net profit or loss (after tax) for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.

Diluted earnings per share is calculated by dividing the net profit or loss (after tax) for the year attributable to equity shareholders and the weighted average number of equity shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

Note 4 - Use of Significant Accounting Estimates, Judgments and Assumptions

In the process of applying the Company's accounting policies, management has made the following estimates and judgements, which have significant effect on the amounts recognised in the financial statements:

A. Depreciation and useful lives of Property, Plant and Equipment

Property, plant and equipment are depreciated over the estimated useful lives of the assets, after taking into account their estimated residual value. Management reviews the estimated useful lives and residual values of the assets annually in order to determine the amount of depreciation to be recorded during any reporting period. The useful lives and residual values are based on the Company's historical experience with similar assets and take into account anticipated technological changes. The depreciation for future periods is adjusted if there are significant changes from previous estimates.

B. Recoverability of trade receivables

Judgments are required in assessing the recoverability of overdue trade receivables and determining whether a provision against those receivables is required. The Company uses a provision matrix to determine impairment loss allowance on its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed.

C. Defined Benefit plans

The cost of the defined benefit plan and other post-employment benefits and the present value of such obligation are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, a

Notes to the Financial Statements

For year ended 31st March 2022

a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

D. Provisions:

Provisions and liabilities are recognized in the period when it becomes probable that there will be a future outflow of funds resulting from past operations or events and the amount of cash outflow can be reliably estimated. The timing of recognition and quantification of the liability require the application of judgement to existing facts and circumstances, which can be subject to change. Since the cash outflows can take place many years in the future, the carrying amounts of provisions and liabilities are reviewed regularly and adjusted to take account of changing facts and circumstances.

E. Impairment of financial assets:

The impairment provisions for financial assets are based on assumptions about risk of default and expected cash loss rates. The Company uses judgment in making these assumptions and selecting the inputs to the impairment calculation, based on Company's past history, existing market conditions as well as forward looking estimates at the end of each reporting period.

Estimates and judgments are based on historical experience and other factors, including expectations of future events that may have a financial impact on the Company and that are believed to be reasonable under the circumstances. They are continuously evaluated.

F. Fair Value measurement:

The Company measures financial instrument such as certain investments, at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities
- Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

Note 5- Amendment to Existing issued IndAS :

On March 23, 2022, the Ministry of Corporate Affairs (MCA) has notified Companies (Indian Accounting Standards) Amendment Rules, 2022. This notification has resulted into amendments in the following existing accounting standards which are applicable to company from April 1, 2022.

Notes to the Financial Statements

For year ended 31st March 2022

Ind AS 101 - First time adoption of Ind AS
Ind AS 103 - Business Combination
Ind AS 109 - Financial Instrument
Ind AS 16 - Property, Plant and Equipment
Ind AS 37 - Provisions, Contingent Liabilities and Contingent Assets
Ind AS 41 - Agriculture

Application of above standards are not expected to have any significant impact on the company's financial statements.

Notes to the Financial Statements

For year ended 31st March 2022

Note 6 - Property, Plant & Equipment

(Rs. in Lakhs)

Particulars	Land	Pen Land	Rights on Lease Hold Land	Factory Building	Office premises	Plant & Machinery	Furniture & Equipment	Computer	Motor Car	Office Equipment	Air Conditioners	Electrical Installations	Laboratory Equipment	Mobile Phone	Computer software	Total
Gross Block																
As at 01/04/2020	29.88	-	96.78	261.02	133.24	1556.39	103.58	50.22	131.20	25.09	28.54	45.36	237.67	13.47	18.40	2730.84
Additions	-	-	-	-	-	12.41	0.49	5.16	1.53	0.60	0.56	-	8.58	1.93	10.65	41.93
Disposals/ Transfers	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
As at 31/03/2021	29.88	-	96.78	261.02	133.24	1568.80	104.08	55.38	132.72	25.69	29.10	45.36	246.25	15.40	29.05	2772.77
Additions	-	734.65	-	-	-	65.51	1.55	2.49	-	3.93	-	0.21	1.38	1.46	9.02	820.18
Disposals/ Transfers	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
As at 31/03/2022	29.88	734.65	96.78	261.02	133.24	1634.31	105.63	57.87	132.72	29.62	29.10	45.57	247.63	16.86	38.07	3592.95
Accumulated Depreciation																
As at 01/04/2020	-	-	-	247.97	79.08	1135.56	76.23	43.28	109.65	19.68	24.56	25.03	180.55	9.22	13.39	1964.20
Depreciation Charge for the Year	-	-	-	-	2.63	70.44	6.80	4.77	6.46	2.33	0.53	5.09	13.85	0.94	0.26	114.10
As at 31/03/2021	-	-	-	247.97	81.71	1206.00	83.03	48.05	116.11	22.01	25.09	30.13	194.41	10.16	13.65	2078.30
Depreciation Charge for the Year	-	-	-		2.50	61.00	4.96	4.49	3.54	2.17	0.51	3.75	11.52	0.97	1.01	96.42
As at 31/03/2022	-	-	-	247.97	84.21	1267.00	87.99	52.54	119.65	24.18	25.60	33.88	205.93	11.13	14.66	2174.72
Net Block																
As at 31/03/2022	29.88	734.65	96.78	13.05	49.03	367.31	17.64	5.31	13.08	5.45	3.50	11.69	41.70	5.73	23.41	1418.24
As at 31/03/2021	29.88	-	96.78	13.05	51.53	362.80	21.05	7.31	16.62	3.68	4.01	15.23	51.85	5.25	15.40	694.47

Notes to the Financial Statements

For year ended 31st March 2022

Note 7 – Investments

A] Non-Current Investments		(Rs. in Lakhs)
Particulars	**As at 31st March 2022**	**As at 31st March 2021**
Non-Trade Investments		
A. Investments in Shares:		
i. Quoted Shares: (At Fair Value through Other Comprehensive Income)		
[Equity Shares of Face value Rs.10/- each, fully paid-up, unless otherwise stated]		
15 (31st March 2021 : 15) - Bengal and Assam Co Ltd.	0.35	0.20
1,000 (31st March 2021: 1000) - Century Enka Ltd.	5.55	2.54
500 (31st March 2021 : 500) - Century Textiles &Ind Ltd.	4.27	2.33
200 (31st March 2021 :200) - Colgate Palmolive India Ltd.	3.08	3.12
720 (31st March 2021 : 720) - J K Laxmi Cement Ltd.	3.42	3.12
400 (31st March 2021 : 400) - Pfizer Ltd.	17.39	18.10
62 (31st March 2021 :62) - Ultratech Cement Ltd.	4.09	4.18
Fair Value of Quoted Instruments (Total of A.i)	**38.17**	**33.58**
ii. Unquoted Shares:		
Investment in Indian Subsidiary (At Cost) - Monarchy Healthserve Pvt Ltd		
[Preference Shares of Face value Rs. 10/- each, fully paid-up, unless otherwise stated]		
4,20,000 (P.Y. 4,20,000) Monarchy Healthserve Pvt Ltd	4,200.00	4,200.00
[Equity Shares of Face value Rs. 10/-each, fully paid-up, unless otherwise stated]		
50,860 (P.Y. 50860) Monarchy HealthservePvt. Ltd.	2.02	2.02
Investment in Foreign Subsidiary		
67% Investment in KilitchEstro Biotech PLC.	419.68	419.68
Book Value of Unquoted Instruments (Total of A.ii)	**4,621.70**	**4,621.70**
Total Investment in Shares (A.i + A. ii)	**4,657.85**	**4,655.28**
B. Investment in Portfolio Management Scheme		
(At Fair Value through Other Comprehensive Income)		
Club millionaire Financial Services Pvt Ltd.	47.60	43.32
C. Investment in the Capital of Partnership Firm (LLP) (At Cost)		
Arham Neeta Realities LLP	2,246.29	2,246.29
D. Investments in Bonds:		
i. Quoted Bonds: (At Fair Value through Other Comprehensive Income)		
National Highways Authority of India	54.16	55.93
Housing And Urban Development Corporation Ltd	8.96	9.22
Total Investment in Bonds (D)	**63.12**	**65.15**
Aggregate Fair Value of All Non- current Investments (A+B+C+D)	**7,014.88**	**7,010.04**

Notes to the Financial Statements

For year ended 31st March 2022

B] Current Investments		(Rs. in Lakhs)
Particulars	**As at 31st March 2022**	**As at 31st March 2021**
Investment in Units of Mutual Funds : (At fair value through Other Comprehensive income)		
Mutual Fund - Kotak		
118,772.2330 (31st March 2021:118,772.2330) HDFC Small Cap Fund Regular Growth	84.34	62.77
77,649.1390 (31st March 2021: 77,649.1390) L &T Midcap Fund Growth	157.60	136.09
20,58,500.4490 (31st March 2021:19,59,250.2460) Mirae Asset Midcap Fund Regular Plan Growth	423.31	315.03
206,930.0720 (31st March 2021: 2,06,930.0720) Aditya Birla Sun Life Corporate Bond Fund Growth	186.63	177.76
715,151.4420 (31st March 2021: 7,15,151.4420) HDFC Short Term Debt Fund Regular Plan Growth	183.74	175.69
476,441.9750 (31st March 2021:345,990.9000) Axis Focused 25 Fund Growth	205.39	129.68
NIL (31st March 2021: 426.7640) Kotak Liquid Scheme - Regular Plan Growth	-	17.67
21,16,536.3590 (31st March 2021: 21,16,536.3590) IDFC Banking Debt Fund Regular Plan Growth	423.65	407.11
NIL (31st March 2021 :821,723.2730) NIPPON INDIA Arbitrage Fund Dividend- DR	-	102.57
15,00,000 (31st March 2021 : 15,00,000) IDFC Fixed Term Plan Series 149 Direct Plan Growth	195.18	187.46
15,00,000 (31st March 2021 : 15,00,000) IDFC Fixed Term Plan Series 149 Regular Plan Growth	193.47	186.2
14,390.0320 (31st March 2021: 14,390.0320) Axis Banking & PSU Debt Fund Growth	308.05	296.35
491,005.8650 (31st March 2021: 405,368.2200) Axis Blue Chip Fund Growth	219.87	156.92
395,200.7610 (31st March 2021: 395,200.7610) ICICI Prudential Banking and PSU debt Fund Growth	103.28	98.73
185,493.6510 (31st March 2021 : 479,294.1150) Kotak Flexi Cap Fund Regular Plan Growth	96.40	215.5
424,033.3490 (31st March 2021 :374,262.0030) Mirae Asset India Equity Fund Regular Plan Growth	328.26	245.16
537,127.7120 (31st March 2021 : 537,127.7120) HDFC Corporate Bond Fund Regular Plan Growth	140.37	133.89
53,068.1590 (31st Match 2021: 3649.5270) Kotak Overnight Fund Regular Plan Growth	600.12	40
15 (31st March 2021 : 10) ShriRam City Union Finance Limited	162.34	102.31
100 (31st March 2021 : 55) SpandanaSpoorty Financial Ltd (Debenture)	112.80	55
52.50 (31st March 2021 : 40) WELSPUN ONE LOGISTICS PARKS FUND-1	52.50	39.97
3 (31st March 2021 : NIL) LENDINGKART FINANCE LIMITED BR NCD	32.12	-
772419.6500 (31st March 2021 : 397,544.4960) MotilalOswalNasdaq 100 Fund of Fund Reg Plan Growth	178.30	79.11
63212.3980 (31st March 2021 :NIL) Kotak NASDAQ 100 Fund Regular Plan Growth	7.24	-
NIL (31st March 2021 : 3011.6290) AXIS Liquid Fund Growth	-	68.45
NIL (31st March 2021 : 3252.5590) Mirae Asset Overnight Fund Reg Plan Growth	-	34.24
5 (31st March 2021 :NIL) PIRAMAL ENTERPRISES LTD	53.26	-
99995 (31st March 2021 :NIL) ICICI Prodential Long short fund Series II Class B1 December 2021_Regular	100.00	-
121561.7820 (31st March 2021 :NIL)Edelweiss Greater China Equity Off shore Fund Regular Plan Growth Option	48.72	-
Mutual Fund - SPA Capital		
NIL (31st March 2021 : 130,116.845) Franklin India Income Opportunities Fund (SPA)	-	29.74
NIL (31st March 2021 : 14,183.380) HDFC Prudence Fund (SPA)	-	33.45
NIL (31st March 2021 : 24,717.259) UTI MID CAP FUND GROWTH (SPA)	-	36.48
UTI Structured Debt Opportunities Fund I (SPA)	44.22	76.73
Mutual Fund – RNB CORPORATE		
51,130.478 (31st March 2021: NIL) HDFC DYNAMIC DEBT G	37.34	-
17,508.552 (31st March 2021: NIL) UTI FLEXI CAP REG G	42.89	-
Market Value of Unquoted Investments	**4,723.42**	**3,640.05**
Aggregate Fair Value of All Current Investments	**4,723.42**	**3,640.05**

Notes to the Financial Statements

For year ended 31st March 2022

Note 8-Loans and Advances

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
(a) Deposits	35.58	31.82
(b) Advance to Related parties	4614.79	4,357.46
(c) Other Advances	9.44	11.03
Total	**4,659.80**	**4,400.31**

Note 9 - Other Financial Assets

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
Fixed Deposits with Bank (more than 12 months)	213.59	176.34
Total	**213.59**	**176.34**

Note 10 - Deferred Tax Asset

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
At the Start of the year	127.44	96.28
Charges/(credit) to profit and loss	23.32	31.26
At the end of the year	**150.76**	**127.44**
Deferred tax Asset		
Related to Property, Plant and Equipment	19.66	21.62
Provision for Gratuity/Leave Encashment	20.89	19.41
Provision for Doubtful Debtors	110.20	86.41
Total	**150.76**	**127.44**

Note 11 - Inventories

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
[As taken, valued and certified by the Management]		
a. Raw Materials and components	415.61	278.88
b. Work-in-progress	39.86	34.56
c. Finished goods	44.56	45.17
Total	**500.02**	**358.61**

Note 12 - Trade Receivables

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
[Unsecured, considered good unless otherwise stated]		
Considered Good	4,142.19	2,291.84
Less : Allowance for expected credit loss	-	-
Credit impaired	423.86	332.36
Less : Allowance for expected credit loss	(423.86)	(332.36)
Total	**4,142.19**	**2,291.84**

Notes to the Financial Statements

For year ended 31st March 2022

Note 13 - Cash and Cash Equivalents

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
a. Cash on hand	0.45	0.71
b. Balances with banks	244.51	576.68
Total	**244.96**	**577.39**
Bank Balances include:		
Earmarked Balances (eg/unpaid dividend accounts)	3.88	3.88
Margin money	1.34	1.34

Note 14 - Other Financial Assets

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
Accrued Interest/Dividend Receivable	2.02	1.97
Total	**2.02**	**1.97**

Note 15 - Other Current Asset

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
Balances with Government Authorities	153.96	300.91
Advance to Suppliers	0.45	2.78
Prepaid Expenses	4.97	2.61
Total	**159.38**	**306.30**

Note 16 - Equity Share Capital

(Rs. In Lakhs)

Particulars	As at 31st March, 2022		As at 31st March, 2021	
	Number	Amount	Number	Amount
Authorised				
200,00,000 (31st March 2021 : 200,00,000) Equity Shares of Rs.10 each	2,00,00,000	2,000.00	2,00,00,000	2,000.00
Issued, Subscribed & Paid up				
1,55,82,129 (31st March 2021 : 1,54,94,544) Equity Shares of Rs. 10 each fully paid up	1,55,82,129	1,558.23	1,54,94,354	1,549.45
Total	**1,55,82,129**	**1,558.23**	**1,54,94,354**	**1,549.45**

Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period

Particulars	As at 31st March, 2022		As at 31st March, 2021	
	Number	Amount (Rs. In Lakhs)	Number	Amount (Rs. In Lakhs)
Equity Shares outstanding at the beginning of the year	1,54,94,354	1549.45	1,54,34,000	1543.42
Add : ESOP allotment during the year	87,775	8.78	60,354	6.03
Equity Shares bought back during the year	-	-	-	-
Equity Shares outstanding at the end of the year	**1,55,82,129**	**1,558.23**	**1,54,94,354**	**1,549.45**

Shares in the company held by each s hareholder holding more than 5 Percent shares

	As at 31st March, 2022		As at 31st March, 2021	
Name of Shareholder	No. of Shares held	% of Holding	No. of Shares held	% of Holding
Kilitch Company Pharma Limited	66,29,342	42.54%	66,29,342	42.79%
Mukund Prataprai Mehta	8,90,647	5.72%	8,90,647	5.75%
Bhavin Mukund Mehta	20,02,416	12.85%	20,02,416	12.92%
Neeta Mukund Mehta	11,11,768	7.13%	11,11,768	7.18%

The company has only one class of Equity Shares having a face value of Rs. 10 per share. Eachholder of Equity Share is entitled to one vote per share.

Notes to the Financial Statements

For year ended 31st March 2022

% Changes in Promoter holding

	As at 31st March, 2022	As at 31st March, 2021	As at 31st March, 2021
Name of Shareholder	**% of Holding**	**% of Holding**	**% of Changes**
Kilitch Company Pharma Limited	42.54%	42.79%	(0.25%)
Mukund Prataprai Mehta	5.72%	5.75%	(0.03%)
Bhavin Mukund Mehta	12.85%	12.92%	(0.07%)
Neeta Mukund Mehta	7.13%	7.18%	(0.05%)

Note 17 - Other Equity

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
a. Securities Premium	3,832.63	3,832.63
b. General Reserve	1,579.74	1,579.74
c. Employee Stock Options	35.42	35.42
d. Other Reserves (Call on shares forfeited A/c)	58.00	58.00
e. Retaining Earnings As per last Balance Sheet	8,771.30	8155.76
f. Money Received Against Share Warrents	250.00	-
(-) Dividend [incl. DDT] - declared in AGM	-	-
(+) Net Profit For the current year	1,052.77	615.54
	9,824.07	**8,771.30**
f. Other Comprehensive Income		
As per last Balance Sheet	466.88	(55.99)
(+/-) Change in Fair value of Investments at FVOCI	198.15	522.87
At the end of the Year	665.03	466.88
Total	**16,244.89**	**14,743.96**

1) Securities Premium: Securities premium reserve represents premium received on equity shares issued, which can be utilised only in accordance with the provisions of the Companies Act, 2013 for specified purposes.
2) Share Option Outstanding Account: Reserve relates to stock options granted by the Company to the employees under an employee stock options plan.
3) General Reserve: General reserve is created from time to time by transferring profits from retained earnings and can be utilised for purposes such as dividend payout, bonus issue, etc.

Note 18 - Provisions - (Non Current)

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
Gratuity	27.54	38.06
Total	**27.54**	**38.06**

Note 19 - Borrowings

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
Bank Overdraft (Kotak Bank)	747.08	-
Working Capital Loan - Kotak Bank *	238.87	290.00
Export Packing Credit Loan (Kotak Mahindra Bank)	1,047.53	1,180.68
Total	**2,033.48**	**1,470.68**

*The above stated Borrowings were secured against the Mutual Funds managed by Kotak Wealth.

Notes to the Financial Statements

For year ended 31st March 2022

Note 20 - Trade Payables

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
i) Dues to Micro & Small Enterprises#	-	-
ii) Dues to Others	2,776.84	1,424.33
Total	**2,776.84**	**1,424.33**

#There are no Micro and Small Enterprises, to whom the company ows dues, for more than 45days during the year as at March 31, 2022 and March 31, 2021. The above information regarding Micro and Small Enterprises has been dertemined to the extent such parties have been identified on the basis of information available with the company. This has been relied upon by the Auditor. The disclosure pursuant to the said Act is as under :

	As at 31st March 2022	As at 31st March 2021
a) Principal amount due to supplier under MSMED Act, 2006	-	-
b) Interest Accrued and due on the above amount, unpaid	-	-
c) Payment made beyond the appointed day during the year	-	-
d) Interet paid	-	-
e) Interest due annd payable for the period of delay	-	-
f) Interest remaining due and payable in succeeding year	-	-

(Rs. In Lakhs)

Aging of Trade Payable	Past Due						Amount
	0-120 Days	120-150 days	150-180 days	180-365 days	365-730 Days	Greater than 730 days	Total
As at 31st March 2022	2,424.12	275.97	57.95	18.80	-	-	2,776.84

Aging of Trade Payable	Past Due						Amount
	0-120 days	120-150 days	150-180 days	180-365 days	365-730 Days	Greater than 730 days	Total
As at 31st March 2021	1,238.26	138.27	29.35	18.45	-	-	1,424.33

Note 21 - Other financial liabilities

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
Unpaid dividends	3.88	3.88
Total	**3.88**	**3.88**

Note 22 - Provisions (Current)

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
Provision for employee benefits:		
Salary & Reimbursements	48.08	44.06
Gratuity	43.93	30.71
Leave Encashment	8.87	5.83
Total	**100.88**	**80.60**

Note 23 - Tax Liabilities (Current)

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
Tax Liabilities (Net)	439.62	262.30
Total	**439.62**	**262.30**

Note 24 - Other Current Liabilities

(Rs. In Lakhs)

Particulars	As at 31st March, 2022	As at 31st March, 2021
Statutory dues	43.90	11.50
Total	**43.90**	**11.50**

Notes to the Financial Statements

For year ended 31st March 2022

Note 25 - Revenue from Operations

(Rs. In Lakhs)

Particulars	Year Ended 31st March, 2022	Year Ended 31st March, 2021
Sale of products/services:		
Local sales	2,941.89	1,092.68
Out Of Maharashtra Sales	1,191.50	1,269.11
Export Sales	6,255.01	4,616.53
incl. 84.25 Lakhs (P.Y. Rs. 212.23 Lakhs) to subsidiary - Kilitch Estro Biotech PLC		
Otheroperating revenues	127.58	39.48
(Less) Sales Return	-	(16.12)
Total	**10,515.98**	**7,001.68**

Note 26 - Other Income

(Rs. In Lakhs)

Particulars	Year Ended 31st March, 2022	Year Ended 31st March, 2021
Interest Income	195.96	177.34
Dividend Income	3.05	5.55
Foreign Exchange Gain :		
Realised	103.85	98.66
Unrealised	-	-
Profit on Sale of Investments	135.92	120.31
Sundry balances written back	-	1.03
Misc. Income	17.11	16.53
Total	**455.90**	**419.43**

Note 27 - Cost of Materials Consumed

(Rs. In Lakhs)

Particulars	Year Ended 31st March, 2022	Year Ended 31st March, 2021
Opening Stock	278.88	367.13
Purchases	6,165.28	3,709.21
Less: Closing Stock	(415.61)	(278.88)
Total	**6,028.55**	**3,797.46**

Note 28 - Variation in inventories of Finished Goods and work- In- progress

(Rs. In Lakhs)

Particulars	Year Ended 31st March, 2022	Year Ended 31st March, 2021
Opening Stock :		
Work-in-Process	34.56	44.64
Finished Goods	45.17	143.90
	79.73	**188.54**
Closing Stock :		
Work-in-Process	39.86	34.56
Finished Goods	44.56	45.17
	84.42	**79.73**
Total	**(4.69)**	**108.81**

Note 29 - Employee benefits expenses

(Rs. In Lakhs)

Particulars	Year Ended 31st March, 2022	Year Ended 31st March, 2021
Salaries and incentives	568.23	477.59
Contributions to Provident fund	23.45	18.74
Gratuity fund contributions & Leave Encashment	3.41	4.83
Staff welfare expenses	20.36	20.58
Total	**615.45**	**521.74**

Notes to the Financial Statements

For year ended 31st March 2022

Note 30 - Export Product Registration/Commission

(Rs. In Lakhs)

Particulars	Year Ended 31st March, 2022	Year Ended 31st March, 2021
Export Product Registration Expenses		
Export product registration	237.59	215.30
Export Expenses	13.67	32.28
Export Commission Expenses	291.53	200.72
Total	**542.79**	**448.30**

Note 31 - Other Expenses

(Rs. In Lakhs)

Particulars	Year Ended 31st March, 2022	Year Ended 31st March, 2021
Consumption of stores and spare parts.	211.99	81.44
Labour Charges	228.73	223.25
Power and Fuel	192.38	157.02
CSR Expenses	21.77	21.51
Water Charges	7.74	6.40
Foreign Exchange Loss – Unrealised	71.76	1.25
Bank & Other Charges	13.24	12.14
Repairs to Buildings	-	2.20
Repairs–Others	150.22	58.34
Insurance	13.02	3.33
Rent, Rates and Taxes	48.76	31.39
Auditors Remuneration (Refer Note : 37)	15.00	15.25
Miscellaneous expenses	115.64	46.89
Donation	1.16	-
Directors' Sitting Fees	0.74	0.57
Foreign Travelling Expenses	42.15	37.74
Printing & Stationery	10.77	8.52
Professional charges	93.75	182.59
Communication Expenses	16.90	13.65
Vehicle Expenses	11.00	13.28
Travelling Expenses:		
Directors	2.81	-
Others	70.05	10.17
Factory	-	29.70
Business Promotion Expenses	59.52	65.94
Advertising / Sales Commission Expenses	2.14	2.34
Discount Allowed [Sales]	2.02	3.31
Clearing & Forwarding Expenses	123.84	176.38
Calibration/validation Charges	2.87	1.75
Bad Debts/Balances written off	14.95	33.73
Share of Loss from Partnership Firm	0.20	0.20
Freight	562.57	216.05
Reserve for Doubtful Debts (P&L)	91.51	119.71
Office expenses	28.67	19.06
VAT Expenses	-	9.33
Factory License	0.23	-
Sponsorship Expenses	5.00	-
Discount Allowed GST	1.16	-
Total	**2234.27**	**1604.43**

Notes to the Financial Statements

For year ended 31st March 2022

Note 32 - Disclosure as per IND AS – 19 "employee benefits".

(A) Expenses recognised for Defined Contribution Plan:

Employer's Contribution to Provident and Pension Fund Rs.14.46Lakhs (PY Rs. 13.22 Lakhs).

Employer's Contribution to ESIC Rs. 8.99 Lakhs (PY Rs. 3.08 Lakhs)

The Company makes contributions towards provident fund and pension fund for qualifying employees to the Regional Provident Fund Commissioner.

(B) Expenses recognised Defined Benefit Plan:

The company provides gratuity benefit to itsemployees which is a defined benefit plan. The present value of obligation is determined based on actuarial valuation using the Projected Unit Credit Method, which recognizes each period of service as giving rise to additional unit of employee benefit entitlement and measures each unit separately to build up the final obligation. The obligation for leave encashment is recognised in the same manner as gratuity.

I. Change in Defined Benefit Obligation during the year:

(Rs. in Lakhs)

Particulars	2021-22	2020-21
	Gratuity	Gratuity
Present value of the obligation at the beginning of the year	68.77	68.34
Current Service Cost	4.43	5.52
Interest Cost	4.00	4.61
Actuarial (Gain) / Loss on Obligation	(5.21)	(8.4)
Benefits Paid	(0.52)	(1.30)
Present value of the obligation at the end of the year	**71.47**	**68.77**

ii. Amount to be recognized in Balance sheet

(Rs. in Lakhs)

Particulars	2021-22	2020-21
	Gratuity	Gratuity
Present Value of Defined Benefit Obligation	48.1	57.7
Fair value of Plan Assets at the end of the year	(10.23)	(11.37)
Amount to be recognized in Balance sheet	**37.87**	**46.33**

iii. Current/Non-Current bifurcation

(Rs. in Lakhs)

Particulars	2021-22	2020-21
	Gratuity	Gratuity
Current Benefit Obligation	10.33	30.71
Non-Current Benefit Obligation	27.54	38.06

iv. Expenses recognised in the statement of financial position for the year

(Rs. in Lakhs)

Particulars	2021-22	2020-21
	Gratuity	Gratuity
Current Service Cost	4.43	5.52
Interest cost on Obligation	4.00	4.61
Net Actuarial (Gain) / Loss recognised in the year	-	-
Net Cost Included in Personnel Expenses	**8.43**	**10.13**

Notes to the Financial Statements

For year ended 31st March 2022

v. Maturity profile of defined benefit obligation

(Rs. in Lakhs)

Particulars	2021-22	2020-21
Within the next 12 months	19.46	13.57
between 2 to 5 Years	10.86	29.81
between 6 to 10 Years	17.36	96.65

vi. Actuarial Assumptions used for estimating defined benefit obligation

Rs. in Lakhs)

Particulars	2021-22	2020-21
Discount Rate	6.80% P.A.	6.72% P.A.
Salary Escalation Rate	6.50% P.A.	6.50% P.A.
Expected Return on Plan Assets	0.57	(0.063)
Mortality Rate	IALM (2012-14)	IALM (2012-14)
Withdrawal Rate	1.00%	1.00%
The Weighted Average Duration of the Plan	13 Years	13 Years
No. of Employees	143	44
Average Age	34	43
Total Salary (Rs. in Lakhs)	19.62	128.16
Average Salary (Rs. in Lakhs)	0.14	10.68
Average Service	5 Years	6 Years
Accrued Benefit	71.47	68.77
Actuarial Liability	37.87	46.33

Notes:

1. Salary escalation rate is arrived after taking into account regular increments, price inflation and promotion and other relevant factors such as supply and demand in employment market.
2. Discount rate is based on prevailing market yields of Indian Government Securities as at balance sheet date for estimated term of obligations.
3. Attrition rate/withdrawal rate is based on Company's policy towards retention of employees, historical data and industry outlook.
4. The above information is certified by actuary.

vii. Sensitivity analysis:

Increase/ (decrease) on present value of defined benefits obligations at the end of the year:

(Rs. in Lakhs)

Particulars	Change in assumption	Effect on Gratuity obligation	
		2021-22	2020-21
Discount rate	+1%	68.43	63.57
	-1%	74.79	74.81
Salary Escalation rate	+1%	74.30	74.77
	-1%	69.07	63.52

These gratuity plan typically expose the Company to actuarial risks such as: investment risk, interest risk, longevity risk and salary risk.

Investment Risk:

The present value of the defined benefit plan liability is calculated using a discount rate which is determined by reference to

Notes to the Financial Statements

For year ended 31st March 2022

For other defined benefit plans, the discount rate is determined by reference to market yield at the end of reporting period on high quality corporate bonds when there is a deep market for such bonds; if the return on plan asset is below this rate, it will create a plan deficit.

Interest risk
A decrease in the bond interest rate will increase the plan liability; however, this will be partially offset by an increase in the return on the plan debt investments.

Longevity risk
The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.

Salary risk
The present value of the defined plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability

C) Unfunded Schemes – Earned Leaves

(Rs.in Lakhs)

Particulars	Year ended 31st March 2022	Year ended 31st March 2021
Present value of unfunded obligations	37.87	46.33
Expenses recognised in the statement of profit and loss	1.55	(1.0)
In Other comprehensive income	(5.78)	(8.34)
Actuarial (Gain) / Loss- Plan liabilities	-	-
Actuarial (Gain) / Loss - Return On Plan Assets	-	-
Net (Income)/ Expense For the period Recognized in OCI	(5.78)	(8.34)
Discount rate (per annum)	6.80%	6.72%
Salary escalation rate (per annum)	6.50%	6.72%

Note 33 - Segment Reporting

The Company is mainly engaged in the development and operations of Pharmaceutical business. Accordingly, the Company has only one identifiable segment reportable under Ind AS 108 - Operating Segments.
Managing Director (the 'Chief Operational Decision Maker' as defined in Ind AS 108) monitors the operating results of the company's business for the purpose of making decisions about resource allocation and performance assessment.

The revenues from transactions with a single customer exceeding 10 per cent or more of the company's revenues were stated below:

(Rs. In lakhs)

Party Name	Country	As on 31st March 2022	As on 31st March 2021
M/s Tedis SA	France	1428.72	1276.44
Grand Total		**1428.72**	**1276.44**

Note 34 - Related Party Disclosures 1

In view of the INDAS 24 "Related Parties Disclosures", the disclosure in respect of related party transactions for the year ended on 31st March 2022 is as under:

Notes to the Financial Statements

For year ended 31st March 2022

RELATIONSHIPS	
Category I : Subsidiaries of the Company	
Indian Subsidiary – Monarchy Healthserve Private Limited	
Foreign Subsidiary– KilitchEstro Biotech PLC	
Category II : Key Managerial Personnel	
Key Person	Designation
Mukund Prataprai Mehta	Chairman & Managing Director
Bhavin Mukund Mehta	Whole-time Director
Mira Bhavin Mehta	Whole-time Director
Sunil Jain	Chief Financial Officer
Garima Trivedi (from 01.03.2021 to 13.10.2021)/ Pincy Asati (from 13.10.2021)	Company Secretary & Compliance Officer
Category III : Enterprises over which Key Managerial Personnel are able to exercise significant control	
NBZ Healthcare LLP.	
Arham Neeta Realties LLP	
KilitchPharma (Co.) Ltd.	

	Transactions during the year:			(Rs. In Lakhs)
	TRANSACTIONS	**Category I**	**Category II**	**Category III**
1	Purchases	NIL 5.08	-	112.74 51.44
2	Sales	84.25 212.23	-	485.69 NIL
3	Remuneration and Sitting Fees	-	184.50 183.45	-
4	Expenses incurred by KDL	-	21.86 24.89	-
5	Advance/Loan Given to Parties	135.28 383.79	-	2,313.22 972.72
6	Advance Returned By Parties	-	-	2,334.14 984.16
7	Interest accrued on Loan	174.05 160.32	-	-

The following balances were due from / to the related parties as on 31-03-2022

Sr.No.	TRANSACTIONS	Category I	Category II	Category III
1	Loans/Advances/Receivables	4621.11 4400.55	-	1.29 1.29
2	Loans/Borrowings/Payables	-	-	45.06 29.50

Note: Figures in brackets indicates previous year figure.

The transactions with related parties are made on terms equivalent to those that prevail in arm's length transactions. Review of outstanding balances is undertaken each financial year through examining the financial position of the related party and the market in which related party operates. These balances are unsecured and their settlement occurs through banking channel.

Compensation of key management personnel:

The remuneration of director and other member of key management personnel during the year was as follows:

Notes to the Financial Statements

For year ended 31st March 2022

(Rs. In Lakhs)

Particulars	2021-22	2020-21
Short-term benefits	184.50	183.45
Other long term benefits	-	-

Note 35 - Earning per Share (EPS)

Basic as well as Diluted EPS	2021-22	2020-21
Net Profit after Tax (Rs. in Lakhs)	1052.77	615.54
Weighted Average No. of Equity Shares for Basic EPS	1,55,66,110	1,54,79,893
Weighted Average No. of Equity Shares for Diluted EPS	1,55,66,110	1,54,79,893
Nominal Value of Equity Shares (Rs.)	10	10
Basic Earnings Per Share (Rs.)	6.76	3.98
Diluted Earnings Per Share (Rs.)	6.76	3.98

Note 36 - contingent liabilities not provided for in Respect of:

a) Demand notices received on account of Property Tax pertaining to FY 2019-20 is aggregating's. 53.20 Lakhs (P.Y. Rs. 53.20 Lakhs)are disputed by the Company. The Company has filed a suit and the matter is pending the Supreme Court and Company has not yet deposited any amount in this regard.

b) Demand notices received on account of principal amount of CESS during FY 2019-20 pertaining to FY 1999-2000 and FY 2000- 2001 is aggregating Rs.22.85 Lakhs (P.Y.Rs.22.85 Lakhs) are disputed by the Company. The Company has filed a suit and the matter is pending the Supreme Court and Company has not yet deposited any amount in this regard.
The above litigations are not expected to have any material adverse effect on the financial position of the company.

Note 37 - Auditors' Remuneration:

(Rs. In Lakhs)

Particulars	2021-22	2020-21
Audit fees	15.00	15.00
Other Professional Fees	-	0.25
Total	**15.00**	**15.25**

Note 38 - loans and Advances In the nature of loans given to Subsidiaries and Associates:

(Rs. In Lakhs)

Sr. No.	Particulars	Relationship	As at 31st March 2022	Maximum balance during the year	As at 31st March 2021	Maximum balance during the year
1	Monarchy Healthserve Private Limited	Subsidiary	60.70	60.70	72.26	72.26
2	KilitchEstro Biotech PLC	Subsidiary	4552.79	4552.79	4282.60	4282.60
3	Arham Neeta Realities LLP	Subsidiary	1.30	1.30	1.30	1.30

Note 39 – Impairment of Assets

The Company's Board, out of abundant caution and as a prudent practice in line with the standard accounting practices has not made any impairment provision against its investments for the financial year 2021-22.

Note 40 – Third Party Balance Confirmation

The balances in respect of Trade Receivables & Payables, loans and advances, as appearing in the books of accounts are subject to confirmations by the respective parties and adjustments/reconciliation arising there from, if any.

Notes to the Financial Statements

For year ended 31st March 2022

Note 41 – Investment in Limited Liability Partnership

The Company is a partner in a partnership firm M/s. Arham Neeta Realties LLP. The accounts of the partnership firm have been finalized up to the financial year 2021-22. The details of the Capital Accounts of the Partners as per the latest Financial Statements of the firm are as under:

(Rs. in Lakhs)

Sl. No.	Name of the Partners	Profit Sharing Ratio	Total Capital on31st March 2022	Total Capital on31st March 2021
1	Kilitch Drugs (India) Limited	65%	2246.49	2246.49
2	Mukund Mehta	16.25%	(3.04)	(3.04)
3	Bhavin Mehta	16.25%	(3.04)	(3.04)
4	Mira Mehta	2.5%	(1.94)	(1.94)

The Company has accounted for its share of loss amounting to Rs. 0.20 Lakhs (P.Y. Rs. 0.24 Lakhs) pertaining to the financial year 2021-22.

Note 42 - Event after Reporting Date:
There are no major events occurred after the reporting date.

Note 43 - Corporate Social Responsibility:
The company is required to comply the requirements of CSR as per Section 135 of the Companies Act, 2013 read with Schedule VII.

Accordingly the company has spent an amount of Rs. 21.77 Lakhs during the Financial Year 2021-22.
Expenditure related to corporate social responsibility is :

(Rs. In Lakhs)

Perticulars	Amount March 2022	Amount March 2021
1) Amount spend towards CSR		
2) Educational actives for children	11.45	21.00
3) Animal welfare activities	0.26	0.51
4) Livelihood enhancement of differently able people	10.06	-
Total	**21.77**	**21.51**

Note 44 - Fair Value of Financial Assets and Liabilities:

Set out below is the comparison by class of carrying amounts and fair value of Company's financial instruments that are recognised in the financial statements:

(Rs. In Lakhs)

Particulars	As at 31st March 2022		As at 31st March 2021	
	Carrying Value	Fair Value	Carrying Value	Fair Value
Financial assets designated at fair value through Other Comprehensive Income				
Investments				
in Equity shares	4707.47	4707.47	4,655.28	4,655.28
in Bonds	63.13	63.13	108.47	108.47
in Mutual Funds	4,723.42	4,723.42	3,640.05	3,640.05

Notes to the Financial Statements

For year ended 31st March 2022

Financial assets designated at amortised cost				
Investments				
Capital Investment in Partnership firm	2,246.29	2,246.29	2,246.49	2,246.49
Trade Receivables	4,142.19	4,142.19	2,291.84	2.291.84
Cash and Cash Equivalents	244.96	244.96	577.39	577.39
Loans and Advances	4659.80	4659.80	4,400.31	4,400.31
Other financial assets	213.59	213.59	176.34	176.34
Total	**21,000.85**	**21,000.85**	**18,096.17**	**18,096.17**
Financial liabilities designated at amortised cost				
Borrowings	2,033.48	2,033.48	1,470.68	1,470.68
Trade payables and others	2,776.84	2,776.84	1,355.74	1,355.74
Other financial liabilities	3.88	3.88	3.88	3.88
Total	**4,814.20**	**4,814.20**	**2,830.30**	**2,830.30**

Fair valuation techniques:

The Company maintains policies and procedures to value financial assets or financial liabilities using the best and most relevant data available.
The following methods and assumptions were used to estimate the fair values

- Fair value of the Equity Shares are based on price quoted on stock exchange.
- Fair value of investment in unquoted equity shares are considered same as carrying value as the same are recently acquired.
- Fair value of Financial Assets & Financial Liability (except which are show at their fair value) are carried at amortised cost is not materially different from its carrying cost.

Fair Value hierarchy:
The following table provides the fair value measurement hierarchy of Company's asset and liabilities, grouped into Level 1 to Level 3 as described below:

Level 1: Quoted prices / published NAV (unadjusted) in active markets for identical assets or liabilities. It includes fair value of financial instruments traded in active markets and are based on quoted market prices at the balance sheet date.

Level 2: Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices). Fair value of the financial instruments that are not traded in an active market is determined by using valuation techniques. These valuation techniques maximise the use of observable market data where it is available and rely as little as possible on the company specific estimates. If all significant inputs required to fair value an instrument are observable then instrument is included in level 2

Level 3: Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs). If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3

(Rs. In Lakhs)

Purchases	**As at 31st March 2022**			**As at 31st March 2021**		
	Level 1	**Level 2**	**Level 3**	**Level 1**	**Level 2**	**Level 3**
- in Equity shares	85.77	-	4621.70	76.90	-	4621.70
- in Bonds	63.13	-	-	65.15	-	-
-in Mutual Funds	4723.42	-	-	3,640.05	-	-

Notes to the Financial Statements

For year ended 31st March 2022

Note 45 - Financial Risk Management:
The Company's activities expose it to credit risk, liquidity risk and market risk. This note explains the sources of risks which the entity is exposed to and how it mitigates that risk.

Market risk:
Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprise three types of risk: currency rate risk, interest rate risk and other price risks, such as equity price risk and commodity risk. Financial instruments affected by market risk include loans and borrowings and investments in securities.

Foreign currency risk:
Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

The Company is exposed to foreign exchange risk through purchases of goods or services from overseas supplier in foreign currency. The Company generally transacts in US dollar. The foreign exchange rate exposure is balanced by purchasing of goods or services in the respective currency.

The Company is exposed to insignificant foreign exchange risk as at the respective reporting dates.

Interest rate risk:
Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

The Company is not exposed to interest rate risk as the Company has fixed rate of borrowings as at the respective reporting dates.

Commodity and Other price risk
The Company is not exposed to the commodity and other price risk.

Credit Risk
Credit risk is the risk of financial loss to the Company that a customer or counter party to a financial instrument fails to meet its obligations. The Company is exposed to credit risk from its operating activities (primarily trade receivables) and from its financing activities, including deposits with banks, mutual funds, financial institutions and other financial instruments

Trade and other receivables:
The Company extends credit to customers in normal course of business. The Company considers factors such as credit track record in the market and past dealings for extension of credit to customers. To manage credit risk, the Company periodically assesses the financial reliability of the customer, taking into account the financial condition, current economic trends, and analysis of historical bad debts and aging of accounts receivables. Outstanding customer receivables are regularly monitored to make an assessment of recoverability. Receivables are provided as doubtful / written off, when there is no reasonable expectation of recovery. Where receivables have been provided / written off, the Company continues regular follow-up, engage with the customers, legal options / any other remedies available with the objective of recovering these outstanding.

The Company is not exposed to concentration of credit risk to any one single customer since services are provided to vast spectrum and hence, the concentration of risk with respect to trade receivables is low. The Company also takes security deposits, advances, post-dated cheques etc. from its customers, which mitigate the credit risk to an extent."

Notes to the Financial Statements

For year ended 31st March 2022

Cash and cash equivalents another investments:
The Company is exposed to counter party risk relating to medium term deposits with banks and investment in mutual funds.

The Company considers factors such as track record, size of the institution, market reputation and service standards to select the banks with which balances and deposits are maintained. Generally, the balances are maintained with the institutions with which the Company has also availed borrowings. "

Exposure to credit risk:
The gross carrying amount of financial assets, net of impairment losses recognised represents the maximum credit exposure.

The maximum exposure to credit risk as at 31st March 2022 and 31st March 2021 is as follows:

(Rs. In Lakhs)

Particulars	As at 31st March 2022	As at 31st March 2021
Financial assets for which loss allowances is measured using 12 months Expected Credit Losses (ECL):		
Cash and cash equivalents	244.96	577.39
Loans and advances	4,659.80	4,400.31
Other financial assets	213.59	176.34
Financial assets for which loss allowances is measured using Life time Expected Credit Losses (ECL):		
Trade receivables	4,142.19	2,291.84

Life time Expected credit loss for Trade receivables under simplified approach

(Rs. In Lakhs)

Aging of Trade Receivables	Past Due						
	0-120 Days	120-150 days	150-180 days	180-365 days	365-730 Days	Greater than 730 days	Total
As at 31st March 2022							
Gross Carrying Amount	2,493.86	820.89	335.17	350.63	280.23	285.27	4,566.05
Expected credit losses (Loss allowance provision)	-	(2.25)	(2.67)	(59.20)	(164.89)	(194.85)	(423.86)
Net Carrying Amount	**2,493.86**	**395.39**	**398.35**	**889.60**	**115.34**	**90.42**	**4,142.19**
As at 31st March 2021							
Gross Carrying Amount	1409.43	56.69	13.82	328.21	349.86	466.20	2624.20
Expected credit losses (Loss allowance provision)	-	(0.90)	(0.69)	(29.60)	(135.82)	(165.35)	(332.36)
Net Carrying Amount	**1409.43**	**55.79**	**13.13**	**298.61**	**214.04**	**300.85**	**2,291.84**

Reconciliation of Changes in the life time expected credit loss allowance:

(Rs. In Lakhs)

Particulars	2021-22	2020-21
Loss allowance on 1 April	332.36	212.64
Provided during the year	91.5	119.72
Reversal of provision	-	-
Loss allowance on 31st March	423.86	332.36

Cash and Cash equivalent, other Investment, Loans and other financial assets are neither past due nor impaired. Management is of view that these financial assets are considered good and 12 months ECL is not provided.

Notes to the Financial Statements

For year ended 31st March 2022

Liquidity risk:

Liquidity risk is the risk that the Company may not be able to meet its present and future cash and collateral obligations without incurring unacceptable losses.

The Company's objective is to at all times maintain optimum levels of liquidity to meet its cash and collateral requirements. The Company relies on a mix of borrowings, capital infusion and excess operating cash flows to meet its needs for funds. The current borrowings are sufficient to meet its short to medium term expansion needs. Management monitors the Company's net liquidity position through rolling forecasts on the basis of expected cash flows.

The Company is required to maintain ratios (such as debt service coverage ratio and secured coverage ratio) as mentioned in the loan agreements at specified levels and also cash deposits with banks to mitigate the risk of default in repayments. In the event of any failure to meet these covenants , these loans become callable to the extent of failure at the option of lenders, except where exemption is provided by lender.

(Rs. In Lakhs)

Particulars	As at 31st March 2022					
	Carrying Amount	On Demand	Less than 12 months	2- 5 years	>5 years	Total
Borrowings	2,033.48	-	1,795.48	238	-	2,033.48
Other Financial Liabilities	3.88	3.88	-	-	-	3.88
Trade and other payables	2,776.84	2,776.84	-	-	-	2,776.84

Particulars	As at 31st March 2021					
	Carrying Amount	On Demand	Less than 12 months	2- 5 years	>5 years	Total
Borrowings	1,470.68	-	1,180.68	290	-	1,470.68
Other Financial Liabilities	3.88	3.88	-	-	-	3.88
Trade and other payables	1,355.74	1,355.74	-	-	-	1,355.74

Capital management

The primary objective of the Company's capital management is to maximize the shareholder value. The Company's primary objective when managing capital is to ensure that it maintains an efficient capital structure and healthy capital ratios and safeguard the Company's ability to continue as a going concern in order to support its business and provide maximum returns for shareholders. The Company also proposes to maintain an optimal capital structure to reduce the cost of capital. No changes were made in the objectives, policies or processes during the year ended March 31, 2022 and March 31, 2021.

For the purpose of the Company's capital management, capital includes issued capital, share premium and all other equity reserves. Net debt includes, interest bearing loans and borrowings, trade and other payables less cash and short term deposits.

Particulars	2021-2022	2020-21
-Loans and Borrowings	2033.48	1,470.68
Less: Cash and cash equivalents + Bank Deposits	(458.55)	(753.73)
Net Debt	1574.93	716.95
Total Capital	17803.12	16,293.41
Capital + Net Debt	19378.05	17,010.36
Gearing Ratio	0.09	0.04

Notes to the Financial Statements

For year ended 31st March 2022

Note 46 – Taxation:

Income tax related to items charged or credited to profit or loss during the year: (Rs. In Lakhs)

A. Statement of Profit or Loss		
Particulars	**2021-22**	**2020-21**
1. Current Income Tax (Net of MAT Credit)	363.37	166.55
2. Deferred Tax expenses/ (benefits):		
Relating to origination and reversal of temporary differences	(23.32)	(31.26)
Total Income tax Expenses (1 to 2)	**340.05**	**135.29**

B. Reconciliation of Current Tax expenses:		
Particulars	**2021-22**	**2020-21**
Profit /(Loss) from Continuing operations	1,392.82	750.83
Applicable Tax Rate	29.12%	27.82%
Computed tax expenses	**405.59**	**208.88**
Income not allowed/exempt for tax purposes	(0.89)	(15.21)
Expenses not allowed for tax purposes	32.18	6.32
Other temporary allowances	2.64	2.30
Tax paid at lower rate	(24.51)	(8.43)
MAT Credit set off	(64.76)	(80.57)
Interest Provision	13.11	22.00
Tax Expenses	363.37	135.29

Deferred Tax Recognised in statement of profit and Loss relates to the following:		
Particulars	**2021-22**	**2020-21**
Difference between book and Tax depreciation	(1.98)	0.70
Expenses allowable on payment basis	25.28	30.56
Deferred Tax Liabilities/ (Asset)	**23.32**	**31.26**

Reconciliation of deferred tax liabilities/(asset) net:		
Particulars	**2021-22**	**2020-21**
Opening balance as on 1st April	127.86	96.18
Tax expenses / (income) during the period	23.32	31.26
Closing balance as on 31st Marach	**151.18**	**127.44**

Note 47 – Share Based Payments and Arrangements:

As per the ESOS, 2007 as amended from time to time the outstanding ESOPs which can be exercised by our employees at Rs. 10 each (Face Value Rs. 10/ share). Detailed analysis of the same has been enumerated below:

Sr. No.	Particulars of Options / Scheme	Total (Numbers)
1	Outstanding as at beginning of the Year	106030
2	Add : Granted during the Year	NIL
3	Less : Forfeited/Cancelled/Lapsed during the Year	(729)
4	Less : Exercised and allotted during the Year	(87775)
5	Outstanding as at the end of the Year	17526

Notes to the Financial Statements

For year ended 31st March 2022

Note 48 - The previous year figures have been regrouped, reworked, rearranged and reclassified, wherever necessary and are to be read in relation to the amounts and other disclosures relating to the current year.

Note 49 - Additional regulatory information required by Schedule III :

Details of benami property held -
No proceedings have been initiated on or are pending against the company for holding benami property under the benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.

Borrowing secured against current assets
The company does not have borrowings from banks and financial institutions on the basis of security of current assets.

Wilful defaulter
Company have not been declared wilful defaulter by any bank or financial institution or government or any government authority.

Relationship with struck off companies
The company has no transactions with the companies struck off under Companies Act, 2013 or Companies Act, 1956

Compliance with number of layers of companies
The company has complied with the number of layers prescribed under the Companies Act, 2013.

Compliance with approved scheme(s) of arrangements
The company has not entered into any scheme of arrangement which has an accounting impact on current or previous financial year.

Utilisation of borrowed funds and share premium
The company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the company shall:

a. directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

b. provide any guarantee, security or the like on behalf of the ultimate beneficiaries

Undisclosed income
There is no income surrendered or disclosed as income during the current or previous year in the tax assessments under the Income Tax Act, 1961, that has not been recorded in the books of account.

Details of crypto currency or virtual currency
The company has not traded or invested in crypto currency or virtual currency during the current or previous year.

Valuation of PP&E, intangible asset and investment property
The company has not revalued its property, plant and equipment (including right-of-use assets) or intangible assets or both during the current or previous year.

Notes to the Financial Statements

For year ended 31st March 2022

Ratio	Numerator	Denominator	Current Period	Previous Period	% Variance
Current Ratio	9,771.99	5,398.60	1.81	2.21	(0.40)
Debt-Equity Ratio	2,033.48	17,803.12	0.11	0.09	0.02
Debt Service Coverage Ratio	4,492.11	2,094.53	2.14	2.00	0.14
Return on Equity Ratio	1,052.77	17,803.12	0.06	0.04	0.02
Inventory/Stock turnover ratio	10,515.98	679.33	15.48	15.27	0.21
Trade Receivables turnover ratio	10,515.98	3,217.00	3.27	3.50	(0.23)
Trade payables turnover ratio	6,165.28	2,066.29	2.98	3.46	(0.48)
Net capital turnover ratio	10,515.98	4,373.38	2.40	1.78	0.62
Net profit ratio	1,052.77	10,971.88	0.10	0.08	0.02
ROI	1,052.77	17,803.12	0.06	0.04	0.02

The previous year figures have been regrouped, reworked, rearranged and reclassified, whenever necessary and are to be read in relation to the amounts and other disclosures relating to the current year.

As per our report of even date	
For Suryaprakash Maurya & Co. Chartered Accountants	For and on behalf of the Board of Directors Kilitch Drugs India Limited
FRN: 147410W Suryaprakash Maurya	Mukund P. Mehta (Managing Director) [DIN: 00147876]
Partner M.No. 178258	Bhavin M. Mehta (Whole-time Director) [DIN: 00147895]
	Sunil Jain Chief Financial Officer
Place : Mumbai Dated: 26th May 2022	Puspha Nyoupane (Company Secretary)

INDEPENDENT AUDITORS' REPORT

TO
THE MEMBERS
KILITCH DRUGS (I) LIMITED

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying Consolidated financial statements of Kilitch Drugs (India) Limited (herein referred to as the Holding Company) and its subsidiaries (the Holding company and its subsidiaries together referred together as "The Group"), comprising of the Consolidated Balance Sheet as at March 31, 2022 the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated Cash Flow Statement and the Consolidated Statement of Changes in Equity for the year then ended, and a summary of the significant accounting policies and other explanatory information (herein referred to as "the Consolidated Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, the consolidated profit and total comprehensive income, consolidated changes in equity and its consolidated cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the consolidated financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the independence requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Consolidated financial statements.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provie a separate opinion on these matters.

Sr. No.	Key Audit Matter	Auditor's Response
1	**Revenue Recognition [Export Sales]**	Obtaining an understanding of an assessing the design, implementation and operating effectiveness of the Company's key internal controls over revenue recognition process. • Testing a sample of contracts and testing the revenues recognised with respect thereto by agreeing information back to contract terms. • Testing the controls over the sale data collated for the purpose of recognizing the revenue on sample basis. • Assessing the adequacy of company's disclosure with respect to revenue recognised.
2	**Trade Receivables**	Our audit procedures to assess the appropriateness of Trade receivables disclosure and provision against trade receivables included the Note 12 & Note 3 paragraph "H" of significant accounting policies.

Information Other than the Financial Statements and Auditor's Report Thereon The Company's Board of Directors is responsible for the preparation of the other information.

The other information comprises the information included in the Management Discussion and Analysis, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

When we read the Annual Report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

Management's Responsibility for the Consolidated Financial Statements The Holding Company's management and Board of Directors are responsible for the preparation and presentation of these consolidated financial statements in terms of the requirements of the Act that give a true and fair view of the consolidated state of affairs, consolidated profit and other comprehensive income, consolidated statement of changes in equity and consolidated cash flows of the Group inaccordance with the accounting principles generally accepted in India, including the Ind AS specified under section 133 of the Act. The respective Board of directors of the entities are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors are also responsible for overseeing the Company's financial reporting process of each entity.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

• Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

• Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(I) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.

• Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

• Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion.

Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality

Materiality is the magnitude of misstatements in the consolidated financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial statements.

Communication with those charged with Governance

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

(a) We did not audit the financial statement other information of One subsidiary, whose financial statements reflect total assets of Rs 2,115.53 lakhs as at March 31, 2022, total revenues of Rs 44.91 lakhs, total net loss after tax of Rs 81.83 lakhs, total comprehensive income of Rs 81.83 lakhs, for the quarter and the year ended on that date respectively, and net cash inflows of Rs 0.21 lakhs for the year ended March 31, 2022, as considered in the Statement which have been audited by another independent auditor. Whose report have been furnished to us by the management of the Company and our opinion in so far as it relates to the amounts included in respect of these subsidiary is based solely on the report of other auditor.

(b) We have relied on the unaud ted financial statements of one foreign subsidiary, whose financial statements reflects total assets of Rs. 6,437.01 Lakhs as at 31st March, 2022, total revenue of Rs. 955.86 Lakhs, total net loss after tax of Rs. 349.59 Lakhs and total comprehensive loss Rs. 349.59 Lakhs for year ended 31st March, 2022 and net cash inflow of Rs. 88.31 Lakhs for the year ended 31st March, 2022 as considered in the consolidated financial statements. These unaudited financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of the said subsidiary is solely based on such unaudited financial statements certified by the management.

Our conclusion on the consolidated financial statement is not modified in respect of the other matters above.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of 143 of the Act, based on our audit and on the consideration of report of the other auditors on separate financial statements and the other financial information of the group companies, incorporated in India, there are no matters which require reporting as specified in paragraph 3(xxi) of the Order. The Holding Company did not have any associate company incorporated in India and did not exercise joint control over any entity incorporated in India.

2. As required by Section 143(3) of the Act, based on our audit and on the consideration of report of other auditors on separate financial statements and the other financial information of group companies, as noted in the 'other matter' paragraph we report, to the extent applicable, that:

a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements;

b. In our opinion, proper books of account as required by law have been kept by the Company so far as appears from our examination of those books.

c. The Consolidated Balance Sheet, Consolidated Statement of Profit and Loss including Other Comprehensive Income, the Consolidated Cash Flow Statement and Consolidated Statement of changes in Equity dealt with by this report are in agreement with the books of account maintained for the purpose of preparation of the Consolidated Financial Statements.

d. In our opinion, the aforesaid consolidated financial statements comply with the accounting standards specified under section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015 as amended;

e. On the basis of written representations received from the directors of the Holding Company as on 31st March, 2022 taken on record by the Board of Directors of the Holding Company and the reports of the statutory auditors of its subsidiary companies and associate companies incorporated in India, none of the directors of the Group companies and its associate companies incorporated in India is disqualified as on 31st March, 2022 from being appointed as a director in terms of Section 164(2) of the Act.

f. With respect to the adequacy of the internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate Report in "Annexure A" which is based on the auditor's reports of the subsidiary companies incorporated in India. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Group internal financial controls over financial reporting;

g. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us:

i. The consolidated financial statements disclose the impact of pending litigations on the consolidated financial position of the Group - Refer Note 36 to the consolidated financial statements;

ii. The Group did not have any material foreseeable losses on long-term contracts including derivative contracts during the year ended 31st March, 2022, and

iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Group.

I. (a)The respective managements of the Holding Company and its subsidiaries which are companies incorporated in India whose financial statements have been audited under the Act have represented to us and the other auditors of such subsidiaries respectively that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Holding Company or any of such subsidiaries to or in any other person(s) or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the respective Holding Company or any of such subsidiaries ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b)The respective managements of the Holding Company and its subsidiaries which are companies incorporated in India whose financial statements have been audited under the Act have represented to us and the other auditors of such subsidiaries respectively that, to the best of its knowledge and belief, no funds (which are material either individually or in the aggregate) have been received by the respective Holding Company or any of such subsidiaries from any person(s) or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Holding Company or any of such subsidiaries shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the ultimate Beneficiaries; and (c) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances performed by us and those performed by the auditors of the subsidiaries and associate which are companies incorporated in India whose financial statements have been audited under the Act, nothing has come to our or other auditor's notice that has caused us or the other auditors to believe that the representations under sub-clause (a) and (b) contain any material misstatement.

v. The Company has not declared or paid any dividend during the year.

For Suryaprakash Maurya & Co.
Chartered Accountants
Registration No : 147410W
Suryaprakash Maurya
Membership No. : 178258
ICAI UDIN: 22178258AJQUFN8110

Place : Mumbai
Dated : 26th May, 2022

"Annexure A" to Independent Auditors' report referred of even date on the Consolidated Financial Statements.

(Referred to in paragraph 2 (f) under 'Report on Other Legal and Regulatory Requirements' of our report of even date)

We have audited the internal financial controls over financial reporting of Kilitch Drugs (India) Limited (herein after referred to as ("the Holding") and its subsidiary companies (the Holding Company and its subsidiaries together referred to as "the Group") which are companies incorporated in India as of 31st March, 2022 in conjunction with our audit of the consolidated financial statements of the Company for the year then ended.

Management's Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding company, its subsidiary companies which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal controls over financial reporting criteria established by the Company considering the essential components of internal controls stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected.

Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Holding Company, its subsidiary companies, which are companies incorporated in India, have, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March, 2022, based on the internal controls over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the ICAI.

Other matters

Our report under Section 143(3)(I) of the Act on the adequacy and operating effectiveness of the internal financial controls with reference to consolidated financial statements of the Holding Company, in so far as it relates to one subsidiary, which is incorporated in India, is based on the corresponding reports of the auditors of such subsidiary. The Holding Company did not have any associate company incorporated in India and did not exercise joint control over any entity incorporated in India.

For Suryaprakash Maurya & Co.
Chartered Accountants
Registration No : 147410W
Suryaprakash Maurya
Membership No. : 178258
ICAI UDIN: 22178258AJQUFN8110
Place : Mumbai
Dated : 26th May, 2022

KILITCH DRUGS (INDIA) LIMITED

Consolidated Balance Sheet

As at 31st March, 2022

(Rs. In Lakhs)

Particulars	Note No.	As at 31st March, 2022	As at 31st March, 2021
ASSETS			
Non-current assets			
Property, Plant and equipment	6	4324.23	790.41
Capital work-in-progress	6	316.11	6,547.98
Other Intangible assets	6	2129.77	2,206.02
Financial assets			
- Investments	7(A)	2,393.18	2,388.34
- Loans & Advances	8	46.31	44.14
- Other Financials Assets	9	213.59	176.34
Deferred tax assets (Net)	10	151.18	127.87
(A)		**9,574.37**	**12,281.10**
Current assets			
Inventories	11	500.02	358.61
Financial assets			
- Investments	7(B)	4,723.42	3,640.05
- Trade receivables	12	4,141.17	2,291.84
- Cash and cash equivalents	13	1,006.15	1,250.05
- Other Financials Assets	14	2.02	1.97
Other current assets	15	1037.67	493.93
(B)		**11,410.45**	**8,036.45**
TOTAL ASSETS (A + B)		**20,984.82**	**20,317.55**
EQUITY AND LIABILITIES			
Equity			
Equity Share capital	16	1,558.23	1,549.45
Other equity	17	12,350.41	11,163.42
Equity attributable to the owners		**13,908.64**	**12,712.87**
Non-controlling interest		120.72	235.00
(A)		**14,029.36**	**12,947.87**
Liabilities			
Non-Current Liabilities			
Provisions	18	27.54	38.06
Current liabilities			
Financial liabilities			
- Borrowings	19	2,043.18	1,480.38
- Trade Payables	20		
Micro and Small Enterprises		-	-
Others		4,286.91	5,365.46
- Other financial liabilities	21	3.88	3.88
Provisions	22	100.88	82.76
Current tax Liabilities (net)	23	439.62	262.30
Other current liabilities	24	53.45	136.84
(B)		**6,955.46**	**7,369.68**
TOTAL EQUITY AND LIABILITIES(A+B)		**20,984.82**	**20,317.55**
Significant Accounting Policies and Notes on Financial Statements	**1 to 53**		

As per ourreport of even date	
ForSuryaprakash Maurya & Co. Chartered Accountants	For and on behalf of the Board of Directors Kilitch Drugs India Limited
FRN: 147410W	Mukund P. Mehta (Managing Director) [DIN: 00147876]
Suryaprakash Maurya Partner	Bhavin M.Mehta (Whole-time Director) [DIN: 00147895]
M.No. 178258	Sunil Jain Chief Financial Officer
Mumbai Dated: 26th May, 2022	Pushpa Nyoupane (Company Secretary) M No. A64047

KILITCH DRUGS (INDIA) LIMITED

Consolidated Statement of Profit and Loss

For the year ended 31st March 2022

(Rs. In Lakhs)

Particulars	Note No.	Year Ended 31st March 2022	Year Ended 31st March 2021
INCOME			
Revenue from Operations	25	11,423.42	6,852.31
Other Income	26	290.93	266.73
Total		**11,714.35**	**7,119.05**
EXPENDITURE			
Cost of Materials Consumed	27	6,548.03	3,621.91
Variation in inventories of finished goods & work -in-progress	28	(4.69)	108.81
Employee benefits expenses	29	618.31	523.98
Finance Cost	30	119.84	75.44
Depreciation and amortization expense	6	246.56	198.61
Export Product Registration/Commission	31	548.13	448.30
Other expenses	32	2,676.73	1,630.03
Total Expenses		**10,752.91**	**6,607.08**
PROFIT BEFORE TAX EXCEPTIONAL ITEMS AND TAX		**961.44**	**511.96**
Add: Exceptional Item		-	-
PROFIT BEFORE TAX		**961.44**	**511.96**
Less :Tax Expenses			
Current Income Tax		363.37	166.55
Deferred Tax		(23.30)	(31.25)
PROFIT AFTER TAX		**621.37**	**376.66**
Add/(Less) : Share of Profit/(Loss) in Associates			-
PROFIT FOR THE YEAR		**621.37**	**376.66**
Other comprehensive income			
A) Items that will not be reclassified To Profit & Loss A/c			
Change in fair value of Investments		259.96	695.23
Employee benefits		5.78	8.40
B) Income Tax relating to the items that will not bereclassified to			
Change in fair value of Investments		(67.59)	(180.76)
Total comprehensive income for the Year		198.15	522.87
PROFIT AFTER TAX & Comprehensive Income		819.52	899.53
Net Profit / (Loss) attributable to			
a) Owner of the Company		736.72	367.11
b) Non-Controlling interest		(115.36)	9.55
Other Comprehensive Income attributable to			
a) Owner of the Company		**198.15**	**522.87**
b) Non-Controlling interest		-	-
Total Income attributable to			
a) Owner of the Company		934.87	889.98
b) Non-Controlling interest		(115.36)	9.55
Earning per share	**35**		
(a) Basic (not annualised)		4.73	2.37
(b) Diluted (not annualised)		4.73	2.37
Significant Accounting Policies and Notes on Financial Statements	**1 to 53**		

As per our report of even date	
For Suryaprakash Maurya & Co. Chartered Accountants	For and on behalf of the Board of Directors Kilitch Drugs India Limited
FRN: 147410W	Mukund P. Mehta (Managing Director) [DIN: 00147876]
Suryaprakash Maurya Partner M. No.178258	Bhavin M. Mehta (Whole-time Director) [DIN: 00147895]
	Sunil Jain (Chief Financial Officer)
Place: Mumbai Dated: 26th May 2022	Pushpa Nyoupane (Company Secretary)

KILITCH DRUGS (INDIA) LIMITED

Consolidated Cash Flow Statemen

For the year ended 31st March 2022

(Rs. In Lakhs)

Particulars	For the Year Ended 31st March, 2022		For the Year Ended 31st March, 2021	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit / (Loss) before extraordinary items		961.44		511.96
and tax Adjustments for:				
Depreciation and amortisation	246.56		198.61	
Interest income	(21.91)		(17.03)	
Dividend income	(3.05)		(5.55)	
(Profit)/Loss on sale of Investments	(135.92)		(120.31)	
Share of (Profit)/ Loss from Partnership Firm	0.20		0.20	
Sundry Balances written back	-		(1.03)	
Provision for Gratuity & Leave Encashment			4.83	
Interest Expenses	119.84		75.44	
Share Based Payment cost	-		(15.74)	
Bad Debts / Provision for Doubtful Debts	108.58		153.29	
Net unrealised exchange (gain) / loss	71.76	389.46	7.25	279.96
Operating profit / (loss) before working capital changes		1350.90		791.92
Changes in working capital:				
Operating Assets:				
Inventories	(141.41)		197.06	
Trade receivables	(2029.66)		(866.48)	
Other financial Assets	(0.05)		64.18	
Other current assets	(543.74)		(183.77)	
Deposits/Advances	(2.17)		(8.13)	
Operating Liabilities:				
Trade payables	2,271.50		4,656.09	
Other financial liabilities				
Other current liabilities	(83.39)		18.44	
Short-term provisions	9.97	(518.96)	(2.17)	3,875.22
Gross cash flow from / (used in) operating activities		831.94		4,667.14
Direct Taxes (Paid) / refunded		(253.64)		(101.25)
Net cash flow from / (used in) operating activities (A)		**578.30**		**4.565.89**
B. CASH FLOW FROM INVESTING ACTIVITIES				
Property,Plant & Equipment Purchased	(820.18)		(3,629.79)	
Proceeds (Net) from the sale of Current investments	(687.48)		(43.47)	
(Purchase)/Sale (Net) of long-term investments	(5.04)		16.27	
Movement in other Bank balance	(37.25)		(122.51)	
Interest received	21.86		17.03	
Dividend received	3.05		5.55	
		(1,525.04)		(3,756.92)
Net cash flow from / (used in) investing activities (B)		**(1,525.04)**		**(3,756.92)**
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from Shares issued (Net of Conversion of Warrants)	8.78		6.04	
Proceeds from Borrowings (Net of Repayments)	250.00		219.46	
Interest Expenses	562.81		(75.44)	
Proceeds from Minorities	1.08		9.55	
Dividends paid (Inclusive of tax on Dividend)	(119.84)		1.81	

KILITCH DRUGS (INDIA) LIMITED

Consolidated Cash Flow Statemen

For the year ended 31st March 2022

Net cash flow from / (used in) financing activities (C)		**702.83**		**161.42**
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		**(243.91)**		**970.39**
Cash and cash equivalents at the beginning of the year		1250.05		279.66
Cash and cash equivalents at the end of the year		**1,006.15**		**1,250.05**
Cash and cash equivalents at the end of the year *				
* Comprises:				
(a) Cash on hand		0.58		0.85
(b) Balances with banks				
(i) In current accounts		1,001.69		1,245.32
(ii) In earmarked accounts		3.88		3.88
		1,006.15		**1,250.05**

As per our report of even date	
ForSuryaprakash Maurya & Co. Chartered Accountants	Forand on behalf of the Board of Directors Kilitch Drugs India Limited
FRN: 147410W	Mukund P. Mehta (Managing Director) [DIN: 00147876]
Suryaprakash Maurya Partner	Bhavin M. Mehta (Whole-time Director) [DIN: 00147895]
M.No. 178258	Sunil Jain ChiefFinancial Officer
Mumbai Dated: 26th May, 2022	Pushpa Nyoupane (Company Secretary) M No. A64047

KILITCH DRUGS (INDIA) LIMITED

Consolidated Statement of Changes in Equity

For the year ended 31st March 2022

(Rs. In Lakhs)

(a) Equity Share Capital				
As at 1stApril 2020	Changes during the Year	As at 31st March 2021	Changes during the Year	As at 31st March 2022
1,543.42	6.03	1,549.45	8.78	1,558.23

Particulars	Securities Premium account	General Reserve	Employee Stock Options	Foreign Exchange Fluctuation Reserve	Other Reserves (Call on shares forfeited A/c)	Other Equity	Other Comprehensive Income	Surplus in the Statement of Profit and Loss	Capital reserve on consolidation	Total Other Equity	Non-controlling interest	Total
Balance as on 1st April, 2020	**3,832.63**	**1,511.76**	**119.13**	**18.06**	**58.00**	**-**	**(85.51)**	**4,814.49**	**13.28**	**10,281.84**	**225.45**	**10507.29**
Profit for the Year	-	-	-	-	-	-	-	367.11	-	367.11	9.55	376.66
Change In Fair Value of Investments	-	-	-	-	-	-	522.87	-	-	522.87	0	522.87
Premium on issue of Shares during the year	-	67.98	(83.72)	7.32	-	-	-	-	-	(8.40)	0	(8.40)
Balance as on 31st March, 2021	**3,832.63**	**1,579.74**	**35.42**	**25.38**	**58.00**	**-**	**437.36**	**5,181.60**	**13.28**	**11,163.42**	**235.00**	**11398.42**
Profit for the Year	-	-	-	-	-	-	-	736.72	-	736.72	-115.36	621.36
Change In Fair Value of Investments	-	-	-	-	-	-	-	198.15	-	198.15	0	198.15
Foreign Exchange Fluctuation Warrents	-	-	-	2.12	-	-	-	-	-	2.12	1.08	3.20
Money Received Against Share	-	-	-	-	-	250.00	-	-	-	250.00	0	250.00
Balance as on 31st March,2022	**3,832.63**	**1,579.74**	**35.42**	**27.50**	**58.00**	**250.00**	**437.36**	**5,918.32**	**13.28**	**12350.41**	**120.72**	**12471.13**

As per our report of even date	
For Suryaprakash Maurya & Co. Chartered Accountants	For and on behalf of the Board of Directors Kilitch Drugs India Limited
FRN: 147410W Suryaprakash Maurya	Mukund P. Mehta (Managing Director) [DIN: 00147876]
Partner M.No. 178258	Bhavin M. Mehta (Whole-time Director) [DIN: 00147895]
	Sunil Jain Chief Financial Officer
Mumbai Dated:26th May 2022	Puspha Nyoupane (Company Secretary)

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Note 1: Corporate Information

Kilitch Drugs India Limited ("KDIL" or "Parent") is domiciled and incorporated under the provisions of the Companies Act applicable in India and its shares are publicly traded on the National Stock Exchange ('NSE') and the Bombay Stock Exchange ('BSE'), in India. The registered office of the company is located at C-301-2, M.I.D.C. TTC Industrial Area, Pawane Village, Thane – 400705, Maharashtra, India.

Group is engaged in operation and management of Pharmaceutical Products.

These financial statements were approved and adopted by the Board of Directors of the Company in their meeting dated 26th May, 2022.

Note 2 - Basis of Preparation of Financial Statements:
The Financial Statements have been prepared to comply in all material aspects with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015, as amended.

The significant accounting policies used in preparing financial statements are set out in Note 3 of the Notes on Financial Statements and are applied consistently to all the periods presented.

Note 3 - Significant Accounting Policies:

• **Functional and presentation of currency:**
The financial statements are presented in Indian Rupees, which is the Group's functional currency and all amounts are rounded to the nearest rupees in lakhs.

• **Basis of measurement:**
The consolidated financial statements have been prepared on an accrual basis and under the historical cost convention except following which have been measured at fair value, except the following:

• Certain financial assets and liabilities are measured at fair value.
• Defined benefit plans – plan assets measured at fair value.
• Share Based Payments.

• **Basis of consolidation**
The consolidated financial statements of the Group incorporate the financial statements of the Parent Company and its subsidiaries and associates. The Parent Company has control over the subsidiaries as it is exposed, or has rights, to variable returns from its involvement with the investee; and has the ability to affect its returns through its power over the subsidiaries. Generally, there is a presumption that a majority of voting rights result in control. To support this presumption and when the Group has less than a majority of the voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including the contractual arrangement with the other vote holders of the investee, rights arising from other contractual arrangements, the Group's voting rights and potential voting rights and the size of the Group's holding of voting rights relative to the size and dispersion of the holdings of the other voting rights holders. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control.

An associate is an entity over which the Group has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but has no control or joint control over those policies.

Consolidation Procedure:
• Combine like items of assets, liabilities, equity, income, expenses and cash flows of the parent with those of its subsidiaries. For this purpose, income and expenses of the subsidiary are based on the amounts of the assets and liabilities recognised in the consolidated financial statements at the acquisition date.

• Consolidation of a subsidiary begins when the Parent Company obtains control over the subsidiary and ceases when the Parent Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date the Parent Company gains control until the date when the Parent Company ceases to control the subsidiary.

• Profit or loss and each component of other comprehensive income are attributed to the owners of the Parent Company and to the non-controlling interests. Total comprehensive income of subsidiaries is attributed to the owners of the Parent Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

• Adjustments are made to the financial statements of subsidiaries, as and when necessary, to bring their accounting policies into line with the Group's accounting policies.

• All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

• Carrying amount of the Parent's investment in each subsidiary and the Parent's portion of equity are eliminated. Business combinations policy explains how the related goodwill is accounted at the time of acquisition of subsidiary.

• Changes in the Group's ownership interests in subsidiaries that do not result in the Group losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the Group's interests and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the noncontrolling interests are adjusted and the fair value of the consideration paid or received is recognised directly in equity and attributed to owners of the Parent Company.

• Investment in Associates has been accounted under the equity method as per Ind AS 28 - Investments in Associates and Joint Ventures. The Company accounts for its share of postacquisition changes in net assets of associates, after eliminating unrealised profits and losses resulting from transactions between the Company and its associates to the extent of its share, through its Consolidated Statement of Profit and Loss, to the extent such change is attributable to the associates' Statement of Profit and Loss and through its reserves for the balance based on available information.

• Use of Estimates:

The preparation of the financial statements requires management to make estimates, judgements and assumptions that affect the reported balances of assets and liabilities, disclosure of contingent liabilities as on the date of financial statements and reported amounts of income and expenses during the period.
Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year. The Company based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. Such changes are reflected in the assumptions when they occur.

• Business Combinations

The acquisitions of businesses are accounted for using the acquisition method. The cost of the acquisition is measured at the aggregate of the fair values at the date of exchange of assets given, liabilities incurred or assumed and equity instruments issued by the Group in exchange for control of the acquiree. The acquiree's identifiable assets, liabilities and contingent liabilities that meet the condition for recognition are recognized at their fair values at the acquisition date except certain assets and liabilities required to be measured as per the applicable standard. Goodwill arising on acquisition is recognized as an asset and initially measured at cost, being the excess of the cost of the business combination over the Group's interest in the net fair value of the identifiable assets acquired, liabilities recognized and contingent liabilities assumed. In the case of bargain purchase, resultant gain is recognized in other comprehensive income on the acquisition date and accumulated to capital reserve in equity. The interest of non-controlling shareholders in the acquiree is initially measured at the noncontrolling shareholders proportionate share of the acquiree's identifiable net assets.

• Property, Plant and Equipment

Freehold land is carried at historical cost. Capital work in progress, and all other items of property, plant and equipment are stated at historical cost net of accumulated depreciation and accumulated impairment losses, if any.
Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced.

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred. Depreciation methods, estimated useful lives and residual value Leasehold land is amortized over the period of lease. Depreciation on other fixed assets (excluding land and lease land in perpetuity) is provided on written down value method as per the useful life specified in schedule II to the Companies Act, 2013, in the manner state therein. The residual values are not more than 5% of the original cost of the asset. The assets' residual values and useful lives and method of depreciation are reviewed, and adjusted if appropriate, at the end of each reporting period.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in the statement of profit or loss.

• Intangible Assets

Identifiable intangible assets are recognized a) when the Group controls the asset, b) it is probable that future economic benefits attributed to the asset will flow to the Group and c) the cost of the asset can be reliably measured. Intangible assets acquired are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses.

Intangible assets are amortised over the period on straight line basis. The assets useful life reviewed at each financial year end.

• Financial Instrument:

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instruments of another entity. Classifications of financial instruments are in accordance with the substance of the contractual arrangement and as per the definitions of financial assets, financial liability and an equity instruments.

Financial Assets and investments

• Initial recognition and measurement:
At initial recognition, the group measures a financial asset (other than financial asset at fair value through profit or loss) at its fair value plus or minus, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at fair value through profit or loss are expensed in the statement of profit & loss.

• Subsequent recognition and measurement:

Subsequent measurement of financial asset depends on the group's business model for managing the asset and the cash flow characteristics of the asset. For the purpose of subsequent recognition and measurement financial assets are classified in four categories:

• Debt instrument at amortised cost:

Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortised cost. A gain or loss on a debt investment that is subsequently measured at amortised cost and is not part of a hedging relationship is recognised in profit or loss when the asset is derecognised or impaired. Interest income from these financial assets is included in finance income using the effective interest rate method.

• Debt instrument at fair value through other comprehensive income (FVOCI):
Assets that are held for collection of contractual cash flows and for selling the financial assets, where the assets' cash flows represent solely payments of principal and interest, are measured at fair value through other comprehensive income (FVOCI). Movements in the carrying amount are taken through OCI, except for the recognition of impairment gains or losses and interest revenue which are recognised in the statement of profit & loss. When the financial asset is derecognised, the cumulative gain or loss previously recognised in OCI is reclassified from equity to profit or loss and recognised in other gains/ (losses).

Interest income from these financial assets is included in other income using the effective interest rate method.

• Debt instrument at fair value through profit and loss (FVTPL):

Assets that do not meet the criteria for amortised cost or FVOCI are measured at fair value through profit or loss. A gain or loss on a debt investment that is subsequently measured at fair value through profit or loss and is not part of a hedging relationship is recognised in the statement of

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

profit & loss and presented net in the statement of profit & loss within other gains/(losses) in the period in which it arises. Interest income from these financial assets is included in other income.

• Equity instruments:

All equity instruments other than in associates are initially measured at fair value. Any subsequent fair value gain/loss is recognised through profit or loss if such investments are held for trading purposes. The fair value gains or losses of all other equity investments are recognised in Other Comprehensive Income.

• Investment in Associates:
The Group has accounted for its Investment in associates at cost

• Derecognition:
A financial asset is primarily derecognised i.e. removed from Group's financial statements when:
• The rights to receive cash flows from asset have expired, or
• The Group has transferred its right to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under pass- through' arrangement and either;
• The Group has transferred substantially all the risks and rewards of the assets,
• The Group has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset or has entered into a passthrough arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Group continues to recognise the transferred asset to the extent of the Group's continuing involvement. In that case, the Group also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the group could be required to repay.

• Trade receivables:
A receivable is classified as a 'trade receivable' if it is in respect to the amount due from customers on account of goods sold or services rendered in the ordinary course of business. Trade receivables are recognised initially at fair value and subsequently measured at fair value less provision for impairment.

Financial Liabilities:

• Initial recognition and measurement:

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Group's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts.

• Subsequent measurement:
The measurement of financial liabilities depends on their classification, as described below:

Financial liabilities at fair value through profit and loss financial liabilities at fair value through profit or loss include financial liabilities held for trading and has designated upon initial measurement recognition at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term.

Gains or losses on liabilities held for trading are recognised in the statement of profit & loss.

Financial liabilities designated upon initial recognition at fair value through profit or loss are designated as such at the initial date of recognition, and only if the criteria in Ind AS 109 are satisfied.

• Loans and Borrowings:

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the effective interest rate (EIR) method. Gains and losses are recognised in the statement of profit & loss when the liabilities are derecognised as well as through the EIR amortisation process.

Amortised cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR.

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

The EIR amortisation is included as finance costs in the statement of profit and loss.

• Trade and other payables:
These amounts represent liabilities for goods and services provided to the group prior to the end of financial year which are unpaid. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period.

Derecognition:

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the Derecognition of the original liability and the recognition of a new liability.

The difference in the respective carrying amounts is recognised in the statement of profit or loss.

• Impairment of Assets

An asset is considered as impaired when at the date of Balance Sheet there are indications of impairment and the carrying amount of the asset, or where applicable the cash generating unit to which the asset belongs exceeds its recoverable amount (i.e. the higher of the net asset selling price and value in use).

• Impairment of Goodwill

For the purposes of impairment testing, goodwill is allocated to each of the Group's cash-generating units (or groups of cash generating units) that is expected to benefit from the synergies of the combination.

A cash-generating unit to which goodwill has been allocated is tested for impairment annually, or when there is an indication that the unit may be impaired. The recoverable amount of cash generating unit is determined for each legal entity based on a value in use calculation which uses cash flow projections and appropriate discount rate is applied. The discount rate takes into account the expected rate of return to shareholders, the risk of achieving the business projections, risks specific to the investments and other factors. If the recoverable amount of the cash-generating unit is less than its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro rata based on the carrying amount of each asset in the unit. Any impairment loss for goodwill is recognised directly in profit or loss. An impairment loss recognised for goodwill is not reversed in subsequent periods.

On disposal of the relevant cash-generating unit, the attributable amount of goodwill is included in the determination of the profit or loss on disposal.

• Impairment of Non – Financial Asset:

The Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Group estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or Cash Generating Unit's (CGU) fair value less costs of disposal and its value in use. It is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or a groups of assets. Where the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount.

In assessing the value in use, the estimated future cash flows are discounted to their present value using pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account, if no such transactions can be identified, an appropriate valuation model is used.

• Impairment of Financial asset:

The Group assesses impairment based on expected credit losses (ECL) model to the following:

- Financial assets carried at amortised cost;
- Financial asset measured at FVOCI debt instruments.

The Group follows 'simplified approach' for recognition of impairment loss allowance on Trade receivables or contract revenue receivables.

The application of simplified approach does not require the Group to track changes in credit risk.

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

The Group uses a provision matrix to determine impairment loss allowance on its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed.

For recognition of impairment loss on other financial assets and risk exposure, the Group determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If, in a subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12-month ECL.

Lifetime ECL are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12-month ECL is a portion of the lifetime ECL which results from default events that are possible within 12 months after the reporting date.

For assessing increase in credit risk and impairment loss, the group combines financial instruments on the basis of shared credit risk characteristics with the objective of facilitating an analysis that is designed to enable significant increases in credit risk to be identified on a timely basis.

• Cash and cash equivalents

Cash and cash equivalents includes cash on hand and at bank, deposits with banks and other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

• Inventories

Inventories are valued at lower of cost or net realisable value. Cost is determined on FIFO basis.

Cost of inventories also includes all other costs incurred in bringing the inventories to their present location and condition. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

• Foreign currency transactions:

The transactions denominated in foreign currency are recorded at the exchange rate prevailing on the date of transaction. Monetary items denominated in foreign currency at the end of year are translated using the closing rate of exchange. Non- monetary items that are to be carried at historical cost are recorded using exchange rate prevailing on the date of transaction. Non- monetary items that are to be carried at fair value are recorded using exchange rate prevailing on the date of fair value measured. Any income or expenses on account of exchange difference either on settlement or on translation is recognised in the statement of profit or loss.

• Classification of assets and liabilities as current and non- current:

The Group presents assets and liabilities in Balance Sheet based on current/non-current classification.

An asset is classified as current when it is:

• Expected to be realised or intended to be sold or consumed in normal operating cycle,
• Held primarily for the purpose of trading,
• Expected to be realised within twelve months after the reporting period, or
• Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is classified as current when:
• It is expected to be settled in normal operating cycle,
• It is held primarily for the purpose of trading,
• It is due to be settled within twelve months after the reporting period, or
• There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

All other liabilities are classified as non-current.

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

• Equity share capital

Ordinary shares are classified as equity. Incremental costs net of taxes directly attributable to the issue of new equity shares are reduced from retained earnings, net of taxes.

• Revenue recognition

Revenue is recognised to the extent that it is probable that the future economic benefits will flow to the entity and it can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties collected on behalf of the government.

• Sale of goods

Revenue from sale of goods is recognised when the significant risks and rewards of ownership have been transferred to the buyer, usually on delivery of goods, it is probable that the economic benefit will flow the Group, the associated costs and possible return of goods can be estimated reliably, there is neither continuing management involvement to the degree usually associated with ownership nor effective control over the goods sold and the amount of revenue can be measured reliably.

Provisions for chargeback, rebates, discounts and medical aid payments are estimated and provided for in the year of sales and recorded as reduction of revenue.

• Sales Returns

With respect to established products, the Group considers its historical experience of sales returns, levels of inventory in the distribution channel, estimated shelf life, product discontinuances, price changes of competitive products, and the introduction of competitive new products, to the extent each of these factors impact the Company's business and markets. With respect to new products introduced by the Group, such products have historically been either extensions of an existing line of product where the Group has historical experience or in therapeutic categories where established products exist and are sold either by the Group or the Group's competitors.

• Interest income

Interest income from debt instrument is recognised using effective interest rate method. The effective interest rate is the rate that discounts estimated future cash receipts through the expected life of financial asset to the gross carrying amount of financial asset. When calculating effective interest rate, the Group expects cash flows by considering all contractual terms of financial instrument but does not consider the expected credit losses.

• Dividends

Dividends are recognised when the right to receive the payment is established.

• Borrowing Costs

General and specific borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are capitalised during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for their intended use or sale.

Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for such capitalisation.

Other borrowing costs are expensed in the period in which they are incurred.

Borrowing costs consist of interest and other costs that are incurred in connection with the borrowing of funds.

• Employee Benefits

• Short-term Employee benefits:

All employees' benefits payable wholly within 12 months rendering services are classified as Short Term obligations. Benefits such as salaries, wages, short term compensated absences, performance incentives, expected cost of bonus and ex-gratia are recognised during the period in which the employees renders related services.

• Post-employment benefits

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

• Defined Contribution Plan

The defined contribution plan is post-employment benefit plan under which the Group contributes fixed contribution to a government administered fund and will have no legal or constructive obligation to pay further contribution. The Group's defined contribution plan comprises of Provident Fund, Labour Welfare Fund and Employee State Insurance Scheme. The Group's contribution to defined contribution plans are recognised in the statement of profit & loss in the period in which the employee renders the related services.

• Defined benefit plan

The Group has defined benefit plans comprising of gratuity. Group's obligation towards gratuity liability is partially funded as Management has initiated a decision to be funded and managed by Life Insurance Corporation of India over the period of 20 equated quarterly instalments over a period of 5 years.

The present value of the defined benefit obligations is determined based on actuarial valuation using the projected unit credit method. The rate used to discount defined benefit obligation is determined by reference to market yields at the Balance Sheet date on Indian Government Bonds for the estimated term of obligations.

Re-measurements comprising of (a) actuarial gains and losses, (b) the effect of the asset ceiling (excluding amounts included in net interest on the net defined benefit liability) and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability) are recognised immediately in the balance sheet with a corresponding debit or credit to retained earnings through other comprehensive income in the period in which they occur. Re-measurements are not reclassified to the statement of profit & loss in subsequent periods.

The expected return on plan assets is the Group's expectation of average long-term rate of return on the investment of the fund over the entire life of the related obligation. Plan assets are measured at fair value as at the Balance Sheet date.

The interest cost on defined benefit obligation and expected return on plan assets is recognised under finance cost.

Gains or losses on the curtailment or settlement of defined benefit plan are recognised when the curtailment or settlement occurs.

• Other long-term benefits

The Group's employees have other long-term benefits in the form of leave benefits. The present value of the other long term employee benefits is determined based on actuarial valuation using the projected unit credit method. The rate used to discount defined benefit obligation is determined by reference to market yields at the Balance Sheet date on Indian Government Bonds for the estimated term of obligations.

Actuarial gains or losses arising on account of experience adjustment and the effect of changes in actuarial assumptions are recognised immediately in the statement of profit & loss as income or expense.

Gains or losses on the curtailment or settlement of other long-term benefits are recognised when the curtailment or settlement occurs.

• Share-based payments

Share-based compensation benefits are provided to employees via Employee Stock Option Plans with the ESOS 2007.
The fair value of options granted under the Employee Option Plan is recognised as an employee benefits expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted:

• including any market performance conditions(e.g., the entity's share price)
• excluding the impact of any service and non-market performance vesting conditions (e.g.
profitability, sales growth targets and remaining an employee of the entity over a specified time period), and
• Including the impact of any non-vesting conditions (e.g. the requirement for employees to save or holdings shares for a specific period of time).

The total expense, other than in respect of options granted to employees of group companies, is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. The cost of options granted to employees of group companies is debited to the cost of the investment of the respective companies. At the end of each period, the Group revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions.

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

It recognises the impact of the revision to original estimates, if any, in the statement of profit & loss / Investment, with a corresponding adjustment to other equity.

• Income Taxes:

• Current Income Tax:

Current Income Tax liabilities are measured at the amount expected to be paid to the taxation authorities using the tax rates and tax laws that are enacted or subsequently enacted at the end of the reporting period. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and creates provisions where appropriate.

• Deferred Tax:

Deferred Tax is provided, using the Balance sheet approach, on temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred Tax is determined using the tax rates and tax laws that are enacted or subsequently enacted at the end of the reporting period.

Deferred Tax liabilities are recognised for all temporary differences. Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and the deferred tax balances relate to the same taxation authority.

Current tax asset and liabilities are offset where the Group has a legally enforceable right and intends either to settle on net basis, or to realise the asset and settle the liability simultaneously.

Current and deferred tax is recognised in the statement of profit & loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively.

• Provisions and contingencies

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. If the effect of the time value of money is material, provisions are discounted using the government securities' interest rate for the equivalent period. Unwinding of the discount is recognised in the Statement of Profit and Loss as a finance cost. Provisions are reviewed at each balance sheet date and are adjusted to reflect the current best estimate. Provisions are not recognised for future operating losses.

Contingent liabilities are disclosed when there is a possible obligation arising from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Group or a present obligation that arises from past events where it is either not probable that an outflow of resources will be required to settle or a reliable estimate of the amount cannot be made. Information on contingent liability is disclosed in the notes to the financial statements. Contingent assets are not recognised. However, when the realisation of income is virtually certain, then the related asset is no longer a contingent asset, but it is recognised as an asset.

• Earning per share:

Basic earning per share is calculated by dividing the net profit or loss (after tax) for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.

Diluted earning per share is calculated by dividing the net profit or loss (after tax) for the year attributable to equity shareholders and the weighted average number of equity shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

Note 4 - Use of Significant Accounting Estimates, Judgments and Assumptions In the process of applying the Group's accounting policies, management has made the following estimates and judgements, which have significant effect on the amounts recognised in the financial statements:

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

• Depreciation and useful lives of Property, Plant and Equipment

Property, plant and equipment are depreciated over the estimated useful lives of the assets, after taking into account their estimated residual value. Management reviews the estimated useful lives and residual values of the assets annually in order to determine the amount of depreciation to be recorded during any reporting period. The useful lives and residual values are based on the Group's historical experience with similar assets and take into account anticipated technological changes. The depreciation for future periods is adjusted if there are significant changes from previous estimates.

• Recoverability of trade receivables

Judgments are required in assessing the recoverability of overdue trade receivables and determining whether a provision against those receivables is required. The Group uses a provision matrix to determine impairment loss allowance on its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analysed.

• Defined Benefit plans

The cost of the defined benefit plan and other post-employment benefits and the present value of such obligation are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases, mortality rates and attrition rate. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

• Provisions

Provisions and liabilities are recognized in the period when it becomes probable that there will be a future outflow of funds resulting from past operations or events and the amount of cash outflow can be reliably estimated. The timing of recognition and quantification of the liability require the application of judgement to existing facts and circumstances, which can be subject to change.

Since the cash outflows can take place many years in the future, the carrying amounts of provisions and liabilities are reviewed regularly and adjusted to take account of changing facts and circumstances.

• Impairment of financial assets

The impairment provisions for financial assets are based on assumptions about risk of default and expected cash loss rates. The Group uses judgment in making these assumptions and selecting the inputs to the impairment calculation, based on Group's past history, existing market conditions as well as forward looking estimates at the end of each reporting period.

Estimates and judgments are based on historical experience and other factors, including expectations of future events that may have a financial impact on the Group and that are believed to be reasonable under the circumstances. They are continuously evaluated.

• Fair Value measurement

The Group measures financial instrument e.g. investments, at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

• In the principal market for the asset or liability, or

• In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Group.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 - Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3 - Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the financial statements on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

Note 5- Amendment to Existing issued Ind AS :

On March 23, 2022, the Ministry of Corporate Affairs (MCA) has notified Companies (Indian Accounting Standards) Amendment Rules, 2022. This notification has resulted into amendments in the following existing accounting standards which are applicable to company from April 1, 2022.

Ind AS 101 - First time adoption of Ind AS
Ind AS 103 - Business Combination
Ind AS 109 - Financial Instrument
Ind AS 16 - Property, Plant and Equipment
Ind AS 37 -Provisions, Contingent Liabilities and Contingent Assets
Ind AS 41 - Agriculture
Application of above standards are not expected to have any significant impact on the company's financial statements.

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Note 6 - Property, Plant & Equipment

(Rs.in Lakhs)

Particulars	Land	Pen Land	Rights on Lease Hold Land	Factory	Office premises	Plant & Machinery	Furniture & Equipment	Computer	Motor Car	Office Equipment	Air Conditioners	Electrical Installations	Laboratory Equipment	Mobile Phone	Computer software	Goodwill	CapitalWIP	Total
Gross Block																		
As at 01/04/2020	29.88	-	96.78	261.02	133.24	1653.18	106.33	50.61	144.30	25.66	28.54	47.22	237.67	13.47	18.40	4212.73	2960.14	10019.17
Additions	-	-	-	-	-	12.41	0.49	5.16	1.53	0.61	0.57	-	8.58	1.93	10.65	-	3587.84	3629.77
Disposals/ Transfers	-		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
As at 31/03/2021	29.88	-	96.78	261.02	133.24	1665.59	106.82	55.77	145.83	26.27	29.11	47.22	246.25	15.40	29.05	4212.73	6547.98	13648.94
Additions	-	734.65	-	-	-	3684.27	1.55	2.49	-	3.93	-	-	1.38	1.46	9.02		0	4438.75
Disposals/ Transfers	-		-	-	-	-	-	-	-	-	-	-	-	-	-	-	6231.87	6231.87
As at 31/03/2022	29.88	734.65	96.78	261.02	133.24	5,349.86	108.37	58.26	145.83	30.2	29.11	47.22	247.63	16.86	38.07	4212.73	316.11	5623.95
Accumulated Depreciation																		
As at 01/04/2020	-	-	-	247.97	79.08	1,135.83	77.56	43.66	109.65	20.23	24.56	26.36	180.55	9.22	13.39	1,937.86	-	3,905.92
Depreciation Charge for the Year	-	-	-	-	2.63	70.44	6.90	4.78	6.46	2.33	0.53	5.23	13.85	0.94	0.26	84.26	-	198.61
As at 31/03/2021	-	-	-	247.97	81.71	1,206.27	84.46	48.44	116.11	22.56	25.09	31.59	194.40	10.16	13.65	2,022.12	-	4,104.53
Depreciation Charge for the Year			-	-	2.50	126.70	5.04	4.49	3.54	2.17	0.51	3.83	11.52	0.97	1.01	84.25		246.53
As at 31/03/2022	-		-	247.97	84.21	1,332.97	89.50	52.93	119.65	24.73	25.60	35.42	205.92	11.13	14.66	2,106.37	-	4,351.06
Net Block																		
As at 31/03/2022	29.88		96.78	13.05	49.03	4,016.89	18.87	5.33	26.18	5.47	3.51	11.80	41.71	5.73	23.41	2,106.36	316.11	6,770.11
As at 31/03/2021	29.88		96.78	13.05	51.53	459.32	22.35	7.33	29.72	3.71	4.02	15.63	51.85	5.24	15.40	2,190.61	6,547.98	9,544.41

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Note 7 – Investments

(Rs.In Lakhs)

A] Non - Current Investments		
Particulars	**As at 31st March, 2022**	**As at 31st March, 2021**
Non-Trade Investments		
A. Investments in Shares:		
i. Quoted Shares: (At Fair Value through Other Comprehensive Income)		
[Equity Shares of Face value Rs. 10/each, fully paid-up, unless otherwise stated]		
15 (31st March 2021 : 15) - Bengal and Assam Co Ltd.	0.35	0.20
1,000 (31st March 2021 : 1000) Century Enka Ltd.	5.55	2.54
500 (31st March 2021 : 500) - Century Textiles &Ind Ltd.	4.27	2.33
200 (31st March2021 :200) - Colgate Palmolive India Ltd.	3.08	3.12
720 (31st March 2021 : 720) - J K Laxmi Cement Ltd.	3.42	3.12
400 (31st March 2021 : 400) - Pfizer Ltd.	17.39	18.10
62 (31st March 2021 :62) - Ultratech Cement Ltd.	4.09	4.18
Fair Value of Quoted Instruments (Total of A. i)	**38.17**	**33.58**
ii. Unquoted Shares:		
Total Investment in Shares (A. i + A. ii)	**38.17**	**33.58**
B. Investment in Portfolio Management Scheme		
(At Fair Value through OtherComprehensive Income)		
Club millionaire Financial Services Pvt Ltd.	47.60	43.32
C. Investment in the Capital of Partnership Firm (LLP) (At Cost)		
ARHAM NEETA REALITIES LLP	2,246.29	2,246.49
D. Investments in Bonds:		
Quoted Bonds: (At Fair Value through Other Comprehensive Income)		
National Highways Authority of India	54.16	55.93
Housing And Urban Devel	8.98	9.22
Total Investment in Bonds:	**63.13**	**65.15**
Aggregate Fair Value of All Non-current Investments (A+B+C+D)	**2393.18**	**2,388.34**

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

B] Current Investments		(Rs.In Lakhs)
Particulars	**As at 31st March, 2022**	**As at 31st March, 2021**
Investment in Units of Mutual Funds : (At fair value through Other Comprehensive income) Mutual Fund-Kotak		
118,772.2330 (31st March 2021:118,772.2330) HDFC Small Cap Fund Regular Growth	84.34	62.77
77,649.1390 (31st March 2021: 77,649.1390) L &T Midcap Fund Growth	157.60	136.09
20,58,500.4490 (31st March 2021:19,59,250.2460) Mirae Asset Midcap Fund Regular	423.31	315.03
206,930.0720 (31st March 2021: 2,06,930.0720) Aditya Birla Sun Life Corporate Bond	186.63	177.76
715,151.4420 (31st March 20217,15,151.4420) HDFC Short Term Debt Fund Regular	183.74	175.69
476,441.9750 (31st March 2021:345,990.9000) Axis Focused 25 Fund Growth	205.39	129.68
NIL (31st March 2021: 426.7640) Kotak Liquid Scheme Regular Plan Growth	-	17.67
21,16,536.3590 (31st March 2021: 21,16,536.3590) IDFC Banking Debt Fund Regular	423.65	407.11
NIL (31st March 2021 :821,723.2730) NIPPON INDIA Arbitrage Fund Dividend-DR	-	102.57
15,00,000 (31st March 2021 : 15,00,000) IDFC Fixed Term Plan Series 149 Direct Plan	195.18	187.46
15,00,000 (31st March 2021 : 15,00,000) IDFC Fixed Term Plan Series 149 Regular Plan	193.47	186.20
14,390.0320 (31st March 2021: 14,390.0320) Axis Banking & PSU Debt Fund Growth	308.05	296.35
491,005.8650(31st March 2021: 405,368.2200) Axis Blue Chip Fund Growth	219.87	156.92
395,200.7610 (31st March 2021: 395,200.7610) ICICI Prudential Banking and PSU debt	103.28	98.73
185,493.6510 (31st March 2021 : 479,294.1150) Kotak Flexi Cap Fund Regular Plan	96.40	215.50
424,033.3490 (31st March 2021 :374,262.0030) Mirae Asset India Equity Fund Regular	328.26	245.16
537,127.7120 (31st March 2021 : 537,127.7120) HDFC Corporate Bond Fund Regular	140.37	133.89
53,068.1590 (31st Match 2021: 3649.5270) Kotak Overnight Fund Regular Plan Growth	600.12	40.00
15 (31st March 2021 : 10) ShriRam City Union Finance Limited	162.34	102.31
100 (31st March 2021 : 55) SpandanaSpoorty Financial Ltd (Debenture)	112.80	55.00
52.50 (31st March 2021 : 40) WELSPUN ONE LOGISTICS PARKS FUND - 1	52.50	39.97
3 (31st March 2021 : NIL) LENDINGKART FINANCE LIMITED BR NCD	32.12	-
772419.6500 (31st March 2021 : 397,544.4960) MotilalOswalNasdaq 100 Fund of Fund	178.30	79.11
63212.3980 (31st March 2021 :NIL) Kotak NASDAQ 100 Fund Regular Plan Growth	7.24	-
NIL (31st March 2021 : 3011.6290) AXIS Liquid Fund Growth	-	68.45
NIL (31st March 2021 : 3252.5590) Mirae Asset Overnight Fund Reg Plan Growth	-	34.24
5 (31st March 2021 :NIL) PIRAMAL ENTERPRISES LTD	53.26	-
99995 (31st March 2021 :NIL) ICICI Prodential Long short fund Series II Class B1	100.00	-
121561.7820(31st March 2021 :NIL)Edelweiss Greater China Equity Off shore Fund	48.72	-
Mutual Fund-SPA Capital	-	
NIL (31st March 2021 : 130,116.845) Franklin India Income Opportunities Fund (SPA)	-	29.74
NIL (31st March 2021 14,183.380) HDFC Prudence Fund (SPA)	-	33.45
NIL (31st March 2021 : 24,717.259) UTI MID CAP FUND GROWTH (SPA)	-	36.48
UTI Structured Debt Opportunities Fund I (SPA)	44.22	76.73
Mutual Fund- RNB CORPORATE		-
51,130.478 (31st March 2021: NIL) HDFC DYNAMIC DEBT G	37.34	-
17,508.552 (31st March 2021: NIL) UTI FLEXI CAP REG G	42.89	
Market Value of Quoted Investments	**4,723.42**	**3,640.05**
Aggregate Fair Value of All Current Investments	**4,723.42**	**3,640.05**

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Note 8 - Loans and Advances

(Rs. In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
(a) Deposits	35.58	31.82
(b) Other Advances	10.73	12.32
Total	**46.31**	**44.14**

Note 9 - Other Financial Assets

(Rs. In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
Fixed Deposits with Bank (more than 12 months)	213.59	176.34
Total	213.59	176.34

Note 10 - Deferred Tax Asset

(Rs.In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
As at the beginning	127.87	96.62
Charges/(credit) to profit and loss	23.30	31.25
At the end of the year	151.18	127.87
Deferred tax Asset		
Related to Property, Plant and Equipment	19.98	21.96
Provision for Gratuity/Leave Encashment	20.99	19.49
Provision for ECL	110.20	86.42
Total	**151.18**	**127.87**

Note 11 – Inventories

(Rs.In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
[As taken, valued and certified by the Management]		
a. Raw Materials and components	415.61	278.88
b. Work-in-progress	39.86	34.56
c. Finished goods	44.56	45.17
Total	**500.02**	**358.61**

Note 12 - Trade Receivables

(Rs.In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
[UNSECURED]		
Considered Good	4,141.17	2,291.84
Less Allowance forexpected credit loss	-	-
Credit impaired	423.86	332.36
Less Allowance for expected credit loss	(423.86)	(332.36)
Total	4,141.17	2,291.84

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Aging of Trade Receivables	Past Due						
	0-120 Days	120-150 days	150-180 Days	180-365 Days	365-730 Days	Greater than 730 days	Total
As at 31st March 2022							
Gross Carrying Amount	2,458.84	1,443.83	258.97	396.31	-	7.08	4565.02
Expected credit losses (Loss allowance provision)	-	(69.45)	(60.62)	(286.70)	-	(7.08)	(423.86)
Net Carrying Amount	**2,458.84**	**1,374.38**	**198.35**	**109.60**	-	**0.00**	**4141.17**
As at 31st March 2021							
Gross Carrying Amount	1,409.43	56.69	13.82	328.21	349.86	466.20	2,624.20
Expected credit losses (Loss allowance provision)	-	(0.90)	(0.69)	(29.60)	(135.82)	(165.35)	(332.36)
Net Carrying Amount	**1,409.43**	**55.79**	**13.13**	**298.61**	**214.04**	**300.85**	**2,291.84**

Note 13- Cash and Cash Equivalents

(Rs. In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
a. Cash on hand	0.90	0.84
b. Balances with banks	1,005.25	1,249.21
Total	**1,006.15**	**1,250.05**
Bank Balances include:		
Earmarked Balances (eg/- unpaid dividend accounts)	3.88	3.88
Margin money	1.34	1.34

Note 14- Other Financial Assets

(Rs. In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
Accrued Interest/Dividend Receivable	2.02	1.97
Total	**2.02**	**1.97**

Note 15- Other Current Asset

(Rs. In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
Balances with Government Authorities	161.02	305.44
Advance to Suppliers	837.33	180.08
Prepaid Expenses	4.97	2.61
Goods in Transit	28.79	-
Rental Deposit	5.56	5.80
Total	**1037.67**	**493.93**

Note 16- Share Capital

(Rs. In Lakhs)

Particulars	As at 31st March, 2022		As at 31st March, 2021	
	Number	Amount (Rs. In Lakhs)	Number	Amount (Rs. In Lakhs)
Authorised				
200,00,000 (31st March 2021 : 200,00,000) Equity Shares of Rs.10 each	2,00,00,000	2,000.00	2,00,00,000	2,000.00
Issued, Subscribed & Paid up				
1,55,82,129 (31st March 2021 : 154,94,354) Equity Shares of Rs. 10 each fully paid up	1,55,82,129	1,558.23	1,54,94,354	1,549.45
Total	**1,55,82,129**	**1,558.23**	**1,54,94,354**	**1,549.45**

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period

Particulars	As at 31st March, 2022		As at 31st March, 2021	
	Number	Amount (Rs. In Lakhs)	Number	Amount (Rs. In Lakhs)
Equity Shares outstanding at the beginning of the year	1,54,94,354	1,549.45	1,54,34,000	1543.42
Add : ESOP issued	87,775	8.78	60,354	6.03
EquityShares bought back during the year	-	-	-	-
Equity Shares outstanding at the end of the year	**1,55,82,129**	**1,558.23**	**1,54,94,354**	**1,549.45**

Shares in the company held by each shareholder holding more than 5 percent shares

	As at 31st March, 2022		As at 31st March, 2021	
Name of Shareholder	No. of Shares held	% of Holding	No. of Shares held	% of Holding
Kilitch Company Pharma Limited	66,29,342	42.54%	66,29,342	42.79%
Mukund Prataprai Mehta	8,90,647	5.72%	8,90,647	5.75%
Bhavin Mukund Mehta	20,02,416	12.85%	20,02,416	12.92%
Neeta Mukund Mehta	11,11,768	7.13%	11,11,768	7.18%

The company has only one class of Equity Shares having a face value of Rs. 10 per share. Each holder of Equity Share is entitled to one vote per share.

% Changes in Promoter holding

	As at 31st March, 2022	As at 31st March, 2021
Name of Shareholder	% of Holding	% of Holding
Kilitch Company Pharma Limited	42.54%	42.79%
Mukund Prataprai Mehta	5.72%	5.75%
Bhavin Mukund Mehta	12.85%	12.92%
Neeta Mukund Mehta	7.13%	7.18%

Note 17- Other Equity

(Rs. In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
a. Securities Premium	3,832.63	3,832.63
b. General Reserve	1,579.74	1,579.74
c. Employee Stock Options	35.41	35.41
d. Other ReservesCall onshares forfeited A/c	58.00	58.00
e. Amount received against Share Warrants	250.00	-
Foreign Exchange Fluctuation Reserve	27.50	25.38
f. Capital Reserve on Consolidation	13.28	13.28
g. Surplus in the statement of Profit and Loss		
As per Balance Sheet	5181.60	4,814.49
(+/-)Final Dividend including DDT	-	-
(+/-) Net Profit For the current year	736.72	367.11
	5918.32	**5,181.60**
h. Other Comprehensive Income		
As per last Balance Sheet	437.36	(85.51)
(+/-) Change in Fair value of Investments at FVOCI	198.15	522.87
At the end of the Year	635.51	437.36
Total	**12350.41**	**11,163.42**

1.Securities Premium: Securities premium reserve represents premium received on equity shares issued, which can be utilised only in accordance with the provisions of the Companies Act, 2013 for specified purposes.

2.Share Option Outstanding Account: Reserve relates to stock options granted by the Company to the employees under an employee stock options plan.

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

3.General Reserve: General reserve is created from time to time by transferring profits from retained earnings and can be utilised for purposes such as dividend payout, bonus issue, etc.

Note 18–Provisions (Non- Current)

(Rs. In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
Provision for Gratuity	27.54	38.06
Total	**27.54**	**38.06**

Note 19– Borrowings

(Rs. In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
MSME Loan-Kotak Bank*	238.87	290
Bank Overdraft [Kotak Bank]	747.08	-
Export Packing Credit Loan (Kotak Mahindra Bank)	1,047.53	1,180.68
Unsecured Loan (Repayable on Demand)	9.70	9.70
Total	**2043.18**	**1480.38**

*term of upto 40 months but detailed repayment schedule awaited from the bank, hence classified as current.
The above stated Borrowings from Kotak Mahindra Bank were secured against the Mutual Funds managed by Kotak Wealth.

Note 20- Trade Payables

(Rs. In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
i) Dues to Micro & Small Enterprises#	-	-
ii) Dues to Others	4,286.91	5,365.46
Total	**4,286.91**	**5,365.46**

# There are no Micro and Small Enterprises, to whom the groupowes dues, for more than 45days during the year as at March 31, 2022 and March 31, 2021. The above information regarding Micro and Small Enterprises has been determined to the extent such parties have been identified on the basis of information available with the group. This has been relied upon by	As on 31st March, 2022	As on 31st March, 2021
d) Interest paid	-	-
e) Interest due and payable for the period of delay	-	-
f) Interest remaining due and payable in succeeding year	-	-

(Rs. In Lakhs)

Aging of Trade Payable	Past Due						Amount
	0-120 Days	120-150 days	150-180 days	180-365 days	365-730 Days	Greater than 730 days	Total
As at 31st March 2022	3,385.95	804.86	57.95	38.15	-	-	4,286.91

Aging of Trade Payable	Past Due						Amount
	0-120 Days	120-150 days	150-180 days	180-365 days	365-730 Days	Greater than 730 days	Total
As at 31st March 2021	4,286.16	963.80	77.85	37.65	-	-	5,365.46

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Note 21 - Other financial liabilities

(Rs. In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
Unpaid dividends	3.88	3.88
Provision for expenses	-	-
Total	**3.88**	**3.88**

Note 22–Provisions

(Rs. In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
Provision for employee benefits:		
Salary & Reimbursements	48.08	45.86
Gratuity	43.93	31.07
Leave Encashment	8.87	5.83
Total	**100.88**	**82.76**

Note 23 - Current Tax Liabilities

(Rs. In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
Provision for Tax (Net of Taxes Paid)	439.62	262.30
Total	**439.62**	**262.30**

Note 24 - Other Current Liabilities

(Rs. In Lakhs)

Particulars	As on 31st March, 2022	As on 31st March, 2021
Statutory dues	43.90	11.50
Others	8.77	56.60
Outstanding Expenses	0.41	0.15
Provision for Expenses	0.37	68.59
Total	**53.45**	**136.84**

Note 25 - Revenue from Operations

(Rs. In Lakhs)

Particulars	Year Ended 31st March, 2022	Year Ended 31st March, 2021
Sale of products/services:		
Local sales	2,941.89	1,092.68
Out Of Maharashtra Sales	1,191.50	1,269.11
Export Sales	7,162.45	4,467.16
Other operating revenues	127.58	39.48
Less : Sales Return	-	(16.12)
Total	**11,423.42**	**6,852.31**

Note 26 - Other Income

(Rs. In Lakhs)

Particulars	Year Ended 31st March, 2022	Year Ended 31st March, 2021
Interest Income	21.91	17.03
Dividend Income	3.05	5.55
Foreign Exchange Gain :		
Realised	103.85	104.82
Unrealised	-	-
Profit on Sale of Investments	135.92	120.31
Sundry balances written back	-	1.03
Miscellaneous Income	26.20	17.99
Total	**290.93**	**266.73**

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Note 27 - Cost of Materials Consumed

(Rs. In Lakhs)

Particulars	Year Ended 31st March, 2022	Year Ended 31st March, 2021
Opening Stock	278.88	367.14
Purchases	6,684.76	3,533.66
Less: Closing Stock	(415.61)	(278.88)
Total	**6,548.03**	**3,621.91**

Note 28 - Variationin inventories of Finished Goods and work-In- progress

(Rs. In Lakhs)

Particulars	Year Ended 31st March, 2022	Year Ended 31st March, 2021
Opening Stock :		
Work-in-Process	34.56	44.64
Finished Goods	45.17	143.90
	79.73	188.54
Closing Stock :		
Work-in-Process	39.86	34.56
Finished Goods	44.56	45.17
	84.42	79.73
Total	**(4.69)**	**108.81**

Note 29 - Employee Cost

(Rs. In Lakhs)

Particulars	Year Ended 31st March, 2022	Year Ended 31st March, 2021
Salaries and incentives	571.09	495.56
Contributions to Provident fund	23.45	18.74
Gratuity fund contributions	3.41	4.83
Share Based Payment Cost	-	(15.74)
Staff welfare expenses	20.36	20.59
Total	**618.31**	**523.98**

Note 30 - Export Product Registration/Commission

(Rs. In Lakhs)

Particulars	Year Ended 31st March, 2022	Year Ended 31st March, 2021
Export Product Registration		
Export product registration	237.59	215.30
Export Expenses	13.67	32.28
Export Commission Expenses	296.87	200.72
Total	**548.13**	**448.30**

Note 31 - Other Expenses

(Rs. In Lakhs)

Particulars	Year Ended 31st March, 2022	Year Ended 31st March, 2021
Consumption of stores and spare parts	211.99	81.44
Labour Charges	228.73	223.26
Power and Fuel	192.38	157.02
CSR Expenses	21.77	21.51
Water Charges	7.74	6.40
Foreign Exchange Loss- Unrealised	71.76	7.25
Bank & Other Charges	13.26	12.25
Repairs to Buildings	0.00	2.20
Repairs-Others	150.22	58.34

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Insurance	13.02	3.33
Rent, Rates and Taxes	48.76	32.46
Auditors Remuneration [Refer Note No 37]	15.30	15.55
Miscellaneous expenses	554.14	62.08
Donation	1.16	-
Directors' Sitting Fees	0.74	0.57
Foreign Travelling Expenses	42.15	37.74
Printing & Stationery	10.77	8.52
Professional charges	94.95	182.59
Profession Tax	0.03	0.03
Communication Expenses	16.90	13.58
Electricity Charge	0.00	0.03
Fees & Subscription Expenses	0.04	-
Vehicle Expenses	11.00	13.28
Travelling Expenses:		
Directors	2.81	
Others	70.05	10.18
Factory	0.00	29.70
Export Freight Expenses	0.00	2.80
Business Promotion Expenses	59.52	65.94
Advertising / Sales Commission Expenses	2.14	2.34
Discount Allowed [Sales]	2.02	3.31
Clearing & Forwarding Expenses	123.84	176.38
Calibration/validation Charges	2.87	1.75
Bad Debts/Balances written off	0.00	33.73
Share of Loss from Partnership Firm	0.20	0.20
Freight	562.57	216.05
Provisions for Expected Credit Loss		119.56
Office expenses	28.67	19.34
Factory License	0.23	
Sponsorship Exp	5.00	
Reserve for Doubtful Debts [P&L]	91.51	
S Discount allowed GST	1.17	
Bad Debts/Balances written off	17.06	
Software Expenses	0.27	
VAT Expenses		9.33
Total	**2676.73**	**1,630.03**

Note 32 - Disclosure as per IND AS – 19 "employee benefits".
(A) Expenses recognised for Defined Contribution Plan:

Employer's Contribution to Provident and Pension Fund Rs. 14.46Lakhs (PY Rs. 13.22 Lakhs).
Employer's Contribution to ESIC Rs. 8.99 Lakhs (PY Rs. 3.08 Lakhs)
The Group makes contributions towards provident fund and pension fund for qualifying employees to the Regional Provident Fund Commissioner.

(B) Expenses recognised Defined Benefit Plan:
The Group provides gratuity benefit to its employees which is a defined benefit plan. The present value of obligation is determined based on actuarial valuation using the Projected Unit Credit Method, which recognizes each period of service as giving rise to additional unit of employee benefit entitlement and measures each unit separately to build up the final obligation. The obligation for leave encashment is recognised in the same manner as gratuity.

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

I. Change in Defined Benefit Obligation during the year

(Rs. in Lakhs)

Particulars	2021-22 Gratuity	2020-21 Gratuity
Present value of the obligation at the beginning of the year	68.77	68.34
Current Service Cost	4.43	5.52
Interest Cost	4.00	4.61
Actuarial (Gain) / Loss on Obligation	(5.21)	(8.40)
Benefits Paid	(0.52	(1.30)
Present value of the obligation at the end of the year	71.47	68.77

ii. Amount to be recognized in Balance sheet

(Rs. in Lakhs)

Particulars	2021-22 Gratuity	2020-21 Gratuity
Present Value of Defined Benefit Obligation	48.10	68.77
Fair value of Plan Assets at the end of the year	(10.23)	(22.44)
Amount to be recognized in Balance sheet	37.87	46.33

iii. Current/Non - Current bifurcation

(Rs. in Lakhs)

Particulars	2021-22 Gratuity	2020-21 Gratuity
Current Benefit Obligation	10.33	18.43
Non-Current Benefit Obligation	27.54	50.33

iv. Expenses recognised in the statement of financial position for the year

(Rs. in Lakhs)

Particulars	2021-22 Gratuity	2020-21 Gratuity
Current Service Cost	4.43	5.52
Interest cost on Obligation	4.00	3.83
Net Actuarial (Gain) / Loss recognised in the year	-	-
Net Cost Included in Personnel Expenses	8.43	9.35

v. Maturity profile of defined benefit obligation

(Rs. in Lakhs)

Particulars	2021-22	2020-21
Within the next 12 months	19.46	13.57
between 2 to 5 Years	10.86	29.81
between 6 to 10 Years	17.36	96.64

vi. Actuarial Assumptions used for estimating defined benefit obligations

(Rs. in Lakhs)

Particulars	2021-22	2020-21
Discount Rate	6.80% P.A.	6.72% P.A.
Salary Escalation Rate	6.50% P.A.	6.50% P.A.
Expected Return on Plan Assets	0.57	(0.063)
Mortality Rate	IALM (201214)	IALM (201214)
Withdrawal Rate	1.00%	1.00%
The Weighted Average Duration of the plan	13 Years	13 Years
No. of Employees	143	44

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Average Age	34	43
Total Salary (Rs. in Lakhs)	19.62	128.16
Average Salary (Rs. in Lakhs)	0.14	10.68
Average Service	5 Years	13 Years
Accrued Benefit	71.47	68.77
Actuarial Liability	37.87	46.33

Notes:

1. Salary escalation rate is arrived after taking into account regular increments, price inflation and promotion and other relevant factors such as supply and demand in employment market.
2. Discount rate is based on prevailing market yields of Indian Government Securities as at balance sheet date for estimated term of obligations.
3. Attrition rate/ withdrawal rate is based on Group's policy towards retention of employees, historical data and industry outlook.
4. The above information is certified by actuary.

vii. Sensitivity analysis:

Increase/ (decrease) on present value of defined benefits obligations at the end of the year

(Rs. in Lakhs)

Particulars	Change in assumption	Effect on Gratuity obligation	
		2021-22	2020-21
Discount rate	+1%	68.43	63.57
	-1%	74.79	74.81
Salary Escalation rate	+1%	74.30	74.77
	-1%	69.07	63.52

These gratuity plan typically expose the Group to actuarial risks such as: investment risk, interest risk, longevity risk and salary risk.

Investment Risk:

The present value of the defined benefit plan liability is calculated using a discount rate which is determined by reference to market yields at the end of the reporting period on government bonds. For other defined benefit plans, the discount rate is determined by reference to market yield at the end of reporting period on high quality corporate bonds when there is a deep market for such bonds; if the return on plan asset is below this rate, it will create a plan deficit.

Interest risk

A decrease in the bond interest rate will increase the plan liability; however, this will be partially offset by an increase in the return on the plan debt investments.

Longevity risk

The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.

Salary risk

The present value of the defined plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability.

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

C) Unfunded Schemes Earned Leaves

(Rs.in Lakhs)

Particulars	Year ended 31st March, 2022	Year ended 31st March, 2021
Present value of unfunded obligations	37.87	46.33
Expenses recognised in the statement of profit and loss	1.55	(1.0)
In Other comprehensive income	(5.78)	(8.34)
Actuarial (Gain) / LossPlan liabilities	-	-
Actuarial (Gain) / LossReturn On Plan Assets	-	-
Net (Income)/ Expense For the period Recognized in OCI	(5.78)	(8.34)
Discount rate (per annum)	6.80%	6.72%
Salary escalation rate (per annum)	6.50%	6.72%

Note 33 - Segment Reporting

The Group is mainly engaged in the development and operations of Pharmaceutical business. Accordingly, the Group has only one identifiable segment reportable under Ind AS 108 - Operating Segments.

Managing Director (the 'Chief Operational Decision Maker' as defined in Ind AS 108) monitors the operating results of the Group's business for the purpose of making decisions about resource allocation and performance assessment.

The revenues from transactions with a single customer exceeding 10 per cent or more of the Group's revenues were stated below:

(Rs. In Lakhs)

Party Name	Country	FY 21-22	FY 20-21
M/s Tedis SA	France	1428.72	1276.44
Grand Total		1428.72	1276.44

Note 34 - Related Party Disclosures

In view of the INDAS 24 "Related Parties Disclosures", the disclosure in respect of related party transactions for the year ended on 31st March, 2022 is as under:

RELATIONSHIPS	
Category I : Key Managerial Personnel	
Key Person	Designation
Mukund Prataprai Mehta	Chairman & Managing Director
Bhavin Mukund Mehta	Whole-time Director
Mira Bhavin Mehta	Whole-time Director
Sunil Jain	Chief Finance Officer
Garima Trivedi (upto 13.10.2021) / Princy Asati	Company Secretary and Compliance Officer
Category II : Enterprises over which Key Managerial Personnel are able to exercise significant control	
NBZ Healthcare LLP.	
Arham Neeta Realties LLP	
Kilitch Pharma (Co.) Ltd.	

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

(Rs. In Lakhs)

	TRANSACTIONS	Categoryl	Category I
1	Purchases	-	112.74 (103.51)
2	Sales	-	485.69 (NIL)
3	Director's Remuneration and Sitting Fees	184.50 (183.45)	-
4	Advance/Loan Given to Parties	-	2,312.55 (972.72)
5	Advance Returned By Parties	-	2,329.27 (1,036.59)

The Following were due from/ to the relatedparties' balances as on 31-03-2022

Sr.No.	TRANSACTIONS	Category I	Category II
1	Loans/Borrowings/Payables	9.70 (9.70)	45.06 (52.43)

Note: Figures in brackets indicates previous year figure.

The transactions with related parties are made on terms equivalent to those that prevail in arm's length transactions. Review of outstanding balances is undertaken each financial year through examining the financial position of the related party and the market in which related party operates. These balances are unsecured and their settlement occurs through banking channel.

Compensation of key management personnel:
The remuneration of director and other member of key management personnel during the year was as follows:

(Rs. In Lakh)

Particulars	2021-22	2020-21
Short -term benefits	184.50	183.45
Other long term benefits	-	-

Note 35 - Earning per Share (EPS)

Basic as well as Diluted EPS	2021-22	2020-21
Net Profit after Tax (Rs. in Lakhs)	736.72	367.11
Weighted Average No. of Equity Shares for Basic EPS	15566110	15479893
Weighted Average No. of Equity Shares for Diluted EPS	15566110	15479893
Nominal Value of Equity Shares (Rs.)	10.00	10.00
Basic Earnings Per Share (Rs.)	4.73	2.37
Diluted Earnings Per Share (Rs.)	4.73	2.37

Note 36 - Contingent liabilities not provided for in Respect of:

a) Demand notices received on account of Property Tax pertaining to FY 2019-20 is aggregating Rs. 53.20 Lakhs (P.Y. Rs. 53.20 Lakhs)are disputed by the Group. The Group has filed a suit and the matter is pending the Supreme Court and Group has not yet deposited any amount in this regard.

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

b) Demand notices received on account of principal amount of CESS during FY 2019-20 pertaining to FY 1999-2000 and FY 2000-2001 is aggregating Rs.22.85 Lakhs (P.Y.Rs.22.85 Lakhs) are disputed by the Group. The Company has filed a suit and the matter is pending the Supreme Court and group has not yet deposited any amount in this regard.

The above litigations are not expected to have any material adverse effect on the financial position of the Group.

Note 37- Auditors' Remuneration:

Particulars	2021-22 (Rs. In Lakhs)	2020-21 (Rs. In Lakhs)
Audit fees	15.30	15.30
Certification Fees		0.25
Total	**15.30**	**15.55**

Note 38–Subsidiary Companies Considered in these consolidated Financial Statements

Sr. No.	Particulars	Country of Incorporation	Proportion of Ownership FY 2021-22	Proportion of Ownership FY 2020-21
1	Monarchy Healthserve Private Limited	India	100%	100%
2	Kilitch Estro Biotech PLC	Ethiopia	67%	67%

Note 39 – Impairment of Assets

The Company's Board, out of abundant caution and as a prudent practice in line with the standard accounting practices has not made any impairment provision against its investments for the financial year 2021-22.

Note 40 – Balance Confirmation

The balances in respect of Trade Receivables & Payables, loans and advances, as appearing in the books of accounts are subject to confirmations by the respective parties and adjustments/reconciliation arising there from, if any.

Note 41 – Investment in Limited Liability Partnership

The Company is a partner in a partnership firm M/s. Arham Neeta Realties LLP. The accounts of the partnership firm have been finalized up to the financial year 2021-22. The details of the Capital Accounts of the Partners as per the latest Financial Statements of the firm are as under:

(Rs. in Lakhs)

Sl. No.	Name of the Partners	Profit Sharing Ratio	Total Capital on 31st March, 2022	Total Capital on 31st March, 2021
1	Kilitch Drugs (India) Limited	65%	2,246.49	2,246.49
2	Mukund Mehta	16.25%	(3.04)	(3.04)
3	Bhavin Mehta	16.25%	(3.04)	(3.04)
4	Mira Mehta	2.5%	(1.94)	(1.94)

The Company has accounted for its share of loss amounting to Rs. 0.20 Lakhs (P.Y. Rs. 0.24 Lakhs) pertaining to Financial Year 2021-22.

Note 42 - Event after Reporting Date:

There are no major events occurred after the reporting date.

Note 43 - Corporate Social Responsibility:

The company is required to comply the requirements of CSR as per Section 135 of the Companies Act, 2013 read with Schedule

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Expenditure related to corporate social responsibility is :

Perticulars	Amount March 2022	Amount March 2021
1) Amount spend towards CSR		
2) Educational actives for children	11.45	21.00
3) Animal welfare activities	0.26	0.51
4) Livelihood enhancement of differently able people	10.06	-
Total	**21.77**	**21.51**

Note 44 - Additional information as required under section 186 (4) of the Companies Act, 2013:

a. No Investments made in any Body Corporate except its subsidiaries.
b. No Guarantees were given by the Company.
c. No Loans or advances were given by the company to any Body Corporate or Persons.

Note 45 - Investment in Associates

The Group does not have any associates companies. The company's interest in associate is accounted using the equity method in the consolidated financial statements.

Note 46 - Details required as per schedule III of the Companies Act 2013 as below

Details of Net Assets and Share in Profit and Loss Account - Anil sir please change % value which is highlighted with green colour

(Rs. In Lakhs)

Particulars	Net Assets (Total Assets less Total Liabilities)		Share in Profit and Loss		Share in Other Comprehensive Income		Share in Total Comprehensive Income	
	As % of consolidated net assets	Amount	As % of Consolidated Profit	Amount	As % of Consolidated Profit	Amount	As % of Consolidated Profit	Amount
Monarchy Healthserve Private Limited	14.51%	2036.20	-13.17%	81.83)	--	--	10.00%	81.83)
Kilitch Estro Biotech PLC	2.61%	365.82	-56.26%	349.58)	--	--	42.70%	(349.58)

Note 47 - Fair value of financial assets and liabilities: -

Set out below is the comparison by class of carrying amounts and fair value of Company's financial instruments that are recognised in the financial statements.

Particulars	As at 31st March 2022		As at 31st March 2021	
	Carrying Value (Rs. In Lakhs)	Fair Value (Rs. In Lakhs)	Carrying Value (Rs. In Lakhs)	Fair Value (Rs. In Lakhs)
Financial assets designated at fair value through Other Comprehensive Income				
Investments				
in Equity shares	85.77	85.77	76.90	76.90
in Bonds	63.13	63.13	63.15	63.15
in Mutual Funds	4,723.42	4,723.42	3,640.05	3,640.05
Financial assets designated at amortised cost				
Investments				
TradeReceivables	4,141.17	4,141.17	2,291.84	2,291.84
Cash and Cash Equivalents	1,006.15	1,006.15	1,250.05	1,250.05
Loans and Advances	46.31	46.31	44.14	44.14
Other financial assets	215.61	215.61	178.31	178.31
Total	**10,281.56**	**10,281.56**	**7,546.37**	**7,546.37**

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Financial liabilities designated at amortised cost				
Borrowings Fixed rate	2,043.18	2,043.18	1,480.38	1,480.38
Trade payables and others	4,286.91	4,286.91	5,365.46	5,365.46
Other financial liabilities	3.88	3.88	3.88	3.88
Total	**6,333.97**	**6,333.97**	**6,849.71**	**6,849.71**

Fair valuation techniques:

The Group maintains policies and procedures to value financial assets or financial liabilities using the best and most relevant data available. The following methods and assumptions were used to estimate the fair values

Fair value of the Equity Shares are based on price quoted on stock exchange.

Fair value of investment in unquoted equity shares are considered same as carrying value as the same are recently acquired.

Fair value of Financial Assets & Financial Liability (except which are show at their fair value) are carried at amortised cost is not materially different from its carrying cost.

Fair Value hierarchy:

The following table provides the fair value measurement hierarchy of Group's asset and liabilities, grouped into Level 1 to Level 3 as described below:

Level 1: Quoted prices / published NAV (unadjusted) in active markets for identical assets or liabilities. It includes fair value of financial instruments traded in active markets and are based on quoted market prices at the balance sheet date.

Level 2: Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices). Fair value of the financial instruments that are not traded in an active market is determined by using valuation techniques. These valuation techniques maximise the use of observable market data where it is available and rely as little as possible on the Group specific estimates. If all significant inputs required to fair value an instrument are observable then instrument is included in level 2

Level 3: Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs). If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

(Rs. In Lakhs)

Purchases	**As at 31st March, 2022**			**As at 31st March, 2021**		
	Level 1	Level 2	Level 3	Level 1	Level 2	Level 3
Assets/Liabilities measured at fair Value						
Investments						
- in Equity shares	85.77	-	-	76.9	-	-
- in Bonds	-	63.13	-		65.15	-
-in Mutual Funds	4,723.42	-	-	3,640.05	-	-

Note 48 - Financial Risk management:

The Group's activities expose it to credit risk, liquidity risk and market risk. This note explains the sources of risks which the entity is exposed to and how it mitigates that risk.

Market risk:

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market prices comprise three types of risk: currency rate risk, interest rate risk and other price risks, such as equity price risk and commodity risk. Financial instruments affected by market risk include loans and borrowings and investments in securities.

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

The Group is exposed to foreign exchange risk through purchases of goods or services from overseas supplier in foreign currency. The Group generally transacts in US dollar. The foreign exchange rate exposure is balanced by purchasing of goods or services in the respective currency.

The Group is exposed to insignificant foreign exchange risk as at the respective reporting dates.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

The Group is not exposed to interest rate risk as the Group has fixed rate of borrowings as at the respective reporting dates.

Commodity and Other price risk

The Group is not exposed to the commodity and other price risk.

Credit Risk

Credit risk is the risk of financial loss to the Group that a customer or counter party to a financial instrument fails to meet its obligations. The Group is exposed to credit risk from its operating activities (primarily trade receivables) and from its financing activities, including deposits with banks, mutual funds, financial institutions and other financial instruments.

Trade and other receivables

The Group extends credit to customers in normal course of business. The Group considers factors such as credit track record in the market and past dealings for extension of credit to customers. To manage credit risk, the Group periodically assesses the financial reliability of the customer, taking into account the financial condition, current economic trends, and analysis of historical bad debts and aging of accounts receivables. Outstanding customer receivables are regularly monitored to make an assessment of recoverability. Receivables are provided as doubtful / written off, when there is no reasonable expectation of recovery. Where receivables have been provided / written off, the Group continues regular follow-up, engage with the customers, legal options / any other remedies available with the objective of recovering these outstanding. The Group is not exposed to concentration of credit risk to any one single customer since services are provided to vast spectrum and hence, the concentration of risk with respect to trade receivables is low. The Group also takes security deposits, advances, post-dated cheques etc. from its customers, which mitigate the credit risk to an extent.

Cash and cash equivalents another investments

The Group is exposed to counter party risk relating to medium term deposits with banks and investment in mutual funds. The Group considers factors such as track record, size of the institution, market reputation and service standards to select the banks with which balances and deposits are maintained. Generally, the balances are maintained with the institutions with which the Group has also availed borrowings.

Exposure to credit risk

The gross carrying amount of financial assets, net of impairment losses recognised represents the maximum credit exposure. The maximum exposure to credit risk as at 31st March, 2022 and 31st March, 2021 is as follows

Particulars	As at 31st March, 2022	As at 31st March, 2021
Financial assets for which loss allowances is measured using12 months		
Expected Credit Losses (ECL):		
Cash and cash equivalents	1,006.15	1,250.05
Loans	46.31	44.14
Other financial assets	215.61	178.31
Financial assets for which loss allowances is measured using Life time		
Expected Credit Losses (ECL):		
Trade receivables	4,141.17	2,291.84

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Life time Expected credit loss for Trade receivables under simplified approach

Aging of Trade Receivables	Past Due						
	0-120 Days	120-150 days	150-180 Days	180-365 Days	365-730 Days	Greater than 730 days	Total
As at 31st March 2022							
Gross Carrying Amount	2,458.84	1,443.83	258.97	396.31	-	7.08	4565.02
Expected credit losses (Loss allowance provision)	-	(69.45)	(60.62)	(286.70)	-	(7.08)	(423.86)
Net Carrying Amount	**2,458.84**	**1,374.38**	**198.35**	**109.60**	-	**0.00**	**4141.17**
As at 31st March 2021							
Gross Carrying Amount	1,409.43	56.69	13.82	328.21	349.86	466.20	2,624.20
Expected credit losses (Loss allowance provision)	-	(0.90)	(0.69)	(29.60)	(135.82)	(165.35)	(332.36)
Net Carrying Amount	**1,409.43**	**55.79**	**13.13**	**298.61**	**214.04**	**300.85**	**2,291.84**

Reconciliation of Changes in the life time expected credit loss allowance:

Particulars	2021-22	2020-21
Loss allowance on 1 April	332.36	212.79
Provided during the year	91.50	119.72
Reversal of provision	-	(0.15)
Loss allowance on 31st March	423.86	332.36

Cash and Cash equivalent, other Investment, Loans and other financial assets are neither past due nor impaired. Management is of view that these financial assets are considered good and 12 months ECL is not provided.

Liquidity risk

Liquidity risk is the risk that the Group may not be able to meet its present and future cash and collateral obligations without incurring unacceptable losses.

The Group's objective is to at all times maintain optimum levels of liquidity to meet its cash and collateral requirements. The Group relies on a mix of borrowings, capital infusion and excess operating cash flows to meet its needs for funds. The current borrowings are sufficient to meet its short to medium term expansion needs.

Management monitors the Group's net liquidity position through rolling forecasts on the basis of expected cash flows. The Company is required to maintain ratios (such as debt service coverage ratio and secured coverage ratio) as mentioned in the loan agreements at specified levels and also cash deposits with banks to mitigate the risk of default in repayments. In the event of any failure to meet these covenants , these loans become callable to the extent of failure at the option of lenders, except where exemption is provided by lender

Particulars	As at 31st March, 2022					
	Carrying Amount	On Demand	Less than 12 months	2-5 years	>5 years	Total
Borrowings	2,043.18	9.70	2033.48	-	-	2,043.18
Other Financial Liabilities	3.88	3.88	-	-	-	3.88
Trade and other payables	4,286.91	4,286.91	-	-	-	4,286.91

Particulars	As at 31st March, 2021					
	Carrying Amount	On Demand	Less than 12 months	2-5 years	>5 years	Total
Borrowings	1,480.38	9.70	1,470.68	-	-	1,480.38
Other Financial Liabilities	3.88	3.88	-	-	-	3.88
Trade and other payables	5,365.46	5,365.46	-	-	-	5,365.46

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Capital management

The primary objective of the Company's capital management is to maximize the shareholder value. The Company's primary objective when managing capital is to ensure that it maintains an efficient capital structure and healthy capital ratios and safeguard the Company's ability to continue as a going concern in order to support its business and provide maximum returns for shareholders. The Company also proposes to maintain an optimal capital structure to reduce the cost of capital. No changes were made in the objectives, policies or processes during the year ended 31st March, 2022 and 31st March, 2021

Particulars	As at 31st March, 2022	As at 31st March, 2021
Loans and Borrowings	2,043.18	1,480.38
Less: Cash and cash equivalents + Bank Deposits	(1,219.74)	(1,426.39)
Net Debt	823.44	53.99
Total Capital	13,908.64	12,712.87
Capital + Net Debt	14,732.08	12,766.86
Gearing Ratio	0.059	0.004

For the purpose of the Company's capital management, capital includes issued capital, share premium and all other equity reserves. Net debt includes, interest bearing loans and borrowings, trade and other payables less cash and term deposits.

Note 49 - Taxation

Income tax related to items charged or credited to profit or loss during the year:

A. Statement of Profit or Loss		(Rs. In Lakhs)
Particulars	**2021-22**	**2020-21**
1. Current Income Tax [Net of MAT Credit]	363.37	166.55
2. Deferred Tax expenses/ (benefits):		
Relating to origination and reversal of temporary differences	(23.30)	(31.25)
Total Income tax Expenses (1 to 2)	340.07	135.3

B. Reconciliation of Current Tax expenses:		(Rs. In Lakhs)
Particulars	**2021-22**	**2020-21**
Profit /(Loss) from Continuing operations	1,392.85	750.83
Applicable Tax Rate	29.12%	27.82%
Computed tax expenses	**405.59**	**208.88**
Income notallowed/exempt for tax purposes	(0.89)	(15.21)
Expenses not allowed for tax purposes	32.18	6.32
Other temporary allowances	2.64	2.30
Tax paid at lower rate	(24.51)	(8.43)
MAT Credit set off	(64.76)	(80.57)
Interest Provision	13.11	22.00
Tax Expenses	363.37	135.29

Deferred Tax Recognised in statement of profit and Loss relates to the following:		(Rs. In Lakhs)
Particulars	**2021-22**	**2020-21**
Difference between book and Tax depreciation	(1.98)	0.70
Expenses allowable on payment basis	25.28	30.55
Deferred Tax Liabilities/ (Asset)	**23.30**	**31.25**

Consolidated Notes to the Financial Statements

For year ended 31st March 2022

Reconciliation of deferred tax liabilities/(asset) net:		(Rs. In Lakhs)
Particulars	**2021-22**	**2020-21**
Opening balance as on 1st April	127.87	96.62
Tax expenses / (income) during the period	23.31	31.25
(+/-) On Account of Consolidation	-	-
Closing balance as on 31st March	**151.18**	**127.87**

Note 50 – Additional information as required under Section 186 (4) of the Companies Act, 2013 :

a. Investments made in Body Corporate are mentioned in Note 7.
b. No Guarantee is given by the Company.
c. Loans given by the company to Body Corporate or Person: None.

Note 51 – Share Based Payments and Arrangements

As per the ESOS, 2007 as amended from time to time the outstanding ESOPs which can be exercised by our employees at Rs. 10 each (Face Value Rs. 10/ share). Detailed analysis of the same has been enumerated below:

Sr. No.	Particulars of Options / Scheme	Total (Numbers)
1	Outstanding as at beginning of the Year	106030
2	Add : Granted during the Year	NIL
3	Less : Forfeited/Cancelled/Lapsed during the Year	(729)
4	Less : Exercised and allotted during the Year	(87775)
5	Outstanding as at the end dhe Year	17526

Note 52 - The previous year figures have been regrouped, reworked, rearranged and reclassified, wherever necessary and are to be read in relation to the amounts and other disclosures relating to the current year.

As per our report of even date	
For Suryaprakash Maurya & Co. Chartered Accountants	For and on behalf of the Board of Directors Kilitch Drugs India Limited
FRN: 147410W Suryaprakash Mauryai	Mukund P. Mehta (Managing Director) [DIN: 00147876]
Partner M.No. 178258	Bhavin M. Mehta (Whole-time Director) [DIN: 00147895]
	Sunil Jain Chief Financial Officer
Mumbai Dated: 26th May 2022	Puspha Nyoupane (Company Secretary)



KILITCH DRUGS (INDIA) LIMITED

Registered Office:
C-301/2, MIDC, TTC Industrial Area, Pawane Village, Navi Mumbai - 400 705.
Tel.: 022-27670322, 27680913
www.kilitch.com